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PRoSTATe CANCeR
Statistics, Screening and early DetectionAccording to GLOBOCAN estimates, 1.1 million new cases of prostate cancer (PCa) and 307,500 deaths occurred worldwide in 2012, rendering PCa as the second most 
reuent diagnosed cancer among men and te fit eading cause o cancer deat worldwide (1).The highest PCa incidence rates are observed in more developed regions of the world, such as in Australia/New Zealand, Northern America, and Western and 
ortern uropeǤ esides ieste and genetic actorsǡ te use o prostateǦspecific antigen (PSA) testing in developed countries partially accounts for differences in incidence rate worldwide (2). The value of PSA screening is controversial. Although the European Randomized study of Screening for Prostate Cancer (ERSPC) has shown substantial reduction in mortality after 13 years follow-up (3), PSA-testing also leads to overdiagnosis (40-50% screen-detected cases) and unnecessary treatments with associated side effects (4-6ȌǤ odifications o Ǧscreening approaces are eing investigated to reduce the risk of overdiagnosis. New research methods are being developed to complement PSA-screening and separate low-risk cancers from more aggressive cancers, such as non-invasive assays for serum and urine biomarkers. 
Diagnosis and Staging
atients at ris or a are identified ased on dierent actorsǡ suc as ageǡ etnicitǡ family history, PSA level, free/total PSA ratio and digital rectal examination (DRE). Diagnosis is established by transrectal ultrasound-guided prostate biopsy or magnetic resonance imaging (MRI)-transrectal ultrasound (TRUS) fusion biopsy, from which the Gleason score (GS) is derived (7). Clinical T stage is evaluated by DRE and patients 
it ocaized a are cassified in ris groups ȋoǦǡ intermediateǦ or igǦrisȌ according to T stage, GS and PSA level. Staging of metastases is recommended for intermediate- or high-risk patients, using 99mTc bone scan, computed tomography (CT) scan, whole-body MRI or choline positron emission tomography (PET)/CT (7). 
Treatment and Follow-up
Localized PCaWatchful waiting and active surveillance are options for low-risk patients with localized disease. Curative treatment options for low- to intermediate-risk patients include radical prostatectomy, external beam radiotherapy and brachytherapy. For patients with high-risk or locally advanced PCa, treatment options include combinations of external beam radiotherapy with hormone treatment or radical prostatectomy with pelvic lymphadenectomy. Hormone treatment consisting of androgen-deprivation therapy can be given as neoadjuvant as well as adjuvant therapy (7). 
502161-L-sub01-bw-Chatalic
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Recurrent PCa and Castration-Resistant PCa
atients soing recurrence o te disease as refected  increased eves o circulating PSA (i.e. biochemical relapse) after radiotherapy and patient with hormone-naïve metastatic disease may receive androgen-deprivation therapy. For patients with castration-resistant PCa (CRPC), several options are currently available, such as chemotherapeutics (abiraterone, enzalutamide, docetaxel, sipuleucel-T, 
caazitaeȌǡ or te radioparmaceutica adiumǦʹʹ͵ ȋofigoȌ or treatment o one metastases. Radiotherapy can be used to relief pain caused by bone metastases. Disease response/progression should be monitored by regular imaging studies in patients with CRPC (7).
THeRANoSTiCS CoNCePT
Clinical RelevanceEarly diagnosis of PCa is essential, as patient prognosis is strongly diminished for 
advanced disseminated aǤ Ǧscreening enefits are controversiaǡ ecause o te risk of overdiagnosis and overtreatment. Initial diagnosis and staging is performed 
using  and prostate iopsiesǤ ore aǦspecific nonǦinvasive metods are needed to complement currently available methods to facilitate staging and monitoring of treatment effect and disease progression. Moreover, there is an unmet need for a sensitive method to detect tumor lesions in patients with a rise in PSA from unknown source. In addition, there is a need for more effective treatment options of metastatic PCa. A single tool combining diagnosis and therapy in a “theranostic” approach could effectively contribute to a more personalized management of PCa patients, whereby imaging can guide the choice of the most suitable therapeutic option for each patient. 
eranostic agents can e designed to specifica target iomarers overepressed on PCa cells. In nuclear medicine, theranostic agents can be designed with diagnostic and therapeutic radionuclides. This powerful combination would not only allow non-invasive detection of PCa lesions, but also monitoring of progression of disease and 
treatment eficac ȋFigure 1).
Molecular imaging
Imaging ModalitiesImaging can provide valuable insight about numerous pathologies, and multimodal imaging methods can provide complementary information. An overview of different imaging modalities used in preclinical research was recently given by de Jong et al. (9) (Table 1). CT and MRI provide anatomical or physiological information with high spatial resolution, whereas nuclear and optical imaging techniques allow imaging of tumor-
specific metaoic processes or iomarersǡ it ig sensitivitǡ ut reative o spatial resolution.
502161-L-sub01-bw-Chatalic
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Screening Diagnosis Treatment Follow up
Biomarkers
In vitro (ﬂuids)
Ex vivo (biopsies)
In vivo (bioimaging)
Image-based
guidance
Theranos
cs
Personalized medicine
1) Image-guided interven onal 
procedures
2) Radiodiagnosis - radiotherapy
3) Image-controlled drug delivery 
4) Cell therapy
1) At-risk pa ent proﬁle
2) Companion biomarker of targeted   
drugs: selec on, response
3) Early diagnosis of recurrence
A
B
radionuclides radionuclides 
Molecular target 
on cancer cell 
T
Linker 
Radionuclide 
FiGURe 1. (A) Current concept of theranostics; diagram adapted from (8). (B) Schematic representation 
of the theranostic concept in nuclear medicine using radiolabeled molecules binding specific molecular targets overexpressed on cancer cells.
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Nuclear imaging modalities are based on the detection of photons emitted during radioactive decay of radionuclides. Nuclear imaging techniques are very sensitive and allow visualization of molecular targets through attachment of radionuclides to targeting molecules. However, nuclear imaging should be combined with other modalities to provide anatomical references. PET imaging visualizes pairs of annihilation photons, which are emitted in opposite direction when a positron interacts with an electron. Image acquisition is based on the simultaneous detection of pairs of photons of 511 keV by a series of opposing detectors corresponding to several rings of scintillation crystals. A three-dimensional image is reconstructed after acquisition 
o suficient eventsǤ n contrast to ǡ singe poton emission computed tomograp 
ȋȌ measures singe potons emitted  gamma ȋɀȌǦemitting radionucidesǤ Image acquisition is based on detection of photons by a set of rotating detectors, which acquire a series of two-dimensional projections images from multiples angles around the longitudinal axis of the patient. Several reconstruction algorithms are available to reconstruct these tomographic images. Clinical PET imaging systems offer higher spatial resolution and higher sensitivity than SPECT imaging system. In small-animal imaging, however, spatial resolution of SPECT is higher (Table 1). Therefore, SPECT imaging is widely used as well in preclinical studies.Optical imaging techniques can also provide molecular information, but are restricted by the limited penetration range of light in tissue. Optical imaging techniques include 
iouminescenceǦ and fuorescenceǦased imagingǡ and are most restricted to preclinical studies. Bioluminescence allows quantitative imaging, but requires genetic 
modification o cesǡ ic ma impact ioogica processesǤ 	uorescenceǦased 
imaging is imited  tissue autofuorescenceǡ ic renders uantitation o signa challenging. Even though its use in the clinic is restricted, optical imaging has shown 
utiit in te cinic or fuorescenceǦguided surgerǡ and sentine node imaging ȋ10). 
PCa Imaging Current conventional imaging techniques used to detect primary and metastatic PCa for staging include ultrasound, bone scintigraphy, and CT. Functional MRI techniques, e.g. diffusion-weighted MRI (DWI), or dynamic contrast-enhanced MRI (DCE-MRI), are becoming more prominent for imaging of PCa. The glucose metabolism imaging tracer 18	Ǧfuorodeogucose ȋ	
Ȍ as son promise or Ȁ imaging o numerous fast growing cancer types, but its utility for (re)staging of PCa is very limited (11, 12). Choline-based tracers imaging lipid metabolism, e.g. 11C- and 18F-choline, are more useful for staging of PCa, and are currently used in the clinic for assessment of distant metastases in high-risk PCa patients (13). However choline-based PET/CT has limited sensitivity for initial staging, lymph node detection, and restaging of patients with biochemical recurrence (14-16). 
racers targeting aǦspecific iomarers ave son promise or detection o aǤ Gastrin-releasing peptide receptor (GRPR)-targeted tracers are promising for the detection of primary tumors, and could be useful tools for initial staging (17-20). The 
recent deveoped prostateǦspecific memrane antigen ȋȌǦtargeted tracers are 
502161-L-sub01-bw-Chatalic
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1.1
increasingly applied in the clinic for detection of PCa, and we foresee that these tracers will be useful tools for staging and follow up of (primary and) advanced PCa in the near future. Besides the utility of imaging for staging and follow-up of PCa, imaging techniques can be used for surgical guidance. Fluorescence-guided surgery using multimodal tracers is currently used in the clinic using non-targeted probes. Recently, a PSMA-targeted tracer was used for probe-guided surgery, allowing guidance of surgeon during metastatic lymph node dissection (21). A PSMA-targeted multimodal 
proeǡ coming fuorescenceǦ and radiationǦguidance coud ave a significant impact for PCa patient care.
Radionuclides
Diagnostic RadionuclidesPositron emitting radionuclides are used for PET (Table 2). PET visualizes annihilation photons of 511 keV, which are emitted when a positron interacts with an electron. Gamma-emitting radionuclides are used for SPECT (Table 3), which, in contrast with PET, visualizes single photons.Positron emitting radionuclides with lower range in tissue provide higher spatial 
resoutionǡ and iger sensitivit is acieved it ig Ⱦ+ intensity. 18F is one of the most widely used radionuclides for PET imaging, owing to its favorable physical characteristics for PET. 64Cu is emerging as an interesting radionuclide for labeling of peptides and proteins for PET imaging, owing to its favorable physical characteristics and relatively long half-life (12.7 h). In addition, the combination of 64Cu and 67Cu provides a theranostic pair.
99mTc is the most widely radionuclide for clinical SPECT applications. 99mTc is readily available from 99Mo/99mTc generators and emits photons of 140 keV, which is ideal for most SPECT cameras. In addition, the half-life of 6 h allows visualization of tumors while limiting radiation exposure to patients.
Therapeutic Radionuclides
adionucides appied or terap are tose emitting Ƚ or Ⱦ particesǡ and uger or conversion electrons (Table 4-6). These particles travel a relatively short distance through matter and can deliver most of their energy at localized area. Alpha particles 
ave a ver ig energ and ver sort pat engt compared it Ⱦ particesǡ resuting in high linear energy transfer (LET). Alpha-emitters are considered amongst the most 
poeru terapeutic radionucidesǡ ecause te ig  o Ƚ partices causes more complex DNA double-strand breaks (DSBs).
502161-L-sub01-bw-Chatalic
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1.1
Theranostic PairsIn nuclear medicine, theranostic pairs are combinations of radionuclides that can be used for imaging and therapy. True theranostic pairs consist of different radionuclides of the same element, while matched pairs consist of radionuclides of different elements that can be complexed by the same chelator (Table 7).
TABLe 7. Examples of theranostic pairs in nuclear medicine.
True pairs Matched pairs
Diagnostic 
radionuclide
Therapeutic 
radionuclide
Diagnostic 
radionuclide
Therapeutic 
radionuclide
44Sc 47Sc 68Ga/111In 177Lu/90Y/213Bi
64Cu 67Cu 99mTc 186/188Re
68Ga 67Ga
86Y 90Y
124I 131I
177Lu 177Lu
131I 131I
Radionuclide TherapyBesides their application for molecular imaging, radionuclides can also be used for 
terapeutic appicationsǤ nteraction o ȽǦparticesǡ ȾǦparticesǡ uger or conversion electrons with cells can induce several types of DNA damage, among which DSBs are the most genotoxic. Unrepaired DSBs can trigger cell cycle arrest, cell death (apoptosis) and chromosomal aberrations. Therefore, therapeutic radionuclides are being widely applied to destroy cancer cells. Bone-seeking radionuclides can be used for treatment of bone metastases. Tumor-targeted approaches are preferred to minimize exposure of healthy cells. For this purpose, tumor-targeting molecules are labeled with therapeutic radionuclides to selectively kill cancer cells. 
TARGeTS FoR PCA THeRANoSTiCSMolecular targets for PCa theranostics include receptors and enzymes that are overexpressed on PCa cells. GRPR and PSMA are amongst the most widely explored targets for PCa theranostics.
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Gastrin-Releasing Peptide Receptor 
Bombesin Receptor FamilyThe mammalian bombesin (BBN) receptor family consists of three types of G-protein-coupled receptors: GRPR, neuromedin B receptor (NMBR) and bombesin receptor subtype 3 (BRS-3) (24). BBN is an amphibian 14-amino acid peptide, which was isolated from frog skin and was named after the European frog, Bombina Bombina. Two mammalian homologs, gastrin-releasing peptide (GRP) and neuromedin B (NMB), were isolated from porcine stomach and spinal cord, respectively. GRP and its C-terminal decapeptide, Neuromedin C (NMC, GRP(18-27)), share a seven-amino acid sequence with BBN (Trp-Ala-Val-Gly-His-Leu-Met-NH2), accounting for a similar biological activity (25, 26ȌǤ 
s eiit ig afinit or 
 and ǡ ut o afinit 
or Ǥ n contrastǡ s eiit ig afinit or ǡ ut o afinit or 
 and NMC. GRP and NMB elicit a broad spectrum of biological/pharmacological responses in the gastrointestinal tract and central nervous system. GRP is involved in smooth muscle contraction and GI motility, release of GI hormones and neurotransmitters, and secretion and/or hormone release from numerous endocrine organs. In addition, BBN receptors are involved in tumor differentiation and growth. The biology of the BBN receptors was described in detail in a review of Jensen et al. (24)
Receptor ExpressionBBN receptors are used as targets for imaging and therapy, owing to their overexpression on numerous malignancies, including small cell lung cancer, non-small cell lung cancer, pancreatic cancer, PCa, head/neck squamous cell cancers, glioblastomas, neuroblastomas, breast cancer, intestinal carcinoids and bronchial carcinoids (27). In PCa, GRPR expression was found in 45-100% of tested samples (28). In normal tissues, high levels of GRPR mRNAs were found in the pancreas and low levels were found in stomach, adrenal cortex and brain (29).
ǦϐPSMA, also referred to as glutamate carbopeptidase II (GPCII), NǦacetǦȽǦined acidic dipeptidase I (NAALADase I), or folate hydrolase 1 (FOLH1), is a type II transmembrane glycoprotein exhibiting glutamate carboxypeptidase and folate hydrolase enzymatic activity. PSMA is a 750-amino-acid protein with 3 domains: a 19-amino-acid intracellular domain, a 24-amino-acid transmembrane domain, and a 707-amino-acid extracellular domain (30). PSMA is an interesting target for molecular imaging of PCa, as it is overexpressed in 90-100% of local PCa lesions, as well as in cancerous lymph nodes, and bone metastases (31, 32), with some reports indicating PSMA expression levels are further enhanced in high-grade, metastatic, and castration-resistant PCa (31, 33, 34). PSMA is also expressed in other tissues including normal prostate epithelium, small intestine, renal tubular cells, and salivary glands, but the expression in these organs is 100-1,000 fold less than in PCa (35).
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1.1
other TargetsOther targets have been envisaged for imaging and therapy of PCa, which are beyond the scope of this thesis. These include, but are not limited to, the prostate stem cell antigen (PSCA), the androgen receptor (AR), the CXC chemokine receptor 4 (CXCR4), and neuropeptide Y.
GRPR-TARGeTeD iMAGiNG AND RADioNUCLiDe THeRAPYGRPR-mediated imaging strategies have been described in detail in a review of Sancho et al. (27). In addition, the relevance of targeting GRPR in urological cancers was highlighted in a recent review of Mansi et al. (36). Both GRPR agonists and antagonists have been used for targeted imaging and therapy. The targeted imaging and radionuclide therapy approach with radiolabelled GRPR-targeting peptides is depicted in Figure 2.
GRPR AgonistsSeveral GRPR agonists derived from BBN and GRP have been developed for imaging and therapy of PCa (Table 8). The BBN(7-14) sequence was the most widely explored motif, as radiolabeled tracers containing the BBN(7-14) sequence showed high 
A B
Nucleus Nucleus
No cell signalling
GRPR
Radiolabeled GRPR agonist Radiolabeled GRPR antagonist
FiGURe 2: Targeted imaging and radionuclide therapy with radiolabeled bombesin analogues. (a) Radiolabeled GRPR agonists internalize after binding their receptor on the tumor cell and can be visualized (diagnostic radionuclides) or can trigger cell destruction (therapeutic radionuclides). (b) Radiolabeled GRPR antagonists are not internalized, but can be visualized or can trigger cell destruction from the cell membrane. Adapted from (36). 
502161-L-sub01-bw-Chatalic
Chapter 1.1
26
afinit or te 
Ǥ e first precinica studies it ȋ͹ǦͳͶȌ anaogs ave used 99mTc as a radionuclide and have shown the effects of chelator, linker, and glycosylation 
on iodistriution profies o te tracers in mice ȋ37-42). Recently, 99mTc-labeled Demobesin-4 (N4-Pro-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Nle-NH2 peptide conjugate, N4 = 6-(p-carboxyl)-1,4,8,11-tetraazaundecane) was tested in patients. Primary PCa could be detected using 99mTc-Demobesin-4, whereas imaging of refractory PCa was suboptimal (18). Recent studies have used DOTA- and NOTA-derived chelators to label BBN(7-14) with trivalent metal cations, in particular for therapeutic applications. Among those analogs, DOTA-8-AOC-BBN(7-14) (43, 44), DOTA-PESIN (45) and AMBA (46) appeared promising for imaging and therapy. However, in clinical studies, GRPR agonists were shown to induce severe side effects (47, 48).
TABLe 8. Examples of GRPR agonists used in preclinical in vivo imaging and therapy studies. Adapated from (27).
Name Structure RadionuclidesBombesin (BBN) Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 125I, 131I, 18F[Tyr4]BBN Pyr-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 125I[Lys3]BBN Pyr-Gln-Lys-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 99mTc, 18F, 64Cu[Pro1,Tyr4]BBN Pro-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 99mTc, 111In, 64Cu, 86Y
ȏɂǦs3,Tyr4]BBN Pyr-Gln-ɂǦsǦrǦGly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 111In[Pro1,Tyr4,Nle14]BBN Pro-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Nle-NH2 99mTcLitorin [pGlu6,Phe13]BBN(6-14) pGlu-Gln-Trp-Ala-Val-Gly-His-Phe-MetNH2 99mTc[DPhe6,Leu13Ȳe14]BBN(6-14) DPhe-Gln-Trp-Ala-Val-Gly-HisǦeuȲǦeǦNH2[DTyr6ǡ Ⱦa11,Thi13,Nle14]BBN(6-14) DTyr-Gln-Trp-Ala-ValǦȾaǦHis-Thi-Nle-NH2 111In, 68Ga, 177LuBBN(2-14) Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 99mTc, 90Y, 177Lu[Lys14]BBN(2-14) Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Lys-NH2 99mTc
502161-L-sub01-bw-Chatalic

ĊēĊėĆđ ēęėĔĉĚĈęĎĔē
27
1.1
BBN(7-14) Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 99mTc, 111In, 188Re, 186Re, 64Cu, 68Ga, 177Lu, 213Bi 149Pm, 153Sm, 18F[Nle14]BBN(7-14) Gln-Trp-Ala-Val-Gly-His-Leu-Nle-NH2 99mTc
ȏȾa11,Phe13,Nle14]BBN(7-14) Gln-Trp-Ala-ValǦȾaǦHis-Phe-Nle-NH2 111InGRP (13-27) H-Lys-Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 177Lu, 111InGRP (14-27) H-Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 111InGRP (17-27) H-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 111InGRP(18-27) H-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 111In, 99mTc[DAla24]GRP(18-27) H-Gly-Asn-His-Trp-Ala-Val-DAla-His-Leu-Met-NH2 99mTc[DAla24,Nle27]GRP(18-27) H-Gly-Asn-His-Trp-Ala-Val-DAla-His-Leu-Nle-NH2 99mTc[DAla24,Leu27]GRP(18-27) H-Gly-Asn-His-Trp-Ala-Val-DAla-His-Leu-Leu-NH2 99mTc
ȏȾa24]GRP(18-27) H-Gly-Asn-His-Trp-Ala-ValǦȾaǦHis-Leu-Met-NH2 99mTc[Sar24]GRP(18-27) H-Gly-Asn-His-Trp-Ala-Val-Sar-His-Leu-Met-NH2 99mTc
GRPR AntagonistsParticular attention has been drawn to the development of GRPR antagonists after reports have described that GRPR antagonists show higher tumor uptake and lower accumulation in GRPR-positive nontarget tissues than GRPR agonists (49, 50). Several 

 antagonists ave een deveoped  te modification o Ǧtermina residues o GRPR agonists (Table 9), amongst which the statin-based BBN analog JMV594 (H-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2) (51) is the most widely applied for imaging and therapy. 68Ga-labeled GRPR-antagonists derived from the JMV594 sequence were developed for PET imaging, showing good targeting properties in preclinical studies (50, 52-54) and recently also in clinical trials (55, 56). 68Ga-labeled GRPR antagonist BAY86-7548 (68Ga-DOTA-4-amino-1-carboxymethylpiperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2Ȍ as son a specificitǡ sensitivitǡ and accurac o ͺͺΨǡ 81%, and 83%, respectively, for the detection of primary PCa. However, this tracer was suboptimal for the detection of lymph node metastases. 
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Recently, 18F- and 64Cu-labeled GRPR antagonists based on the J594 peptide sequence were also tested in clinical studies, showing no adverse events and clear delineation of primary PCa lesions during imaging (17, 19, 20).
TABLe 9. Examples of GRPR antagonists used in preclinical in vivo imaging and therapy studies. Adapated from (27).
Name Structure Radionuclides[DPhe6,Leu-NHEt13,des-Met14]BBN(6-13) DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-NHEt 99mTc, 18F[DPhe6,Sta13,Leu14]BBN(6-14) DPhe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 99mTc, 111In, 68Ga, 18F, 177Lu, 64Cu, 90Y[Cha13]BBN(7-14) Gln-Trp-Ala-Val-Gly-His-Cha-Met-NH2 99mTc[Cha13,Nle14]BBN(7-14) Gln-Trp-Ala-Val-Gly-His-Cha-Nle-NH2 99mTc, 64Cu[DPhe6ǡ euɗȋǦ2-(CH2)2-CH313,des-Met14]BBN(6-14) DPhe-Gln-Trp-Ala-Val-Gly-HisǦeuɗȋǦCH2-(CH2)2-CH3 111In, 68Ga[DPhe6,Leu-OCH313,des-Met14]BBN(6-14) DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-OCH3 111In
[DPhe6,Leu-NHCH2CH2CH313,des-Met14]BBN(6-14) DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-NH-CH2-CH2-CH3 111Indes-Met indicates the deletion of the BBN 14th amino acid, Methionine. 
 
PSMA-TARGeTeD iMAGiNG AND RADioNUCLiDe THeRAPY
AntibodiesThe murine anti-PSMA antibody 7E11, targeting an intracellular epitope of PSMA, 
as used to deveop te first cinica tracer targeting  or imaging o aǣ 111In-capromab (ProstaScint®). 111In-capromab was indicated for detection of soft-tissue metastases and recurrence of PCa (57), but was not reliable for detection of primary PCa and bone metastases (58, 59). The poor diagnostic accuracy of 111In-capromab has been associated with the intracellular targeting of 7E11, and led to the development of next-generation anti-PSMA monoclonal antibodies (mAb), binding to the extracellular domain of PSMA, e.g. J591. 177Lu- and 90Y-radiolabeled J591 have shown promising 
terapeutic eficac and moderate toicit in patients ȋ60-62). Furthermore, J591 was superior to 111In-capromab to detect soft-tissue and bony metastases (60, 63). However, monoclonal antibodies exhibit slow clearance from nontarget tissues, and are therefore not considered ideal vectors for targeted molecular imaging and radionuclide therapy.
502161-L-sub01-bw-Chatalic

ĊēĊėĆđ ēęėĔĉĚĈęĎĔē
29
1.1
Antibody FragmentsTo circumvent the long circulating time of antibodies, smaller variants of mAb have been engineered, such as antigen-binding fragments (Fab) and F(ab’)2 (64), minibodies, diabodies, and Nanobodies (65-67). These antibody fragments have shown faster 
target recognition and more rapid ood cearanceǡ ut te aso soed unspecific accumulation in liver and kidneys. 
Small-Molecule inhibitorsSmall-molecule inhibitors, binding the enzymatic site in the extracellular domain of PSMA, are increasingly used for imaging and therapy of PCa. These small-molecule PSMA inhibitors consist of zinc-binding compounds attached to a glutamate moiety and include phosphonate-, phosphate-, phosphoramidate-, thiol-, and urea-based inhibitors, which have been discussed in an extensive review by Mease et al. (68). Glu-NH-CO-NH-Lys-(Ahx)-68Ga-HBED-CC, also known as 68Ga-PSMA-11 or 68Ga-PSMA-HBED-CC (Figure 3), is currently the most widely used small-molecule inhibitor in the clinic for imaging of PCa (69, 70). More recently, a promising 18F-labeled PSMA inhibitor, 18F-DCFPyL, was introduced in the clinic as well (71).
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FiGURe 3. Chemical structures of small-molecule PSMA inhibitors PSMA-11, PSMA-617, and PSMA I&T.
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For therapy, the small-molecule PSMA inhibitor [131I]MIP-1095 (72) has shown reduction of bone pain in 85% of PCa patients with bone pain and mild hematological toxicity only. Recently, two PSMA tracers with DOTA- and DOTAGA chelators have been developed, namely PSMA-617 and PSMA I&T (Figure 3 and 4), allowing labeling with both diagnostic and therapeutic radionuclides (73-76). Despite the encouraging preliminary therapeutic results of 177Lu-labeled PSMA-617 
and  Ƭǡ te ig and specific uptae in idnes and saivar gands represent a major disadvantage of small-molecule PSMA inhibitors for therapy. Research aiming to limit radiation-induced damage in those healthy organs is thus warranted. 
 
FiGURe 4. PET imaging of small-molecule PSMA inhibitor 68Ga-PSMA I&T in a preclinical model of PCa (A) and in a PCa patient with liver, lymph node, and bone metastases (B); adapted from (75).
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1.1
oUTLiNe oF THiS THeSiSPCa is one of the most frequently diagnosed cancers in men worldwide. Early detection of PCa is essential, as treatment options for advanced disseminated PCa are limited. A single tool combining diagnosis and therapy in a “theranostic” approach could effectively contribute to a more personalized management of PCa patients, whereby imaging can guide the choice of the most suitable therapeutic option for each patient.The studies described in this thesis focus on the development of theranostic approaches for PCa. The ϐ of this thesis presents the theranostic concept in nuclear medicine. Chapter 1.1 provides a general introduction to PCa, tumor targeting, and the basic principles of molecular imaging and radionuclide therapy. Strategies to improve applications of radiolabeled peptides for imaging and therapy are discussed in Chapter 1.2.The development of theranostic approaches for PCa targeting GRPR is described in the second section. First the development and comparison of 18F- and 68Ga-labeled GRPR antagonist JMV5132 and JMV4168 for PET/CT imaging of PCa is described (Chapter 2.1). In this study, a novel method was used for radiolabeling of peptides with Al18F in a one-step procedure. The same GRPR antagonist was tested in a theranostic approach for PCa (Chapter 2.2). In this chapter an innovative method was investigated to stabilize the radiolabeled peptide using in vivo enzyme inhibition.The third section focuses on PSMA targeting. A novel 111In-labeled anti-PSMA Nanobody was developed for SPECT/CT imaging of PCa (Chapter 3.1). This Nanobody 
as engineered it a Ǧtermina csteine or siteǦspecific couping o a ceatorǤ n 
Chapter 3.2, the application of a PSMA small-molecule inhibitor for imaging and radionuclide therapy of PCa is described. In this chapter we investigated a strategy 
to decrease rena tracer uptaeǤ 	inaǡ Ƚ radionucide terap o a it te antiǦPSMA Nanobody and the PSMA small-molecule inhibitor was explored to further 
improve terapeutic eficac (Chapter 3.3).
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Radiopeptides for 
imaging and Therapy: 
A Radiant Future
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ABSTRACTRadiopeptides are powerful tools for diagnostic imaging and radionuclide therapy 
of various diseases. Since the introduction of the first radiopeptide into the clinical setting to diagnose neuroendocrine tumors about 25 y ago, many advances have 
been made in the field. This short review highlights novel strategies to improve the application of radiopeptides for imaging and therapy. 
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1.2
iNTRoDUCTioN
adiopeptides targeting somatostatin receptor ȋSSTȌ have contributed significantl 
to patient care. The SST agonist octreotide and modifications thereof ȋȏTr3]octreotide [TOC], [Tyr3, Thr8]octreotide [TATE], and [1-Nal3]octreotide [NOC]) are widely used in routine clinical practice for diagnosis of neuroendocrine tumors (NETs). 111In-diethylenetriaminepentaacetic acid-octreotide (OctreoScan; Mallinckrodt Inc.) was 
the first registered radiopeptideǡ and it has become the gold standard for diagnosis and staging of SSTR-positive tumors using SPECT and SPECT/CT. After the successful application of 111In-octreotide for imaging of NETs in the clinic, somatostatin analogs 
radiolabeled with ȾǦemitting isotopes ȋi.e. 177Lu-DOTATATE and 90Y-DOTATOC) were introduced as treatment. Peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTATATE and 90Y-DOTATOC has given impressive results thus far.
The success of radiolabeled somatostatin analogs inspired the scientific communit to develop radiopeptides targeting different receptor families, including gastrin-releasing peptide (GRP), cholecystokinin-2/gastrin (CCK-2/CCK-B), glucagonlike 
peptideǦͳ ȋ
ǦͳȌǡ Ƚ
ɋ
Ⱦ3-integrin, neurokinin-1 (NK-1), melanocyte-stimulating 
Breast 
Somatostatin, bombesin, RGD, 
neurotensin, NPY, LHRH, substance P, 
CXCR4 
Prostate 
Bombesin, NPY, LHRH, CXCR4 
Neuroendocrine  
Somatostatin 
Thyroid 
CCK/gastrin, substance P
Brain 
Somatostatin, RGD, substance  P
Lung 
Somatostatin, bombesin, CCK/
gastrin, RGD,  CXCR4 
Skin 
-MSH, RGD 
Pancreas 
Exendin 
Gastrointestinal 
Exendin, CCK/gastrin, bombesin 
Lymphatic system 
Somatostatin, CXCR4 
Ovarian/endometrial 
CCK/gastrin, RGD, LHRH, CXCR4 
Imaging radionuclides 
- SPECT: 99mTc, 111In, 67Ga, 123I  
- PET: 18F, 68Ga, 64Cu, 86Y, 124I 
Therapeutic radionuclides 
- -emitters: 177Lu, 90Y, 67Cu 
- -emitters: 213Bi, 225Ac 
FiGURe 1. Examples of radiopeptide families, radionuclides and their applications for imaging of tumors. RGD = Arginylglycylaspartic acid.
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hormone (MSH), neuropeptide Y (NPY), luteinizing hormone-releasing hormone (LHRH) and chemokine receptor-4 (CXCR4) (1). Examples of radiopeptide families and their applications for tumor imaging and therapy are shown in Figure 1. Radiopeptides have established themselves as important agents for imaging, but also for PRRT. For medical imaging, peptides can be radiolabelled with radionuclides such as 99mTc, 111In, 67Ga, or 123I for SPECT and 18F, 68Ga, 64Cu, 86Y, or 124I for PET. For 
therapeutic purposesǡ peptides can be labeled with ȾǦemitters such as 177Lu, 90Y or 67Cu, 
and ȽǦemitters such as 213Bi or 225Ac. Current applications of clinical radiopeptides for imaging and therapy have been described in detail by Ambrosini et al. (2). Approaches intending to improve the performance of radiopeptides for imaging and therapy and thereby widen their scope of application are discussed below.
NoVeL PeRSPeCTiVeS FoR iMAGiNGIntensive research efforts have improved pharmacokinetics and in vivo stability of radiopeptides, as well as boosting image quality by identifying radionuclides with more suitable nuclear physical properties or by combining nuclear imaging modalities with complementary modalities. Some examples of novel approaches for radionuclide therapy are shown in Figure 2.
FiGURe 2. (A) PET/CT (top) of insulinoma patient showing focal 68Ga-DOTA-exendin-4 uptake in distal pancreatic tail (consistent with surgically removed insulinoma) that was not shown by SPECT/CT (bottom) with 111In-DOTA-exendin-4. (B) SPECT/CT images of mice with GRPR-expressing PC-3 tumors(arrows) 4 h after injection of bombesin analog 111In-DOTA-PEG2-DTrǦ
lnǦTrpǦlaǦalǦȾlaǦisǦheǦleǦ2 without 
ȋleftȌ or with ȋrightȌ coinection of neutral endopeptidase inhibitor phosphoramidon ȋ͵ͲͲ ɊgȌ
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Change of Paradigm Using Receptor Antagonists
n important eeǦopener in the field of radiopeptides has been the recent introduction of SSTR antagonists, which showed more favorable pharmacokinetics and better tumor visualization than agonists did, despite their poor internalization rate. In a clinical study, the SSTR antagonist 111In-DOTA-BASS (111In-DOTA-pNO2-Phe-c(DCys-Tyr-DTrp-Lys-Thr-Cys)DTyrNH2) resulted in higher tumor uptake and better visualization of metastatic NETs than did the SSTR agonist 111In- diethylenetriaminepentaacetic acid-octreotide (3).Subsequently, radiolabeled GRPR-targeted antagonists also entered the arena, 
showing a more favorable pharmacoinetic profile and fewer side effects than agonists. GRPR-targeted antagonists have shown high potential in early clinical trials for prostate cancer imaging (4).
improving Pharmacokinetics and in Vivo StabilityMany efforts have been made to increase radiopeptide in vivo stability by introducing 
structural modificationsǡ although such modifications can cause undesired changes 
in pharmacoinetics or impaired receptor affinit.  remarable advance in this area is the discovery of the in vivo enzyme inhibition concept, in which radiopeptides are administered together with an enzyme inhibitor as a safeguard against enzymatic degradation. It has recently been shown that coinjection of a neutral endopeptidase inhibitor, such as phosphoramidon (PA), can stabilize radiolabeled bombesin, minigastrin, and somatostatin analogs in vivo, leading to enhanced tumor uptake and improved tumor visualization (5Ȍ. e believe that this strateg will have a significant impact on patient care, as it may enhance the diagnostic sensitivity and therapeutic 
efficac of radiopeptides. 	or that purposeǡ a neutral endopeptidase inhibitor alread applied in patients (e.g. thiorphan) is the preferred choice. 
68Ga Versus 18FRecently, imaging quality has been boosted by selecting radionuclides with more suitable nuclear physical properties. For SPECT imaging, 99mTc is the radioisotope of choice. However, recent developments in PET/CT and PET/MR technologies are 
steering the field towards positron emitters. 
68Ga-radiopeptides are useful tools for PET/CT or PET/MR imaging of diseases, as 68Ga can be obtained in-house from a 68Ge/68Ga generator. The introduction of 68Ga-labeled DOTA-conjugated somatostatin analogs (TOC, TATE, NOC) into the clinic, enabling PET/CT imaging of NETs, is an important advance in somatostatin-based imaging. The superior performance of imaging techniques using these tracers for detection of NET lesions was described by Ambrosini et al. (2). 
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Recently, 68Ga-labeled exendin-4 has been introduced in the clinic for the detection of GLP-1 receptor-positive insulinomas (6). 68Ga-DOTA-exendin-4 PET/CT is preferred over 111In-DOTA-exendin-4 SPECT/CT because of the higher spatial resolution and 
better uantification options obtained with TȀT cameras.
18F-labeled peptides have some advantages over 68Ga-labeled peptides, such as a longer half-life. Moreover, physical properties of 18F are more favorable for PET imaging than those of 68Ga. Indeed, an 18F-labeled GRPR-antagonist, BAY 864367 (3-cyano-4-18	ǦfluorobenolǦlaȋS3H)-Ala(SO3H)-Ava-Gln-Trp-Ala-Val-NMeGly-His-Sta-Leu-NH2), has recently been implemented in the clinical setting (4). A drawback yet to be overcome with 18F-labeled peptides is their higher lipophilicity, which gives rise to less favorable pharmacokinetics. An interesting approach consists of labeling peptides with Al18F via radiometalation chemistry. Several peptides have been labeled with Al18F, such as octreotide, E[c(RGDyK)]2, exendin-4, the bombesin analog NOTA-8-Aoc-BBN(7-14)NH2ǡ and the 
Ǧantagonist Ͷͳ͸ͺ ȋTǦȾlaǦȾlaǦͷͻͶȌ (7, 8). The development of a kit-based method for labeling peptides with 18F would make application of 18F-labeled peptides possible in a wider range of hospitals.
Nuclear/optical Multimodality imagingNuclear imaging technologies available in the clinic (SPECT/CT, PET/CT, and PET/
Ȍ are superior to an other clinical imaging modalit in terms of specificit and sensitivity. However, optical imaging offers interesting applications as well and could complement the nuclear medicine uses (9). An important development 
in the field of radiopeptides has been the introduction of hbrid derivativesǡ 
containing both a fluorescent and radioactive labelǡ as these have significant 
implications in the field of imageǦguide surger. Several hbrid radiopeptides have 
been developedǡ including agents targeting SSTǡ 
ǡ interleuinǦͳͳ receptorǦȽǡ 
Ƚ
ɋ
Ⱦ3-integrin, matrix metalloproteinase, CXCR4, and GLP-1R (10-12). Because of 
the sie and lipophilicit of common fluorescent desǡ the main challenge lies in the optimization the chemical structures of hybrid tracers to preserve receptor 
affinit and biodistribution patterns while maimiing the range of tissue penetration. 
NoVeL PeRSPeCTiVeS FoR THeRAPYNovel strategies might improve the outcome of PRRT. These include the improvement of pharmacokinetics and in vivo stability, the combination of radionuclides, the 
combination of T with chemotherapǡ the use of ȽǦemitting radionuclidesǡ and the use of novel methods to predict therapy response. Recent developments to increase the therapeutic effects of PRRT have been described in detail by Bison et al. (13). Some examples of novel approaches for radionuclide therapy are shown in Figure 3.
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improving Pharmacokinetics and in Vivo StabilityThe success of PRRT would presumably be improved by enhancing the dose delivered to the tumor or limiting the dose delivered to normal healthy tissues. The use of SSTR antagonists has enhanced tumor targeting and prolonged tumor retention compared to SSTR agonists, resulting in an enhanced tumor radiation dose during PRRT. In a clinical study, the SSTR antagonist 177Lu-DOTA-JR11 exhibited higher tumor uptake 
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FiGURe 3. (A) Total body images after each cycle of PRRT with 7.4 GBq 177Lu-octreotate in combination with low-dose capecitabine as chemosensitizer in patient with liver metastases of gastrinoma. Decreasing 
uptae in the liver metastases indicates and preludes tumor responseǡ which was later confirmed with T. (B) Course of tumor markers chromogranin-A (CgA) and gastrin.
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and a longer intratumoral residence time than the SSTR agonist 177Lu-DOTATATE (14). This study was performed on only a few patients, and more systematic clinical studies are needed now to fully evaluate the role of 177Lu-DOTA-JR11 for therapy of NETs.
atients with advanced prostate cancer could also benefit from Tǡ as treatment options for this patient group are limited. 177Lu-GRPR antagonists have not been tested in clinical studies thus far, even though they have shown promising results in preclinical studies (15). Radionuclide therapy using PSMA-targeted tracers has been more widely explored, as PSMA expression has been validated in advanced prostate cancer in several reports. Extensive comparative studies showing target expression of PSMA and GRPR in advanced prostate cancer would guide the choice of therapeutic options for those patients.
Combination Therapies
n the search for increased therapeutic efficac of Tǡ therapeutic radionuclides with different physical characteristics have been combined to target a wider range of tumor lesions. 90Y and 177u ȾǦemitting isotopes suitable for treatment of large and small tumors have been combined in simultaneous or sequential treatment. A recent retrospective study (16Ȍ described the benefits of the combination of 90Y-DOTATOC and 177Lu-DOTATOC over treatment with either radiopeptide alone, with increased survival after the combination treatment. However, patient selection bias cannot 
be ecludedǢ thereforeǡ prospectiveǡ randomied trials are needed before firm conclusions can be drawn.PRRT could also be combined with other therapies to increase tumor response. Chemotherapeutics can sensitize tumor cells to PRRT by modulating DNA damage and repair mechanisms, apoptosis, cell proliferation, cell-cycle synchronization and tumor cell oxygenation. However, careful design of such combination studies is needed, as chemotherapeutics could also alter receptor expression and tumor vascularization. For instance, the DNA alkylating drug temozolomide increased tumor perfusion in a preclinical study (13). Clinical studies combining PRRT using 177Lu-DOTATATE with several chemotherapeutics have been reported. Capecitabine and temozolomide both increased the response rate of 177Lu-DOTATATE in comparison with 177Lu-DOTATATE alone (17). A recent proof-of-concept study described the combination of PRRT with everolimus (18). It was shown that everolimus could be safely combined with 177Lu-octreotate to treat low-grade NETs.
Introduction of Powerful α-Emitters
n important development in the field of radionuclide therap has been the 
introduction of ȽǦparticleǦemitting radionuclides.  firstǦinǦhuman stud showed 213Bi-DOTATOC can eradicate neuroendocrine liver metastases pretreated with 
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90Y/177Lu-DOTATOC. Only moderate acute and midterm hematologic and renal toxicity was observed at effective therapeutic doses (19). Nonoperable and critically located 
gliomas have been treated with ȽǦtargeted therapǡ b local inection of 213Bi-DOTA-substance P, providing local irradiation of the tumor. The short tissue range of 213Bi prevents damage to adjacent brain areas. Up till now, this therapy has proven to be feasible and safe, with only mild adverse effects observed (20). Despite the promising preliminary results obtained with 213Bi-DOTATOC and 213Bi-substance P in patients, the short half-life of 213Bi (45.6 min) and the costs and limited availability of 225Ac/213Bi generators limit clinical use. The recently described accelerator-driven production of 225c ma allow it to be produced in uantities sufficient to suppl centers for clinical trials and make the treatment available to a wider range of centers (21).
innovative Methods as Predictors of Therapeutic ResponseThere is a clear need for personalization and standardization of PRRT to optimize 
efficac and minimie longǦterm toicitǡ as emphasied in a recent review of odei et al. (22). They recommend collecting data on several parameters to construct a patient-
specific treatment planǡ taing into account various patientǦspecific characteristics to predict the probability of response and predisposition to toxicity. Dosimetry can be used as a predictor of therapy response and toxicity; a relationship between tumor-absorbed dose and response has already been demonstrated for 90Y-DOTATOC (23). Markers of DNA-damage and repair, such as phosphorylated variant H2A histone 
famil member  ȋɀǦʹȌǡ ma predict tumor and normalǦorgan radiosensitivities. 
 recent paper described the use of a ɀǦʹǦfoci assa as a predictor of normalǦtissue toxicity after PRRT (24). Genetic components can also predict disease stage and response to therapy (25). 
CoNCLUSioNDerived from natural peptide ligands, radiopeptides can be tailored and optimized to provide personalized treatment for several types of diseases. In recent years, several methods have been developed to optimize radiopeptides for imaging and therapy; these efforts and achievements may bridge the gap between the exciting promises of radiopeptides and their implementation in the clinic. Today, complex multimodal ligands are being designed for theranostic applications, whereas simple radiopeptides combine all key ingredients for effective theranostic applications, including easy 
manufacturingǡ fast clearanceǡ low immunogenicitǡ and efficient targeting. e believe that the recent advances described in this article may lead the way to a radiant future 
for radiopeptides in the field of theranostics.
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ABSTRACTGastrin-releasing peptide receptor (GRPR) is overexpressed in human prostate cancer and is being used as a target for molecular imaging. In this study, we report on the direct comparison of 3 novel GRPR-targeted radiolabeled tracers: Al18F-JMV5132, 68Ga-JMV5132, and 68
aǦͶͳ͸ͺ ȋͷͳ͵ʹ is ǦǦȾlaǦȾlaǦȏǦD-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2Ȑǡ Ͷͳ͸ͺ is TǦȾlaǦȾlaǦȏǦD-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2], and NODA-MPAA is 2-[4-(carboxymethyl)-7-{[4-(carboxymethyl) phenyl]methyl}-1,4,7-triazacyclononan-1-yl]acetic acid). 
MethodsThe GRPR antagonist JMV594 (H-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2) was conjugated to NODA-MPAA for labeling with Al18F. JMV5132 was radiolabeled with 68Ga and 18F, and JMV4168 was labeled with 68Ga for comparison. The inhibitory concentration of 50% values for binding GRPR of JMV4168, JMV5132, natGa-JMV4168 and natGa-JMV5132 were determined in a competition-binding assay using GRPR-overexpressing PC-3 tumors. The tumor-targeting characteristics of the compounds were assessed in mice bearing subcutaneous PC-3 xenografts. Small animal PET/CT images were acquired, and tracer biodistribution was determined by ex vivo measurements. 
ResultsJMV5132 was labeled with 18F in a novel 1-pot, 1-step procedure within 20 
minǡ without need for further purification and resulting in a specific activit of 35 MBq/nmol. Inhibitory concentration of 50% values (in nM) for GRPR binding of JMV5132, JMV4168, natGa-JMV5132, natGa-JMV4168 and AlnatF-JMV5132 were 6.8 (95% 
confidence intervals ȏsȐǡ Ͷ.͸ǦͳͲ.ͲȌǡ ͳ͵.ʹ ȋͻͷΨ sǡ ͷ.ͻǦʹͻ.͵Ȍǡ ͵.Ͳ ȋͻͷΨ sǡ ͳ.ͷǦ6.0), 3.2 (95% CIs, 1.8-5.9) and 10.0 (95% CIs, 6.3-16.0), respectively. In mice with subcutaneous PC-3 xenografts, all tracers cleared rapidly from the blood, exclusively via the kidneys for 68Ga-JMV4168 and partially hepatobiliary for 68Ga-JMV5132 and Al18F-JMV5132. Two hours after injection, the uptake of 68Ga-JMV4168, 68Ga-JMV5132 and Al18F-JMV5132 in PC-3 tumors was 5.96 ± 1.39, 5.24 ± 0.29, 5.30 ± 0.98 
ȋpercentage inected dose per gramȌǡ respectivel. 
 specificit was confirmed 
b significantl reduced tumor uptae of the ͵ tracers after coinection of a ͳͲͲǦfold excess of unlabeled JMV4168 or JMV5132. Small animal PET/CT clearly visualized PC-3 tumors, with the highest resolution observed for Al18F-JMV5132. 
Conclusion
ͷͳ͵ʹ could be rapidl and efficientl labeled with 18F. Al18F-JMV5132, 68Ga-JMV5132, and 68
aǦͶͳ͸ͺ all showed comparable high and specific accumulation in GRPR-positive PC-3 tumors. These new PET tracers are promising candidates for future clinical translation.
502161-L-sub01-bw-Chatalic
18	ǦĆćĊđĊĉ 
 ēęĆČĔēĎĘę
55
2.1
iNTRoDUCTioNProstate cancer (PCa) is the most frequently diagnosed cancer and the second leading cause of cancer death among men in the United States (1). There is a strong need for improved imaging techniques that provide accurate staging and monitoring of this disease, particularly at early stages. Conventional diagnostic techniques, such as ultrasound-guided biopsy, are limited by high false-negative rates (2). Emerging functional imaging techniques, including diffusion-weighted MR imaging, dynamic contrast-enhanced MR imaging, and PET, have shown improved sensitivity and staging accuracy for detecting primary prostate tumors and metastatic lymph nodes (3). Several PET radiotracers have shown promising clinical utility, such as the metabolic agents, 18F-FDG, 11C-/18F-choline, and 11C-/18F-acetate for the assessment of distant metastasis and 18F-NaF for the detection of bone metastasis (4). However, their application is most valuable in late-stage, recurrent, or metastatic PCa. Increasing 
efforts are being made in developing T imaging agents targeting specific biomarers of PCa, such as gastrin-releasing peptide receptor (GRPR) (5Ȍ and prostateǦspecific membrane antigen (6).The GRPR, or bombesin (BBN) receptor subtype II, has been shown to be overexpressed in several human tumors, including PCa (7). Overexpression of GRPR was found in 63-100% of primary prostate tumors and over 50% of lymph and bone metastases (8, 9). The GRPR density was reported to be 26-fold higher in prostate carcinoma than prostatic hyperplasia (9). Because of the low expression in benign prostatic 
hperplasia and inflammator prostatic tissuesǡ imaging of 
 in localied a has potential advantages over choline- and acetate-based radiotracers (9, 10).A variety of radiolabeled BBN analogs have been developed for targeting GRPR-positive tumors and were evaluated in preclinical and clinical studies (5). Several recent reports have shown that GRPR antagonists show properties superior GRPR agonists, affording higher tumor uptake and lower accumulation in physiologic GRPR-positive nontarget tissues (11, 12). Moreover, GRPR agonists were shown to induce side effects in patients, mediated by virtue of their physiologic activity (13, 
14). Therefore, particular attention has been drawn to the development of GRPR antagonists for imaging and radionuclide therapy of PCa. Several GRPR antagonists 
have since been developed b the modification of Ǧterminal residues of 
 agonists, including the statin-based BBN analog, JMV594 (H-D-Phe-Gln-Trp-Ala-Val-Gly- His-Sta-Leu-NH2) (15). 
68Ga-labeled GRPR antagonists were developed for PET imaging, showing good targeting properties in preclinical studies (12, 16-18) and recently also in clinical trials (19, 20). Clinical evaluation of the 68Ga-labeled GRPR antagonist BAY86-7548 (68Ga-DOTA-4-amino-1-carboxymethylpiperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2Ȍ has shown a specificitǡ sensitivitǡ and accurac of ͺͺΨǡ ͺͳΨǡ and 83%, respectively, for the detection of primary PCa. In comparison, it was shown that 11C-choline was not able to discriminate PCa from benign prostatic hyperplasia, 
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because maimum standardied uptae values in a were not significantl different from benign prostatic hyperplasia (21Ȍ. nother stud reported a specificitǡ sensitivity and accuracy of 80%, 29%, and 71%, respectively, for the detection of PCa using 11C-choline (22).  The detection of lymph node metastases with the 68Ga-labeled GRPR antagonist was suboptimal, partially due to the suboptimal physical characteristics of 68Ga, limiting the detection of small lesions (20). Therefore, the aim of the present study was to develop an 18F-labeled GRPR antagonist for high resolution and sensitive PET imaging of primary, recurrent, and metastatic PCa and to compare the imaging properties of this tracer with those of 68Ga-labeled analogs. 18F has superior physical characteristics for PET imaging, such as a lower positron range and a higher positron yield, offering higher resolution and sensitivity (23). However, most methods for labeling peptides with 18F are laborious and require multistep procedures with moderate labeling yields. A good alternative is the Al18F labeling method (24), allowing fast and facile labeling of peptides in a 1-step procedure. 
e designed a new 
Ǧantagonist conugate ȋͷͳ͵ʹ ȏǦǦȾlaǦȾlaǦȋǦD-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2); NODA-MPAA is 2-(4-(carboxymethyl)-7-{[4-(carboxy-methyl)phenyl]methyl}-1,4,7-triazacyclononan-1-yl)acetic acid]), 
analogous to the previouslǦdescribed Ͷͳ͸ͺ ȋTǦȾlaǦȾlaǦȏǦD-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2]) (25), with a NODA-MPAA chelator for high-yield complexation of Al18F (26). Here, we report on the direct preclinical comparison of 3 novel radiolabeled tracers (Al18F-JMV5132, 68Ga-JMV4168 and 68Ga-JMV5132) for PET imaging of PCa. We determined the in vitro characteristics of the radiolabeled peptides and evaluated their tumor targeting properties in vivo in nude mice with subcutaneous human prostate tumors.
MATeRiALS AND MeTHoDS
Synthesis of JMV4168 and JMV5132JMV4168 was synthesized using Fmoc-based solid-phase peptide synthesis as described previously (25). JMV5132 was synthesized in the same manner as JMV4168 but was coupled to tert-butyl (tBu)-protected NODA-MPAA instead of tBu-protected DOTA. NODA-MPAA was prepared as previously described using NO2AtBu (Chematech, Dijon, France) (26). The chemical structures of JMV4168 and JMV5132 are shown in Figure 1.
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2.1
Radiolabeling
Concentration and purification of 18F-18F- solution in enriched water (H218ǡ  clotronȌ was purified from metal 
impurities and concentrated before use. rieflǡ a  cartridge ȋwea cationǦexchange cartridge, Waters, Sep-Pak Accell Plus CM, 130 mg) and a QMA cartridge (strong anion-exchange cartridge, Waters, Sep-Pak Waters Accell Plus QMA Plus Light, 130 mg) were prewashed with 10 mL metal-free ultrapure water (Milli-Q, Millipore). The 18F- solution (8-15 GBq) was pushed slowly through the CM cartridge connected to the QMA cartridge, followed by 6 mL wash with metal-free ultrapure water. Finally, the CM cartridge containing cationic metal impurities was disposed of and 18F- was eluted from the QMA cartridge with a small volume (150-200 µL) of saline.
Radiolabeling of JMV5132 with Al18FLabeling was performed by mixing 18F- solution (15-20 µL, 700-900 MBq), sodium acetate (NaOAc) (0.5 µL of 1 M solution, pH 4.1), Al3+ stock solution (20 nmol, 10 µl of 2 mM AlCl3.6H2O in 0.1 M NaOAc, pH 4.2), acetonitrile (67 % v/v), quenchers (2.5 µL 
of ͷͲ m methionineǡ gentisic acid and ascorbic acidȌǡ and finall ͷͳ͵ʹ ȋʹͲ nmolǡ 3.26 µL of solution [10 µg/µL] in 2 mM NaOAc pH 4.1). The reaction mixture was heated for 15 min at 105°C. To allow injection into mice, the peptide was diluted to less than 0.5 % (v/v) acetonitrile with 0.5% (w/v) bovine serum albumin (BSA), 0.5 % (w/v) polyoxyethylene (20) sorbitan monolaurate solution (polysorbate-20), and quenchers (1 mM methionine, gentisic acid and ascorbic acid) in phosphate-buffered saline (PBS), pH 7.4. Bovine serum albumin and polysorbate-20 were added to reduce binding of radiolabeled peptide to plastic disposables, whereas quenchers (methionine, gentisic acid, and ascorbic acid) were added to prevent radiolysis of radiolabeled peptides.
FiGURe 1. hemical structures of TǦȾlaǦȾlaǦȏǦD-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2] 
ȋͶͳ͸ͺȌ ȋȌ and ǦǦȾlaǦȾlaǦȏǦD-Phe-Gln-Trp-Ala-Val-Gly- His-Sta-Leu-NH2] (JMV5132) (B).
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Radiolabeling of JMV4168 and JMV5132 with 68Ga
lution and purification of 68Ga from a 68Ga/68Ge generator (IGG-100; Eckert & Ziegler Europe) was performed using the sodium chloride-based procedure described earlier (27). A volume of 375 µL of 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic 
acid ȋͳ ǡ p ͵.͸Ȍ was slowl added to ͵ͲͲ ρ of purified 68Ga eluate, followed by addition of quenchers (methionine, gentisic acid, and ascorbic acid, 1.25 mM) and peptide (2 nmol). The reaction mixture was heated for 10 min at 95°C. After reaction, 
ethlenediaminetetraacetic acid ȋͷͲ mȌ was added to a final concentration of ͷ m to complex free 68
a. 	or animal eperimentsǡ the labeled product was purified b reversed-phase high-performance liquid chromatography (RP-HPLC) using the gradient described in the “Quality Control” section and concentrated by evaporation. To allow injection into mice, the radiolabeled peptide was diluted with 0.5% (w/v) bovine serum albumin, 0.5 % (w/v) polysorbate-20, and quenchers (1 mM methionine, gentisic acid, and ascorbic acid) in PBS and neutralized with sodium carbonate (NaHCO3) buffer (1 M, pH 8.5).
Cold labeling of JMV4168 and JMV5132 with natGa and natF2 µL of a Ga(NO3)3 solution (0.2 M) was added to 10 µL of 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) (1 M, pH 3.6), followed by addition of quenchers (methionine, gentisic acid and ascorbic acid, 5 mM) and peptide (100 nmol). Reaction mixture was heated for 10 min at 95°C. Reverse-phase high performance liquid chromatography (RP-HPLC) analysis was performed as described in the section “Quality Control”, showing complete incorporation of nat
aǢ no further purification was needed.10 µL of a AlCl3 solution (0.1 M) was mixed with 5 µL NaF (1 M) and 0.5 µL sodium acetate (NaAc, 2.5 M), followed by addition of 25 µL ethanol and 10 µL JMV5132 (5 mM). Reaction mixture was heated for 15 min at 106°C. AlnatF-JMV5132 was 
purified b Ǧ.
Quality Control
Peptide synthesis
urification of ͷͳ͵ʹ was accomplished b a preparative  ȋaters elta Preparative, Waters 4000 system controller) with a C18 column (40 mm × 100 
mmǡ aters elta acǡ column Ȍ. The final product was characteried b ǦHPLC (Beckman, LC-126) on a reverse phase-18 Chromatolith Speed ROD column (50 mm × 4.6 mm, Merck, column I) and ESI/MS (Waters micromass ZQ, Waters 2695 Separation Module). 
Radiolabeling
abeling efficienc and colloid formation were assessed b instant thin laer chromatography using silica gel coated paper (Agilent Technologies) and 0.1 M ammonium acetate (NH4OAc) pH 5.5: 0.1 M ethylenediaminetetraacetic acid (1:1), or 
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2.1
1 M NH4OAc:methanol (1:3), respectively.  Radiochemical purity of labeled peptides was analyzed by RP-HPLC on an Agilent 1200 system (Agilent Technologies). A C-18 
column ȋn monolithicǡ Ͷ.͸ mm  ͳͲͲ mmǢ henomeneȌ was used at a flow rate of 
ͳ mȀmin with the following buffer sstemǣ buffer ǡ Ͳ.ͳΨ vȀv trifluoroacetic acid in 
waterǢ buffer ǡ Ͳ.ͳΨ trifluoroacetic acid in acetonitrileǢ with a gradient as followsǣ 97% buffer A (0-5 min), 97 to 76% buffer A (5-8 min), 76 to 75% buffer A (8-13 min), 75% buffer A (13-25 min). The radioactivity of the eluate was monitored using an in-
line a radiodetector ȋatest 
mbȌ. lution profiles were analed using 
inaǦstar software (version 2.18; Raytest GmbH). 
Lipophilicity
The octanolȀS partition coefficients of 68Ga-JMV4168, 68Ga-JMV5132, and Al18F-JMV5132 were determined as described previously (28).
Cell Culture and Competitive Cell Binding AssayThe human PCa cell line PC-3 was cultured in Ham’s F-12K (Kaighn’s) Medium (Life Technologies) supplemented with 10% fetal calf serum, penicillin (100 units/mL), 
and streptomcin ȋͳͲͲ ρgȀmȌ. ells were grown in tissue culture flass at ͵͹ι in a 
humidified atmosphere containing ͷΨ 2.
The binding affinities of Ͷͳ͸ͺǡ ͷͳ͵ʹǡ natGa-JMV4168, natGa-JMV5132, and AlnatF-JMV5132 towards the GRPR were determined in a competitive binding assay using frozen cryostat sections (10-µm thick) of PC-3 xenografts and [125I-Tyr4]-BBN as a tracer. Tyr4-BBN (Sigma Aldrich) was iodinated as described earlier (29). Tissue sections were preincubated for 5 min in ice-cold binding buffer (5 mM MgCl2, 167 mM tris(hydroxymethyl)aminomethane hydrochloride, pH 7.6), followed by incubation for 1 h in binding buffer containing 1% w/v BSA, [125I-Tyr4]BBN (5.10-10 M) and JMV4168, JMV5132, natGa-JMV4168 or natGa-JMV5132 in increasing concentrations (range of 10-12 M to 10-6 M). After incubation, the sections were washed successively with ice-cold binding buffer with 0.25 % w/v BSA for 5 min, binding buffer without BSA for 5 min, and ice-cold Ultrapure water for 5 seconds. Dried sections were placed in apposition to phosphor screens (PerkinElmer, Super Resolution) for 1 day. Radioactivity was assessed using a phosphor imager system (Cyclone, Packard, model 
Ͷ͵ͳʹͲͳȌ and uantified using ptiuant software ȋerinlmerǡ althamǡ Ȍ. 
Small-animal PeT/CT and Biodistribution StudiesMale nude BALB/c mice (age, 6-8 wk) were injected subcutaneously near the right shoulder with a PC-3 cell suspension (5 x 106 cells, 200 µL, 66% RPMI, 33% Matrigel [BD Biosciences]). Two to 3 wk after inoculation, when tumor size averaged 200 mm3, mice were injected intravenously with 5-10 MBq of radiolabeled peptide (200 
pmolǡ ʹͲͲ ρȌ. To confirm the receptor specificit of the radiolabeled peptidesǡ 
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additional animals were coinjected with an excess (20 nmol) of unlabeled peptide. Mice were euthanized 1 or 2 h after injection by CO2/O2 asphyxiation. Mice were 
first scanned prone on a small animal TȀT scanner ȋnveonǢ Siemens reclinical Solutions). PET emission scans were acquired for 30-60 min, followed by a CT scan (spatial resolution 113.15 µm; 80 kV; and 500 µA). Scans were reconstructed using Inveon Acquisition Workplace software (version 1.5; Siemens Preclinical Solutions), using a 3-dimensional ordered-subset expectation maximization/maximization a posteriori algorithm with the following parameters: matrix, 256 x 256 x 161; pixel 
sieǡ Ͳ.ͶͲ  Ͳ.ͶͲ  Ͳ.͹ͻ͸ mmǢ and ȾǦvalueǡ ͳ.ͷǡ with uniform variance and 	ast. After scanning, blood, tumor, and relevant organs and tissues were collected, weighed 
and counted in a ɀǦcounter ȋͳͶͺͲ  automatic gamma counterǡ erinlmerǡ 
althamǡ Ȍ with a counting time of ͸Ͳ seconds per sampleǡ isotopeǦspecific energ window and an error not exceeding 5%. The percentage injected dose per gram (%ID/g) was determined for each tissue sample. All animal experiments were approved by local authorities and were in compliance with the institutions guidelines.
Statistical AnalysisStatistical analysis was performed using GraphPad Prism version 5.01 (version 5.01; GraphPad Software). IC50 values were determined with datasets from 3 independent experiments, each in duplicate. Data are represented as percentage of total binding (normalized), with standard error of the mean. An extra sum-of-squares F test was 
used to compare two bestǦfit valuesǡ and the level of significance was set at  δ Ͳ.Ͳͷ. Biodistribution data are represented as the mean %ID/g ± SD, with group sizes of 3 mice, except at 1 h after injection: n = 2 for Al18F-JMV5132 and at 2 h after injection: n = 5 for 68Ga-JMV4168, Al18F-JMV5132. Statistical analysis of biodistribution data was performed using a 1-way ANOVA with a Bonferroni post-hoc test, and the level of 
significance was set at  δ Ͳ.Ͳͷ.
ReSULTS
Synthesis of JMV4168 and JMV5132JMV4168 and JMV5132 (Figure 1) were obtained with an average yield of 
approimatel ͶͲΨ and a purit greater than ͻ͹Ψ as confirmed b Ǧ. Conjugates were characterized by electrospray ionization mass spectrometry (mass/charge, [M+2H]2+/2: JMV4168, calculated: 815.9414, found: 815.9412; JMV5132, calculated: 821.4416, found: 821.4433). 
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2.1
Radiolabeling and Stability StudiesAl18	Ǧͷͳ͵ʹ was obtained with a specific activit of ͶͲ ά Ͷ Ȁnmol ȋͺͺΨ nonǦdecay-corrected yield) and 68Ga-JMV4168 and 68
aǦͷͳ͵ʹ with a specific activit of 
Ͷ͹ ά ʹ  and Ͷ͹ ά Ͷ Ȁnmol after purificationǡ respectivel. Ǧ analsis indicated that the radiochemical purity of the Al18F- or 68Ga-labeled peptide preparations used 
in in vitro and in vivo eperiments alwas eceeded ͻͷΨ. adioǦ elution profiles of Al18F- and 68Ga-labeled peptides are shown in Figure 2A. 68Ga-JMV4168, 68Ga-JMV5132 and Al18F-JMV5132 had retention times of 13.8 min, 19.6 min and 21.9 min, respectively. The addition of quenchers (methionine, gentisic acid, and ascorbic acid) prevented oxidation of the radiolabeled peptides, as shown in Figure 2B. 
Lipophilicity
The octanolȀS partition coefficients were determined to estimate the lipophilicit of the Al18F- or 68Ga-labeled peptides. The log Poctanol/PBS values for 68Ga-JMV4168, 68Ga-JMV5132 and Al18F-JMV5132 were -2.53 ± 0.04, -1.40 ± 0.01, and -1.56 ± 0.08, respectively. This result shows that the 68Ga-DOTA analog (JMV4168) was more hydrophilic than the 68Ga- and 18F-NODA-MPAA analogs (JMV5132). 
FiGURe 2. Radio-high-performance liquid chromatograms of 68Ga-JMV4168 (A), 68Ga-JMV5132 (B), and Al18F-JMV5132 (C). (D) Radio-high-performance liquid chromatogram of 68Ga-JMV5132 without added quenchers. Y-axis = radioactivity in count per second (cps); x-axis = retention time in min. EDTA = ethylenediaminetetraacetic acid; tR = retention time. 
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Competitive Cell Binding Assay
The affinit of Ͷͳ͸ͺǡ ͷͳ͵ʹǡ natGa-JMV4168, natGa-JMV5132, and AlnatF-JMV5132 for the GRPR was determined in a competitive binding assay, using [125I-Tyr4]-BBN as radioligand. The displacement binding curves are shown in Figure 3. Inhibitory concentration of 50% (IC50) values (in nM) for binding to GRPR for JMV5132 (NODA-MPAA), JMV4168 (DOTA) and natl	Ǧͷͳ͵ʹ were not significantl differentǣ ͸.ͺ 
ȋͻͷΨ confidence interval ȏȐǡ Ͷ.͸ǦͳͲ.ͲȌ and ͳ͵.ʹ ȋͻͷΨ ǡ ͷ.ͻǦʹͻ.͵Ȍǡ and ͳͲ.Ͳ n 
(95% CI, 6.3-16.0), respectively. IC50 values for natGa-JMV5132 (3.0 [95% CI, 1.5-6.0]) and natGa-JMV4168 (3.2 [95% CI, 1.8-5.9]) were lower than their unlabeled 
counterpartǡ indicating a higher binding affinit for the 
. 
Small-Animal PeT/CT and Biodistribution StudiesFused PET and CT images obtained at 1 and 2 h after injection are shown in 
Figure 4. Maximum-intensity projections showed clear visualization of PC-3 tumors with very low background. Predominant renal excretion was observed for all 3 
FiGURe 3. Competition binding curves. PC-3 frozen sections were incubated in presence of 5.10-10 M [125I-Tyr4]-BBN and increasing amounts of JMV4168, JMV5132, natGa-JMV4168, natGa-JMV5132, or AlnatF-JMV5132. IC50 values (with 95% CIs in parentheses) were 6.8 nM (4.6-10.0) for JMV5132, 13.2 nM (5.9-29.3) for JMV4168, 3.0 nM (1.5-6.0) for natGa-JMV5132, 3.2 nM (1.8-5.9) for natGa-JMV4168, and 10.0 nM (6.3-16.0) for AlnatF-JMV5132.
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2.1radiolabeled peptides. Partial hepatobiliary excretion was observed for Al18F-JMV5132 and 68Ga-JMV5132, as indicated by 
the nonspecific uptae in the gallbladder and intestines. PET images obtained at 2 h after injection showed partial clearance of radioactivity in nontarget tissues such as pancreas, kidney, and intestines as compared to the images obtained at 1 h after injection.The results of the biodistri-bution studies of 18F- and 68Ga-labeled peptides are summarized in Figure 5. These pharmacokinetic data obtained at 1 and 2 h after injection were in line with the PET images. High 
and specific uptae of the tracer was observed in the PC-3 tumors. There were 
no significant difference for 68Ga-JMV4168, 68Ga-
FiGURe 4. PET/CT images of mice bearing subcutaneous PC-3 xenografts on right shoulder (arrow) injected with 68Ga-JMV4168 (left), 68Ga-JMV5132 (center) or Al18F-JMV5132 (right) at 1 h after injection (A), 2 h after injection (B), and 2 h after injection with coinjection of excess unlabeled peptide (C). Beside tumor (arrow), pancreas, intestines, and kidneys can be observed in the abdominal region. Bladder can be distinguished by hot spot below abdomen. Gallbladder can be recognized as hot spot below rib cage.
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JMV5132, and Al18F-JMV5132, with uptake values (in %ID/g) of 4.46 ± 0.33, 4.73 ± 0.68, 4.96 ± 1.20, respectively, at 1 h after injection and 5.96 ± 1.39, 5.24 ± 0.29, 5.30 ± 0.98, respectively, at 2 h after injection. The uptake in GRPR-positive organs, such as tumor, 
pancreasǡ stomachǡ and intestinesǡ was significantl decreased b coinection of an 
ecess of unlabeled peptideǡ indicating 
Ǧspecific targeting. ll tracers displaed fast blood clearance, with 0.09 ± 0.04, 0.19 ± 0.13, and 0.05 ± 0.01 %ID/g remaining in blood at 2 h after injection for 68Ga-JMV4168, 68Ga-JMV5132, and Al18F-JMV5132, respectively. The 3 tracers cleared rapidly from the GRPR-positive pancreas between 1 h (6.14 ± 0.68, 11.42 ± 0.84, 4.21 ± 1.34 %ID/g) and 2 h after injection (1.00 ± 0.24, 1.33 ± 0.25, and 1.41 ± 0.15 %ID/g) for 68Ga-JMV4168, 68Ga-JMV5132, and Al18F-JMV5132, respectively, whereas PC-3 tumor uptake was preserved. The uptake and retention of all tracers in blood, muscle, heart, lung, liver, and bone were relatively low 
as measured at ʹ h after inection ȋall ζͲ.ͷ ΨȀgȌ. ice inected with l18F-JMV5132 
showed a ȋsignificantlȌ higher uptae in spleen and bone. 
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FiGURe 5. Biodistribution of 68Ga-JMV4168 (red), 68Ga-JMV5132 (blue) and Al18F-JMV5132 (green) in mice bearing PC-3 xenografts at 1 h after injection (A), 2 h after injection (B), and 2 h after injection with coinjection of excess unlabeled peptide (C) and tumor-to-organ ratios at 2 h after injection (D). Int = intestines.
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2.1
DiSCUSSioNThe use of radiolabeled GRPR antagonists for targeting tumors in vivo has attracted considerable attention, starting with somatostatin receptor antagonists showing higher tumor uptake and targeting more receptor-binding sites than their agonists (30Ȍ. This finding was also etended to 
 antagonistsǡ with the seminal wor of Cescato et al. (11). Recently, more articles have appeared showing the promise of novel radiolabeled GRPR antagonists for GRPR-positive tumor imaging (12, 16-18, 25). The studies revealed favorable pharmacokinetics of radiolabeled antagonists, including high tumor uptake and fast clearance from nontargeted tissues. Several 64Cu- and 68Ga-labeled receptor antagonists developed for PET imaging of prostate tumors have shown pharmacokinetics superior to 64Cu- or 18F-labeled GRPR agonists described in earlier literature (12, 16, 17Ȍ. eside a favorable pharmacoinetic profileǡ the use of antagonists should reduce the occurrence of side effects. In a study in which BBN was infused intravenously in a dose of 15 ng/kg/min over a 90-min period, side effects – among 
which were nauseaǡ hot flushǡ and sweating – were observed in 80% of the patients (13).Here, we report on the development of a NODA-MPAA-conjugated GRPR antagonist (JMV5132) labeled with 18F for PET imaging of GRPR-positive tumors and the direct comparison with 68Ga-radiolabeled analogs. In our previous work, the statin-based 

 antagonist ͷͻͶ was lined to T via a ȋȾlaȌ2 linker and labeled with 111In. It showed very good tumor targeting in PC-3 xenografts in mice (25). In the present study, we conjugated JMV594 to NODA-MPAA for radiolabeling with 18F. The 
ǦǦȋȾlaȌ2–JMV594 peptide (JMV5132) was labeled with 18F and 68Ga and compared with the 68
aǦlabeled TǦȋȾlaȌ2–JMV594 peptide (JMV4168).The radiolabeling of peptides via complexation of Al18	 b a T chelator was first described by McBride et al. (24). This novel technique has been successfully applied to several peptides, including a GRPR agonist (28) and recently to GRPR antagonists (31, 32). Recently, McBride et al. reported the labeling of peptides with Al18F in a 1-pot, 1-step procedure using the NODA-MPAA chelator (26, 33), leading to a kit formulation, 
after which the labeled peptide could be purified b solidǦphase etraction. In the present study, we further optimized the labeling conditions to achieve Al18F-labeled JMV5132 in less than 20 min with complete incorporation of 18	Ǧfluorideǡ 
resulting in a high specific activit ȋ͵ͷ ȀnmolȌǡ without the need for purification by solid-phase exctraction. In receptor-binding studies using PC-3 tumor sections, 
the in vitro affinities of ͷͳ͵ʹ and Ͷͳ͸ͺ were comparableǡ as shown b the similar IC50 valuesǡ indicating that both chelators apparentl affected receptor affinit in a similar way. The peptides labeled with nat
a had slightl higher receptor affinities than their unlabeled counterpart, indicating that the presence of Ga3+ in the chelator 
enhanced the affinit of the peptides for the 
. The affinit of the peptide labeled with natl	ǡ on the other handǡ was not significantl different from its unlabeled counterpart, indicating that the presence of AlF in the chelator did not affect the 
affinit of the peptide for the 
.
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The PET images obtained with Al18F-JMV5132 showed higher spatial resolution than the images obtained with the 68Ga-labeled tracers, which is most likely due to the longer positron range of 68Ga (34) as compared with 18F. 
The comparative biodistribution stud showed 
Ǧspecific accumulation of all ͵ radiolabeled GRPR antagonists in the tumor. 68Ga-JMV4168, 68Ga-JMV5132, and Al18F-JMV5132 tracers showed similar uptake in the GRPR-positive tumor and organs, including PC-3 tumor, pancreas, stomach, and colon. The uptake was receptor-
mediatedǡ as confirmed b the reduction of uptae in tumor and other receptorǦpositive organs after coinjection of excess unlabeled peptide. The washout from receptor-positive organs occurred at different rates. The pancreas uptake decreased from 1 to 2 h after injection by a factor of 6.1, 8.6, and 3.0, whereas tumor uptake was increased by a factor of 1.3, 1.1, and 1.1 for 68Ga-JMV4168, 68Ga-JMV5132, and Al18F-JMV5132, respectively. This outcome indicates a higher retention of the tracers in the tumor than in the pancreas. Despite their low internalization rate, the high and persistent tumor uptake of these radiolabeled antagonists was expected, as it was previously described for a few other radiolabeled antagonists (11, 12, 16, 18). This might be explained by a higher number of binding sites for receptor antagonists than agonists, a higher metabolic stability of antagonists, or a strong interaction of the antagonist with the receptor (11, 16). In previous studies using radiolabeled GRPR antagonists, a faster clearance from the pancreas and abdominal organs was already observed between 1 and 4 h after injection, in contrast with data concerning radiolabeled GRPR agonists, which showed more sustained retention of activity in the abdominal region. Several reasons for these differences in tissue clearance kinetics have been postulated, including species 
differences or more efficient perfusion in the pancreas and intestine ȋ16). Possible metabolic degradation of the peptide by enzymes in the pancreas might also explain the faster washout from the pancreas.  Clearance from background tissues, such as blood, muscle, heart, lung, liver, and bone, was very fast for all tracers tested, leading to high tumor-to-background ratios, which allowed clear visualization of the tumor. Overall, Al18F-JMV5132 showed improved imaging properties, compared with the previously reported Al18F-NOTA-8-Aoc-BBN(7-14)NH2 GRPR agonist (28), because that analog showed lower tumor uptake, much higher pancreatic uptake, and higher liver and intestinal uptake in the same animal model.The slightly higher uptake of Al18F-JMV5132 in bone may be due to the presence of trace amounts (<1%) of uncomplexed Al18F or 18	Ǧfluoride or partial defluorination of the tracer in vivo. The uptake of Al18F-JMV5132 in bone was relatively low (0.52 ± 0.13 %ID/g 2 h after injection), in comparison with the values reported for the Al18F-labeled RM1 derivative (1.58 %ID/g 2 h after injection) (31). The increased uptake of Al18F-JMV5132 and 68Ga-JMV5132 in the gallbladder, liver, and gastrointestinal excretions indicates partial hepatobiliary excretion of the tracers, because of their 
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higher lipophilicity, which may be caused by the benzyl group. Considering the clinical application of the tracers, high signal intensity in the intestines may affect 
visualiation of prostateǦconfined tumor or spread to lmph nodes. everthelessǡ considering the superior imaging characteristics of 18F, further development of Al18F-JMV5132 as a tracer for PCa diagnostic and therapy follow-up is certainly warranted.
CoNCLUSioN
ighl sensitive and receptorǦspecific imaging of a with TȀT can be achieved using 68Ga- and 18F-labeled GRPR antagonists. In this study, labeling of JMV5132 with Al18	 was completed within ʹͲ min with high specific activit without a need for 
purification. The 68Ga-JMV4168 tracer showed the most favorable biodistribution, because of its lower hepatobiliary excretion, but the PET images showed a higher resolution with the 18F-JMV5132 tracer. These new PET tracers are promising candidates for future clinical translation.
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ABSTRACTA single tool for early detection, accurate staging, and personalized treatment of 
prostate cancer ȋaȌ would be a maor breathrough in the field of a. 
astrinǦreleasing peptide receptor (GRPR) targeting peptides are promising probes for a theranostic approach for PCa overexpressing GRPR. However, the successful application of small peptides in a theranostic approach is often hampered by their fast in vivo degradation by proteolytic enzymes, such as neutral endopeptidase (NEP). 
ere we show for the first time that coinection of a  inhibitor ȋphosphoramidon (PA)) can lead to an impressive enhancement of diagnostic sensitivity and therapeutic 
efficac of the theranostic 68Ga-/177Lu-JMV4168 GRPR antagonist. Coinjection of PA (300 µg) led to stabilization of 177Lu-JMV4168 in murine peripheral blood. In PC-3 tumor-bearing mice, PA coinjection led to a 2-fold increase in tumor uptake of 68Ga-/177Lu-JMV4168, 1 h after injection. In positron emission tomography (PET) imaging with 68Ga-JMV4168, PA coinjection substantially enhanced PC-3 tumor signal intensity. Radionuclide therapy with 177uǦͶͳ͸ͺ resulted in significant regression 
of Ǧ͵ tumor sie. adionuclide therap efficac was confirmed b production of DNA double strand breaks, decreased cell proliferation, and increased apoptosis. Increased survival rates were observed in mice treated with 177Lu-JMV4168 plus PA as compared to those without PA. This data shows that coinjection of the enzyme inhibitor PA greatly enhances the theranostic potential of GRPR radioantagonists for future application in PCa patients. 
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iNTRoDUCTioNProstate cancer (PCa) is the most frequently diagnosed cancer and the second leading cause of cancer-related death among men in the United States (1). The 5-year relative survival rate for localized and regional PCa is 100%, but decreases to 29% when the cancer has spread to distant sites (2). Prognosis and treatment options are strongly related to disease stage and grade at time of diagnosis. Early diagnosed and locally 
confined tumors can be treated b radical prostatectom andȀor local radiation therapy, whereas for advanced, disseminated PCa curative treatment is not available (2). This underlines the importance of early detection and accurate staging for the successful management of PCa patients. Currently, local staging is mostly based on ultrasound, biopsies, and level of serum 
prostateǦspecific antigen. ecent advances in molecular imaging techniues have highlighted the potential of PET imaging, providing a sensitive and noninvasive detection method for PCa lesions. Metabolic PET radiotracers, such as 18	ǦfluoroǦ2-deoxy-D-glucose (FDG) or 18	ǦfluoroǦcholine have been used to detect recurrent metastatic PCa with high metabolic rates, but are suboptimal for the detection of slow-growing primary tumors.An alternative strategy focuses on the development of receptor-directed PET imaging 
agents. T radiotracers targeting prostateǦspecific membrane antigen ȋSȌ and gastrin-releasing peptide receptor (GRPR) have shown promising results for detection of primary and metastasized PCa in early clinical studies (3-6). Besides their use for diagnostic imaging, these targeting agents may also be used as therapeutic agents for tumor-targeted radionuclide therapy of PCa. PSMA-targeted agents labeled with the 
ȾǦemitting radioisotope 177Lu are currently evaluated in clinical studies (7, 8). The powerful combination of diagnosis and therapy by one single probe in a “theranostic” strategy could effectively contribute to a more personalized management of PCa patients, whereby imaging can guide the choice of the most suitable therapeutic option for each patient. The aim of the present study was to develop a theranostic agent based on a GRPR-antagonist with application prospects in the personalized treatment of PCa patients. GRPRs are overexpressed in the majority of primary prostate tumors and in a subset of patients with lymph node and/or bone metastasis (9, 10), making it an interesting target for radionuclide therapy. GRPR antagonists are promising molecular probes, owing to their superior tumor-targeting and pharmacokinetic properties compared to agonists (11). GRPR agonists were also shown to induce side effects in patients, owing to their physiologic activity (12, 13). The potential of the 68Ga-labeled GRPR antagonist, JMV4168, for PET imaging of prostate cancer was reported previously in preclinical studies (14). 
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However, delivery of radiopeptides to the tumor will be challenged by the action of proteolytic enzymes present in blood, vasculature walls, liver, lungs, kidneys, and gastrointestinal tract. In vivo degradation of radiopeptides by proteolytic enzymes may hamper their targeting properties, thereby limiting their successful application as theranostic probes. One of the key proteolytic enzymes is neutral endopeptidase 24.11 (NEP, EC 3.4.24.11, neprilysin, CD10, MME), a cell surface metallopeptidase responsible for catalytic inactivation of many neuropeptide substrates, including bombesin-like peptides (15-17). NEP is abundantly expressed in the human body, including vasculature walls, major organs, and tissues, potentially hampering radiopeptide-based imaging and therapy by cleaving radiopeptides on the amino side of hydrophobic amino acids. The released inactive radiometabolites will not be able to interact with the tumor-associated target-receptors, and as a result, diagnostic 
sensitivit and therapeutic efficac will be severel compromised. n previous studies we have shown that coinjection of a single enzyme inhibitor, phosphoramidon (PA), could stabilize radiopeptides in vivo by inhibition of NEP. This strategy led to notable enhancement of tumor uptake of radiopeptides, whereas uptake in most nontarget healthy tissues was not affected (18). We hypothesize that this strategy would be 
particularl interesting to enhance the therapeutic efficac of radionuclide therap as well, by delivering a higher cytotoxic radiation dose to cancer cells at similar dose exposure of healthy tissues. The aim of this study was to investigate the effect of in vivo stabilization by PA on 
diagnostic sensitivit and therapeutic efficac of the 
Ǧtargeted theranostic agent 68Ga/177Lu-JMV4168 in nude mice with subcutaneous (sc) human prostate tumors.
MATeRiALS AND MeTHoDS
Peptide, Reagents, Cell Line, and Mice
Ͷͳ͸ͺ ȋTǦȾlaǦȾlaǦȏǦD-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2], Figure 
1) was synthesized as described previously (19). Chemicals were purchased from Sigma-Aldrich, unless otherwise stated. Phosphoramidon (PA) was purchased from Peptides International Inc. 177LuCl3 was purchased from IDB Holland and no-carrier added (n.c.a.) ItG 177LuCl3 was obtained from ITG Isotope Technologies Garching GmbH. 175Lu was obtained from Merck as 1 g/L standard solution in nitric acid. The human PCa cell line PC-3 was obtained from the American Type Culture Collection (CRL 1435) and cell culture reagents from Life Technologies. Cells were cultured in Ham’s F-12K (Kaighn’s) Medium supplemented with 10% fetal bovine serum, penicillin (100 units/
mȌǡ and streptomcin ȋͳͲͲ ρgȀmȌ. ells were grown in tissue culture flass at ͵͹ι 
in a humidified atmosphere containing ͷΨ 2. Male nude BALB/c mice (age, 8 wk) were obtained from Janvier. All animal experiments were approved by the Animal Experiments Committee under the Dutch Experiments on Animal Act and adhered to the European Convention for Protection of Vertebrate Animals used for Experimental Purposes (Directive 86/609/EEC). 
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Labeling of JMV4168 with 68Ga, 177Lu, and 175LuElution of 68Ga from a 68Ga/68Ge generator (IGG-100, Eckert & Ziegler AG) was performed using fractionated elution with 0.1 M HCl (Rotem Industries Ltd). For PET imaging and biodistribution studies, JMV4168 (1-2 nmol) was mixed with 68Ga eluate (200 µL), sodium acetate (0.5 M, 50 µL) and ethanol (30 µL). The reaction mixture was heated for 10 min at 95°C. After reaction, ethylenediaminetetraacetic acid (EDTA, 4 mM) was added to complex free 68
aǡ and the reaction miture was filtered ȋͲ.Ͳʹ ρm WhatmanTM filterǡ 
 ealthcareȌ to remove 68Ga-hydroxides (20). JMV4168 was labeled with carrier-added 177LuCl3 ȋ ollandȌ with a specific activit (ratio between amount of bound radioactivity and total molar quantity of peptide) of 125 MBq/nmol for in vivo stability studies and 60 MBq/nmol for biodistribution studies. Labeling was performed in 20 mM sodium acetate, for 15 min at 80°C. Radioprotectants (gentisic acid, ascorbic acid and methionine, 3.5 mM) were added to prevent radiolysis.
To obtain higher specific activit ȋi.e. ʹͷͲ ȀnmolȌ for in vivo therap studiesǡ JMV4168 was labeled with n.c.a. 177LuCl3 (ITG Munich) as the presence of 176Lu in carrier-added 177LuCl3 limits the maimum achievable specific activit to 125 MBq/nmol. Labeling was performed in 50 mM sodium acetate for 15 min at 80°C with radioprotectants. An excess of diethylenetriaminepentaacetic acid (DTPA, 4 mM) was added to complex free 177LuCl3 after reaction. For control experiments, JMV4168 was labeled with the stable isotope 175Lu. JMV4168 was incubated with a 2-fold molar excess 175Lu in 80 mM sodium acetate, for 15 min at 80°C.
Vehicle for Animal injectionTo allow for injection into mice, the radiolabeled peptide was diluted in a vehicle. For biodistribution studies, vehicle consisted of 5% (v/v) ethanol, 0.05% (w/v) bovine serum albumin (BSA) in phosphate-buffered saline (PBS), pH 7.4, containing a mixture of 0.5 mM radioprotectants. For therapy studies with higher activity concentration, vehicle consisted of 5% (v/v) ethanol, 0.05% (w/v) BSA in PBS, pH 7.4, containing 5 mM radioprotectants. 
FiGURe 1. hemical structure of Ͷͳ͸ͺ ȋTǦȾlaǦȾlaǦȏǦD-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2]).
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Quality Control
abeling efficienc was assessed b instant thin laer chromatograph ȋiTȌ using silica gel coated paper (Varian Medical Systems, Inc.) and 0.1 M citrate buffer pH 5 as eluent. Colloid formation was determined by iTLC using silica gel-coated paper and 1 M NH4OAc:methanol (1:3) as eluent. Radiochemical purity of labeled peptides was analyzed by RP-HPLC on a Breeze system (Waters). A C-18 column (Symmetry Shield, 
Ͷ.͸ mm  ʹͷͲ mmǢ particle sie ͷ Ɋmǡ atersȌ was used at a flow rate of ͳ mȀmin 
with the following buffer sstemǣ buffer ǡ Ͳ.ͳΨ vȀv trifluoroacetic acid in waterǢ buffer B, methanol; with a gradient as follows: 100% buffer A (0-5 min), 60% buffer B (5-5.01 min), 80% buffer B (5.01-20 min), 100% buffer B (20.01-25 min), 100% buffer A (25.01-30 min). The radioactivity of the eluate was monitored using an in-line NaI radiodetector, digital multichannel analyzer and dedicated software (MetorX 
..Ȍ. lution profiles were analed using mpower ͵ software ȋatersȌ. 
in Vivo Stability StudiesNon-tumor bearing mice were injected intraperitoneally (ip) with 177Lu-JMV4168 
ȋʹͷ ǡ ʹͲͲ pmolȌ in vehicleǡ or in vehicle containing  ȋ͵ͲͲ ɊgȌ. lood was drawn 15 min after injection and collected in a polypropylene tube coated with EDTA 
containing  ȋ͵Ͳ ɊgȌǡ and ͷͲ nmol of radioprotectants on ice. lasma proteins were precipitated by adding 50% ethanol, centrifuged for 10 min at 4°C and the extract was analyzed by radio-HPLC. HPLC fractions were collected every min and counted in a 
ɀǦcounter to uantif intact radiopeptide and degradation products. 
Prostate Cancer Xenograft ModelMice were injected subcutaneously on the right shoulder with a PC-3 cell suspension (3 x 106 cells, 200 µL, 67% RPMI, 33% Matrigel [BD Bioscience]). Three to 4 wk after inoculation, tumor size averaged 200 mm3 and mice were used for biodistribution, PET imaging and therapy studies.
Biodistribution Studies68Ga-JMV4168 (1 MBq, 200 pmol) was injected intravenously (iv) with vehicle (control) or with PA (300 µg) in vehicle. Mice were euthanized 1 h or 2 h after injection. 177Lu-JMV4168 (0.7 MBq, 200 pmol) was injected iv or ip with or without 
 ȋ͵ͲͲ ρgȌ in vehicle. ice were sacrificed at ͳ hǡ Ͷ h or ʹͶ h after inection for 177Lu-JMV4168 in controls, and 1 h or 4 h for 177Lu-JMV4168 with PA. Blood, tumor, 
and relevant organs and tissues were collectedǡ weighedǡ and counted in a ɀǦcounter 
ȋǡ erinlmerȌ with a counting time of ͸Ͳ sec per sampleǡ isotopeǦspecific energy window and an error not exceeding 5%. The percentage of the injected dose per gram (%ID/g) was determined for each tissue sample. 
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DosimetryBiodistribution data of 177Lu-JMV4168 in controls (iv and ip) were used to estimate the absorbed radiation doses to the organs with physiologic uptake and tumor. A 
singleǦeponential epression was fitted to the activit data at ͳǡ Ͷǡ and ʹͶ hǡ and the cumulative activity concentration in each organ was calculated by analytic integration 
of the fitted epression. bsorbed radiation doses of 177Lu-JMV4168 with PA were estimated assuming equivalent clearance as without PA from 4 to 24 h. Absorbed radiation doses to the organs were estimated according to the MIRD-scheme (21) with the following equation: ∑( ) ( ) ( )= × ←D r Ã r S r rT r S T SS , with ( )D rT  the absorbed dose to a target organ rT , ( )Ã rS  the time-integrated activity in a source organ rS  and ( )←S r rT S  the absorbed dose rate per unit activity of 177Lu. The S-values were obtained for a standardized 25 g mouse from the RADAR realistic animal models (22). The biodistribution data are measured in activity concentration and hence the time-integrated activity concentration is obtained and this is multiplied with the source organ mass, as used in the phantom for the S-value calculation. The Linear Quadratic (LQ) model was used to predict cell survival for PC-3 radiation response (a = 0.13 /Gy, b = 0.024 /Gy2, doubling time of 11 d, sub-lethal repair half-life Tm = 1 h, clonogenic cell density; 107/g) (23). Radiation sensitivity was estimated by external 137s gamma irradiation ȋdata not shownȌǡ resulting in  model fit ȋearson R2 = 0.99) with a= 0.13 ± 0.02 /Gy, b = 0.025 ± 0.005 /Gy2 (a/b = 5.5 Gy). Doubling 
time was estimated b fitting an eponential growth epression into Ǧ͵ tumor growth curve in our model. Tumor control as a function of absorbed dose D over time T was expressed by Poisson statistics expressing the probability for survival S of 1 or more clonogenic cells from the original number of clonogenic cells Nclonogens by:
( )( )= −TCP N S Dexp clonogens , with the survival
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to infinit for single eponential dose buildup with effective halfǦlife Teff: 
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  (24). A Tumor Control Probability of > 90% was considered as being  successful.
Small-Animal PeTMice were injected iv with 2-8 MBq of 68Ga-JMV4168 (200 pmol) in vehicle or vehicle containing PA (300 µg). Mice were scanned 2 h after injection, on a heated bed under 
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isofluraneȀ2 anesthesia, in a small animal PET scanner (Inveon; Siemens Preclinical Solutions). PET emission scans were acquired for 45 min, followed by a transmission scan (402 s). Scans were reconstructed using Inveon Acquisition Workplace software (version 1.5; Siemens Preclinical Solutions), using a 3-dimensional ordered-subset expectation maximization/maximization a posteriori algorithm with the following 
parametersǣ matriǡ ʹͷ͸  ʹͷ͸  ͳ͸ͳǢ piel sieǡ Ͳ.ͶͲ  Ͳ.ͶͲ  Ͳ.͹ͻ͸ mmǢ and ȾǦvalueǡ 1.0, with uniform variance and OPMAP. Images were rescaled to account for differences in injected dose. 
Therapy StudiesMice received 4 ip injections in 2-d intervals of either PBS, 177Lu-JMV4168 (50 MBq, 200 pmol) in vehicle or 177Lu-JMV4168 (50 MBq, 200 pmol) in vehicle containing PA (300 µg). To exclude a possible antitumor effect of radioprotectants, GRPR-antagonist or PA, a separate experiment was performed: mice received 4 ip injections of PBS, 175Lu-JMV4168 in vehicle, or 175Lu-JMV4168 in vehicle containing PA (300 µg). Tumor size was followed twice weekly by caliper measurements, endpoints were tumor size exceeding 1.5 cm3ǡ or survival of ͻͶ d after the first inection.
GRPR expression, Histology, and Molecular CharacteristicsIn order to study the molecular response of tumor cells to therapy, 2 mice of each group 
were sacrificed ͺ d after start of therapǡ and tumor was dissected. t the endpoint 
of the eperimentǡ tumorǡ idneǡ and pancreas from sacrificed animals of each group 
were dissected. 	or each organ half was froen in liuid nitrogen and half was fied in 
ͳͲΨ neutral buffered formalin at Ͷι. fter fiation and routine dehdrationǡ tissue 
samples were embedded in paraffin.GRPR expression after radionuclide therapy treatment was assessed on frozen tumor sections (10 µm) using autoradiography as described earlier (14). In brief, frozen tissue sections were incubated with 177Lu-JMV4168 (10-10 M) for 1 h in binding buffer containing 1% w/v BSA. Unlabeled JMV4168 was used for blocking (10-6 M). Radioactivity was measured using a phosphor imager system (Cyclone, Packard A431201, PerkinElmer) and data obtained on different phosphor screens was normalized against a positive control slide (PC-295 xenograft tumor (25)). 
istolog was performed on paraffinǦembedded idne and pancreas sections ȋͶ ρmȌ. Sections were stained with hematoxylin and eosin for microscopic examination using 
standard protocols. mmunofluorescence and T staining were performed on 
paraffinǦembedded tumor sections ȋͶ ρmȌ of mice sacrificed ͺ d after therap.
	or immunofluorescence stainingǡ tumor sections were deparaffiniedǡ rehdratedǡ and target antigen retrieval was performed using DAKO Antigen Retrieval buffer (pH 
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6.9) for 15 min at 100oC. Cells were permeabilized in PBS containing 0.1% Triton X-100 for 10 min and incubated in blocking buffer [PBS, 0.1% Triton X-100, 2% BSA]. Primary antibodies [anti-GEMININ (10802-1-AP, Proteintech Group, 1/400 dilution), anti-53BP1 (NB100-304, Novus Biologicals, dilution 1/1000), or anti-gH2AX (05-636, Merck-Millipore, dilution 1/500)] were diluted in blocking buffer and incubated for 90 min at room temperature. Secondary antibodies (Alexa Fluor 594 or 488, Life Technologies; dilution 1/1000) were diluted in blocking buffer and incubated for 60 min at room temperature. For apoptotic cell detection TUNEL staining was performed. Tumor sections were stained using an in situ cell death detection it ȋͳͳ͸ͺͶ͹ͻͷͻͳͲǡ ocheȌ. rieflǡ cells 
were deparaffiniedǡ rehdrated and incubated in S containing Ͳ.ͷΨ Triton ǦͳͲͲ 
and proteinase  ȋʹͲ ɊgȀmlȌ for ͳͷ min at room temperature. ells were incubated in PBS containing 0.1% Triton X-100 and 0.1% sodium citrate for 2 min on ice, followed by TUNEL labeling for 1 h at 37o. maging was performed using a ͶͲͲͲ fluorescent microscope (Leica).
gH2AX and 53BP1 imaging was performed using a TCS SP5 confocal microscope 
ȋeicaȌ and 
 imaging using a ͶͲͲͲ fluorescent microscope ȋeicaȌ. 53BP1/gʹ foci uantification was performed with mage software using automated threshold settings. GEMININ and TUNEL positive cells were counted manually and compared to the total number of DAPI-positive cells. Approximately 1000 (53BP1/gH2AX) or 400 (GEMININ/TUNEL) DAPI-positive cells from different 
microscope fields per condition were evaluated. 
Statistical AnalysisStatistical analysis was performed using GraphPad Prism version 5.01. Biodistribution data are represented as the mean %ID/g ± SD, with group sizes of 3-4 mice. Statistical analysis of biodistribution data was performed using a 2-way ANOVA with a Tukey’s 
multiple comparisons testǡ and the level of significance was set at  δ Ͳ.Ͳͷ. 
ean tumor sie with ͻͷΨ confidence interval were displaed for the period that 
all mice of one group were still in the eperiments. ice were sacrificed when tumor exceeded 1.5 cm3, causing the mean size to drop, which made the comparison of the means not fair after that period. Survival analysis is displayed up to day 94, corresponding to a maximum follow up time.Statistical analysis of mean tumor size of all groups was performed up to day 24, when all animals were still in the experiment. A 2-way ANOVA with repeated measures was used to compare the 3 groups, with a Tukey’s multiple comparison test. Tumor size of the two treated groups was compared up to day 66, with a 2-tailed paired t-test. Statistical analysis of survival data was performed using a Mantel-Cox Chi square 
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testǡ with a level of significance set at  δ Ͳ.Ͳͷǡ corrected to Ͳ.Ͳͳ͸͹ for multiple comparisons.
Tumor growth was analed b performing a nonlinear regression fit of an eponential growth curve to the control group. The Aikake information criterion was used to determine whether the growth was exponential or showed a Gompertzian type 
of growth. The tumor growth data of the treated animals were fitted b an initial exponential growth curve till the onset time of shrinkage and an exponential regrowth curve. Extrapolations of the growth curves for animals that were taken out of the experiment because of too large tumor sizes enabled establishment of a mean growth curve. 
ReSULTS
Radiolabeling of JMV4168 with 68Ga and 177Lu 68
aǦͶͳ͸ͺ was obtained with a specific activit of ͷͲ Ȁnmol. 177Lu-JMV4168 
could be obtained with a specific activit of up to ͳʹͷ Ȁnmol using carrier added 177Lu/176Lu and 250 MBq/nmol using n.c.a. 177Lu. 
abeling efficienc for 68Ga-JMV4168 and 177Lu-JMV4168 exceeded 97% as determined by iTLC. Radio-
peptides were not purified and radiochemical purity of preparations used in in vivo experiments exceeded 96% for 68Ga-JMV4168 and 94% for 177Lu-JMV4168, as determined by RP-HPLC. An excess of EDTA/DTPA was added to complex free 68Ga/177Lu and limit accumulation in bone. Protection of 177Lu-JMV4168 with radio-protectants (methionine, gentisic acid, and ascorbic acid) was required to preserve the peptide from radiolysis (26). Radio-protectants were added in the labeling reaction, 
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FiGURe 2. Radio-HPLC chromatograms of 68Ga-JMV4168 (A) and 177Lu-JMV4168 (B).
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as well as in the formulation for mouse inection. adioǦ elution profiles of 68Ga- and 177Lu-JMV4168 are shown in Figure 2. 68Ga-JMV4168 and 177Lu-JMV4168 had retention times of 9.99 min and 12.57 min, respectively. 
PA Stabilizes 177Lu-JMV4168 in Murine Peripheral BloodIn vivo stability studies resulted in 48% intact 177Lu-JMV4168 in peripheral blood after 15 min, and an increase to 84% intact radiopeptide upon coinjection of PA. 
PA enhances Tumor Uptake of 68Ga- and 177Lu-JMV4168 in PC-3 Xenograft MiceThe results of the biodistribution studies of 68Ga- and 177Lu-JMV4168 are summarized in Figure 3. Biodistribution patterns of 68Ga- and 177Lu-JMV4168 at 1 h after injection were comparable (p > 0.05 for all organs). Tumor uptake (in %ID/g ± SD) at 1 h after iv injection increased from 9.9 ± 1.3 to 19.1 ± 2.6 (68Ga-JMV4168, p < 0.0001) and from 9.0 ± 3.9 to 17.2 ± 1.7 (177Lu-JMV4168, p < 0.0001) upon coinjection of PA. Uptake in the GRPR-positive pancreas was increased at 1 h after iv injection for 68Ga-JMV4168 (p < 0.0001), but not for 177uǦͶͳ͸ͺǡ upon coinection of . o significant increase in uptake in non-target tissue was observed, resulting in high tumor-to-background ratios. A 3-fold decrease in pancreatic uptake was observed for 68Ga-JMV4168 from 1 to 2 h after injection, whereas tumor uptake remained stable, leading to increased tumor/pancreas ratio over time. Biodistribution patterns of 177Lu-JMV4168 after iv or ip injection were fairly comparable. Increased uptake in pancreas was observed at 1 h after ip injection in comparison with iv injection (p < 0.0001), but no differences were observed at later time points. Tumor uptake values (in %ID/g ± SD) at 1, 4, and 24 h after injection were 9.0 ± 3.9, 8.3 ± 1.7, and 4.2 ± 1.0 after iv, versus 8.9 ± 2.4, 7.2 ± 2.1, and 4.5 ± 0.7 after ip injection, respectively. Tumor uptake at 4 h after injection increased to 12.9 ± 3.5 (iv), and 14.5 ± 3.7 (ip) upon coadministration of PA. 
Dosimetry of 177Lu-JMV4168 in PC-3 Xenograft Mice
SingleǦeponential curves could be fitted to the biodistribution dataǢ the tumor showed comparable clearance half-lives for the two types of injection (20.8 ± 8.5 h (iv) and 24.4 ± 8.3 h (ip)). Estimated absorbed radiation doses (in Gy) from 50 MBq 177Lu-JMV4168 in tumor, kidneys, and pancreas were 10, 3.5, 2.5 Gy, and 11, 7.3, 4.4 Gy after iv and ip injections, respectively. Absorbed doses for tumor, kidneys, and pancreas for 177Lu-JMV4168 with PA were 16, 3.7, 3.1 and 20, 7.6, 4.8 Gy after iv and ip injections, respectively, assuming equivalent clearance from 4 to 24 h as without 
. o significant differences were observed for absorbed radiation doses of normal organs for 177Lu-JMV4168 and 177Lu-JMV4168 with PA.
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Based on the absorbed doses in PC-3 tumors, it was predicted that a single ip dose of 367 MBq (81 Gy) 177Lu-JMV4168 would have a 95% probability to elicit full tumor control. However, a maximum of 50 MBq (200 pmol) could be administered per 
inection ȋspecific activit of ʹͷͲ ȀnmolȌ. 	or 177Lu-JMV4168 alone, 8 cycles of therapy (8 x 50 MBq, ip) with 2-d intervals would be needed to reach 98% TCP. Upon 
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FiGURe 3. Effect of phosphoramidon (PA) on the biodistribution of 68Ga-JMV4168 (200 pmol, 1 MBq) administered intravenously (iv) at 1 and 2 h after injection (A) and 177Lu-JMV4168 (200 pmol, 0.7 MBq) administered intravenously (B) or intraperitoneally (C) at 1, 4, and 24 h after injection (n=3-4 per group). Biodistribution of 68Ga-JMV4168 and 177Lu-JMV4168 at 1 h after injection were comparable. Tumor uptake of 177Lu-JMV4168 injected intraperitoneal and intravenously were comparable. Tumor uptake and tumor-to-background ratios were increased in the presence of PA.
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coadministration of 177Lu-JMV4168 and PA, 4 cycles of therapy (4 x 50 MBq, ip) with 2-d intervals would be needed to reach 93% TCP (Figure 4). 
PA enhances Sensitivity of Small-Animal PeT imaging of 68Ga-JMV4168 in PC-3 
Xenograft MicePET images obtained at 2 h after iv injection of 68Ga-JMV4168 are presented in Figure 
5, showing clear, high-contrast visualization of PC-3 tumors. Visualization of PC-3 tumors was substantially improved by coinjection of PA, as shown by the increased signal intensity in the tumors. 
P uments ereutic Efϐicc of 177Lu-JMV4168 in PC-3 Xenograft MiceTherapy studies were conducted in PC-3 tumor-bearing mice receiving 4 cycles of PBS, 177Lu-JMV4168, or 177Lu-JMV4168 plus PA (Figures 6 and 7). The 177Lu-JMV4168-
treated mice showed significant reduction in tumor sie as compared to control ȋSȌ mice. At day 24 after start of therapy, mean tumor volumes (in mm3 ±SD) were 1181 ± 402, 146 ± 35 and 145 ± 45 for PBS, 177Lu-JMV4168 and 177Lu-JMV4168 plus PA, respectively. Tumor regrowth was observed for both treated groups, with mean tumor volumes (in mm3 ± SD) of 770 ± 456 and 381 ± 264 at day 66 for 177Lu-JMV4168 and 177Lu-JMV4168 plus PA, respectively. Consequently, mice in both treated groups had an increased survival as compared to the control group (P < 0.0001) and mice treated with 177Lu-JMV4168 plus PA had an increased survival as compared to mice treated with 177Lu-JMV4168 alone (P = 0.0157). Median survival increased from 35 to 79 d upon treatment with 177Lu-JMV4168, whereas the median survival in mice treated with 177Lu-JMV4168 plus PA was > 94 d, which was the endpoint of the experiment. Animal body weight remained stable during the course of the experiment and no apparent toxicity was observed (Figure 7). 
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FiGURe 4. Theoretical survival curve of clonogenic cells in PC-3 xenograft (200 mg, 2 x 106 clonogenic cells at the start) after therapy with 4 injections (2-d intervals) of 50 MBq of 177Lu-JMV4168 (4 x 11 Gy) and 177Lu-JMV4168 + phosphoramidon (4 x 20 Gy) (A). Tumor control probability (TCP) curve for the therapy with phosphoramidon is shown, reaching a 93% TCP after 9 d (B).
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o significant differences in tumor growth and survival were observed for the groups treated with PBS, 175Lu-JMV4168 or 175Lu-JMV4168 plus PA, showing that vehicle, 175Lu-JMV4168 and PA had no effect on tumor growth (Figure 6). 
177Lu-JMV4168 Radionuclide 
Therapy Results in DNA 
Damage, Apoptosis, and 
Decreased Proliferation 
and Does Not Affect GRPR 
expression of PC-3 TumorsHistological analysis of tumors, kidneys, and pancreas dissected at the endpoint of the experiment showed overall healthy tissue, with some necrotic areas in the tumors (data not shown). Staining of molecular characteristics (DNA 
damageǡ replicationǡ apoptosisǡ and 
 epressionȌ of tumors from mice sacrificed 8 d after the last injection is presented in Figures 8-10. Tumors from the groups treated with 177Lu-JMV4168 and 177Lu-JMV4168 plus PA showed an increased number of DNA double strand breaks (DSBs) as shown by phosphorylated histone 2AX (gH2AX) and p53-binding protein 1 (53BP1) foci formation in the tumor cell nuclei. Coinjection with PA increased the amount of produced DSBs. Furthermore, decreased numbers of cells expressing GEMININ (replicating cells) and increased numbers of TUNEL-positive cells (apoptotic cells) 
FiGURe 5. PET images of duplicate mice bearing subcutaneous PC-3 xenografts near the shoulder (pink arrow) injected with 68Ga-JMV4168 (A), or 68Ga-JMV4168 with phosphoramidon (B) at 2 h after injection, illustrating the higher tumor uptake in the presence of phosphoramidon. Excretion of the radiolabeled peptide in the bladder (white arrow) can be observed. Scale bar; 0 to 105 kBq/mL.
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were observed after 177Lu-JMV4168 treatment. GRPR binding of 177Lu-JMV4168 on frozen tumor sections was preserved in PC-3 tumors from all groups.
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FiGURe 6. ffect of phosphoramidon ȋȌ on therapeutic efficac of 177Lu-JMV4168 to treat subcutaneous PC-3 tumors. Mice were treated with 4 injections of 177Lu-JMV4168 (50 MBq, 200 pmol, n=12 per group) or 175Lu-JMV4168 (200 pmol, n=7 per group) on d 0, 2, 4, and 6, with or without PA. Mean tumor volume with 
ͻͷΨ confidence interval ȋǡ Ȍ are displaed for the duration that no data point was missing. aplanǦeier survival curves (B, D) are displayed for the event of tumor volume exceeding 1500 mm3. All growth curves 
of the control mice could be fitted b an eponential growth curveǡ none should evidence for 
ompertian type of growth. The mean tumor volume doubling time was 11.2 ± 1.2 d. Regrowth of tumors in the treated animals was found after a kick-off time of 32 ± 4 d (177Lu-JMV4168) and 35 ± 6 d (177Lu-JMV4168 + PA) 
and showed comparable regrowth doubling times to the initial and control growth curves. o significant differences in tumor growth and survival were observed for the groups treated with PBS, 175Lu-JMV4168 or 175Lu-JMV4168 with PA.
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DiSCUSSioN
n the search for an improved personalied cancer managementǡ the field of theranostics is emerging, applying imaging diagnostics into the choice of the most suitable therapy for each patient. Bombesin analogs have been widely used for molecular imaging (27) and radionuclide therapy (28-30Ȍ of a. The field was initially focused on bombesin agonists until a change in paradigm was introduced with somatostatin receptor (SSTr) antagonists, which despite their poor internalization rate have shown more favorable pharmacokinetics and higher tumor uptake than agonists (31-33). Similarly to SSTr antagonists, GRPR antagonists have shown superior tumor-targeting and pharmacokinetic properties as compared to agonists (11), with promising characteristics for imaging (3, 4) and therapeutic applications (34). 
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FiGURe 7. Therapeutic efficac of 177Lu-JMV4168 to treat subcutaneous PC-3 tumors. Tumor size (A) and weight (B) followup of mice treated with 4 injections of 177Lu-JMV4168 (50 MBq, 200 pmol) on d 0, 2, 4, and 6, with or without PA (n=12 per group).
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FiGURe 8. Representative pic-tures of 53BP1 and H2AX staining (A), GEMININ staining (B) and TUNEL assay 
ȋȌ on Ǧ͵ paraffinǦembedded tissues, 8 d after radionuclide therapy (control, 177Lu-JMV4168, and 177Lu-JMV4168 with p h o s p h o r a m i d o n (PA)).
Scale bar α ͳͷ Ɋm.
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Moreover, the use of GRPR antagonists should prevent side effects such as nausea, 
hot flushǡ and sweatingǡ which were previousl observed in patients inected with a bombesin receptor agonist (12, 13). In a previous study performed by Dumont et al. (34) the potential of GRPR-targeted radionuclide therapy using a GRPR antagonist, 177uǦʹǡ and enhancement of therapeutic efficac in combination with rapamcin were reported. GRPR antagonists can be used as theranostic agents for PCa, but rapid in vivo degradation of these peptides by proteolytic enzymes may strongly hamper their 
FiGURe 9. Representative pictures of ʹ and ͷ͵ͳ foci staining on Ǧ͵ paraffinǦembedded tissues 8 d after radionuclide therapy (control, 177Lu-JMV4168 and 177Lu-JMV4168 with phosphoramidon (PA)). 
Scale bar α ͵ Ɋm.
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targeting properties. Strategies to improve in vivo stability of radiolabeled peptides 
include various structural modificationsǡ such as e amino acid substitutionsǡ 
reductionȀmethlation of biodegradable bonds or ccliationǡ but these modifications 
can cause undesired changes in pharmacoinetics andȀor impair receptor affinit (35-37). The proteolytic enzyme NEP, which is abundant in the human body (38-40), cleaves peptides on the amino side of hydrophobic amino acids, thereby inactivating a broad range of neuropeptides, including bombesin-like peptides (15-17). Recently we have shown that coinjection of the NEP inhibitor PA (41) could stabilize radiolabeled bombesin, minigastrin, and somatostatin analogs in vivo, leading to enhanced tumor uptake (18, 42).In this preclinical study, we have brought this in vivo stabilization concept to the next level, showing that coinjection of PA can contribute to an impressive enhancement in 
diagnostic sensitivit and therapeutic efficac of a 
Ǧtargeted theranostic agent. We labeled the GRPR antagonist JMV4168 with 68Ga for PET imaging and 177Lu for radionuclide therapy. All in vivo studies were performed with 200 pmol JMV4168, which appeared to be the optimal peptide dose in previous experiments (data not shown). The dose of 300 µg of PA was chosen based on previous experience (18). Optimization of PA-dose for this 68Ga-/177Lu-JMV4168 theranostic pair has not been conducted, because the major purpose of the present study has been to show the PA-effect in therapy in a qualitative “proof-of-principle” approach. 177Lu-labeling of 
Ͷͳ͸ͺ with ver high specific activities ȋʹͷͲ ȀnmolȌ could be achieved using n.c.a. 177Lu. In vivo stability studies in mice showed excellent stabilization of 177Lu-JMV4168 in peripheral blood upon coinjection of PA.Biodistribution of 68Ga-JMV4168 and 177Lu-JMV4168 was compared in nude mice with sc PC-3 human tumors. The similar biodistribution patterns of 68Ga-JMV4168 
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FiGURe 10. uantification of number of ͷ͵ͳ foci per nucleus ȋȌǡ and number of cells scored positive 
for 
 ȋȌ or T ȋȌ on Ǧ͵ paraffinǦembedded tissueǡ ͺ d after radionuclide therap. ȋȌ 
 binding of 177Lu-JMV4168 on PC-3 frozen sections after radionuclide therapy (endpoint).
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and 177Lu-JMV4168 at 1 h after injection indicate that 68Ga-JMV4168 could serve as a surrogate to 177Lu-JMV4168 for PET imaging-based patient selection and followup of therapy outcome. Tumor uptake of 177Lu-JMV4168 was similar to tumor uptake of 177Lu-RM2 reported by Dumont et al. (34). Tumor uptake of 68Ga- and 177Lu-JMV4168 was doubled by coinjection of PA, whereas most nontarget background organs and blood levels were not enhanced, leading to higher tumor-to-background ratios. Although uptake of 68Ga-JMV4168 in the GRPR-positive pancreas was also increased by coinjection of PA at 1 h after injection, rapid washout from the pancreas was observed 
between ͳ h and ʹ h after inectionǡ in agreement with previous findings ȋ14). These increased tumor uptake values were visualized on PET images acquired at 2 h after injection, showing higher signal intensity in the PC-3 tumors in mice that received coinjection of PA, with unaltered low intensity in the pancreas area. This suggests that PA could increase sensitivity of detection of small PCa lesions in patients. Dosimetry of 177Lu-JMV4168 was evaluated to predict therapy outcome and to optimize the design of therapy studies. Administration of 177Lu-JMV4168 via the ip route was preferred to reduce injection failure rate and radiation exposure rate to researchers. Based on dosimetry calculations, therapy studies were conducted in nude mice with sc PC-3 tumors with 4 cycles of 50 MBq of 177Lu-JMV4168 (ip) with 2-d intervals. This schedule resulted in an impressive decrease and stabilization of tumor size as compared to that in untreated mice. More strikingly, coadministration of PA to 177Lu-JMV4168 resulted in increased survival. Several reports have suggested a role of NEP in PCa progression (43-45). Minimal effect of NEP inhibition on PC-3 tumor growth was expected, because previous studies have shown lack of NEP expression in PC-3 cells (45-47). Consistently, our results revealed no effect of PA on PC-3 xenograft tumor growth. However, we would recommend testing the effect of PA for each new model being investigated in similar studies. 
n order to confirm the efficac of radionuclide therap at the molecular levelǡ we evaluated the occurrence of DSBs, proliferation and apoptosis in PC-3 tumors. The 
ȾǦparticles emitted b the radionuclide 177Lu induce several types of DNA damage, among which DSBs are the most genotoxic; because unrepaired DSBs can trigger cell cycle arrest, cell death (apoptosis) or chromosomal aberrations. DSBs produced 
b ioniation radiation activate a cascade of eventsǡ including protein modifications (such as gH2AX) and accumulation of several DNA damage response proteins (one of these proteins is the key DSB repair regulator 53BP1) (48). After DSB induction, 
gH2AX, and 53BP1 can be visualized as nuclear foci at the DSBs providing a measure of DSB induction.PC-3 tumors dissected 8 d after the last therapeutic injection revealed increased number of DSBs, as shown by the increase in gH2AX and 53BP1 foci for the groups treated with 177Lu-JMV4168 and 177Lu-JMV4168 with PA. Furthermore, an increased production of DSBs was observed in mice that received coadministration of PA, which was consistent with the higher 177Lu-JMV4168 tumor uptake and the improved therapeutic outcome. 
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In both treated groups, we also observed decreased replication, as shown by the reduction in the number of cell expressing the cell cycle marker GEMININ. In line with these results, TUNEL staining showed an increased level of apoptosis after treatment. 
o significant difference in the number of 
Ǧ and TǦpositive cells was observed between both treated groups, unlike DNA damage data. This could be due to different kinetics of DNA damage repair, proliferation, and apoptosis. 
ltogetherǡ these parameters confirm tissue damage and subseuent tumor volume reduction induced by the radionuclide treatment with 177Lu-JMV4168. Importantly, GRPR expression was maintained on regrowing PC-3 tumors after radionuclide therapy, excluding the possibility of a selection of GRPR-negative cells, and allowing repeated treatment with the same probe. 
CoNCLUSioNIn conclusion, this study highlights the potential of the GRPR-targeted peptide-based theranostic approach for imaging and treatment of PCa. Besides treatment of PCa patients, this approach could be applied to a wider range of GRPR-expressing tumors, such as breast tumors (49). Moreover, it shows how coinjection of the NEP inhibitor 
 can greatl enhance diagnostic sensitivit and therapeutic efficac. e believe that this strategy may contribute to an improved management of PCa patients and 
warrants translation into a clinical setting. 	or that purposeǡ clinicall certified  inhibitors should be preferred to facilitate translation.
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ABSTRACT
rostateǦspecific embrane ntigen ȋSȌ is overepressed in prostate cancer (PCa) and a promising target for molecular imaging and therapy. Nanobodies (single-domain antibodies, VHH) are the smallest antibody-based fragments possessing ideal 
molecular imaging propertiesǡ such as high target specificit and rapid bacground clearance. We developed a novel anti-PSMA Nanobody (JVZ-007) for targeted imaging and therapy of PCa. Here, we report on the application of the 111In-radiolabeled Nanobody for SPECT/CT imaging of PCa. 
MethodsA Nanobody library was generated by immunization of a llama with 4 human PCa cell lines. Anti-PSMA Nanobodies were captured by biopanning on PSMA-overexpressing cells. JVZ-007 was selected for evaluation as an imaging probe. JVZ-007 was initially produced with a c-mycǦheahistidine ȋhisȌ tag allowing purification and detection. The c-myc-his tag was subsequently replaced by a single cysteine at the C terminus, 
allowing siteǦspecific conugation of chelates for radiolabeling. ǦͲͲ͹ǦcǦmyc-his was conjugated to 2-(4-isothiocyanatobenzyl)-diethylene-triaminepentaacetic acid (p-SCN-DTPA) via the lysines, whereas JVZ-007-cys was conjugated to maleimide-DTPA via the C-terminal cysteine. PSMA targeting was analyzed in vitro by cell-binding 
eperiments using flow ctometrǡ autoradiographǡ and internaliation assas with various PCa cell lines and patient-derived xenografts (PDXs). The targeting properties of radiolabeled Nanobodies were evaluated in vivo in biodistribution and SPECT/CT imaging experiments, using nude mice bearing PSMA-positive PC-310 and PSMA-negative PC-3 tumors. 
ResultsJVZ-007 was successfully conjugated to DTPA for radiolabeling with 111In at room temperature. 111In-JVZ007-c-myc-his and 111In-JVZ007-cys internalized in LNCaP cells and bound to PSMA-expressing PDXs and, importantly, not to PSMA-negative PDXs and human kidneys. Good tumor targeting and fast blood clearance were observed for 111In-JVZ-007-c-myc-his and 111In-JVZ-007-cys. Renal uptake of 111In-JVZ-007-c-
mycǦhis was initiall high but was efficientl reduced b coinection of gelofusine and lysine. The replacement of the c-myc-his tag by the cysteine contributed to further reduction of renal uptake without loss of targeting. PC-310 tumors were clearly visualized by SPECT/CT with both tracers, with very low renal uptake (< 4 percentage injected dose per gram) for 111In-JVZ-007-cys already at 3 h after injection. 
ConclusionWe developed an 111In-radiolabeled anti-PSMA Nanobody, showing good tumor targeting, low uptake in nontarget tissues, and low renal retention, allowing excellent SPECT/CT imaging of PCa within a few hours after injection. 
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iNTRoDUCTioNProstate cancer (PCa) is the second leading cause of cancer-related death among men in the western world. Early detection and accurate staging of PCa is crucial because the survival rate decreases dramatically when the cancer has spread beyond the prostate (1Ȍ. ecause of the heterogeneit of aǡ and the lac of specificit of conventional imaging techniques, there is currently no universal imaging method approved for 
detection of earl a lesions. rostateǦspecific membrane antigen ȋSȌ is an interesting target for molecular imaging of PCa, as it is overexpressed in 90-100% of local PCa lesions, as well as on cancerous lymph nodes, and bone metastases (2, 
3), with some reports suggesting PSMA expression levels are further enhanced in high-grade, metastatic, and castration-resistant PCa (2, 4, 5). PSMA is also expressed in other tissues including normal prostate epithelium, small intestine, renal tubular cells, and salivary glands, but the expression in these organs is 100-1,000 fold less than in PCa (6). PSMA, also referred to as glutamate carbopeptidase II (GPCII), NǦacetlǦȽǦlined acidic dipeptidase I (Naaladase I), or folate hydrolase, is a type II transmembrane glycoprotein exhibiting glutamate carboxypeptidase and folate hydrolase enzymatic 
activit. The first clinical tracer for imaging S was based on the murine antiǦS antibody 7E11, binding to an epitope on the intracellular domain of PSMA. The 111In-labeled version of 7E11, 111In-capromab, commonly known as ProstaScint (Cytogen Corp.), was approved by the Food and Drug Administration in 1997 for detection of soft-tissue metastases and recurrence of PCa (7). Its use for staging primary PCa is 
suboptimalǡ with an average sensitivit and specificit of ͸ͲΨ and ͹ͲΨǡ respectivel (8). 111In-capromab was also not reliable for the detection of bone metastases, which are often the initial site of metastasis in advanced PCa (9). After the discovery of 7E11, next-generation monoclonal antibodies (mAb) binding to the extracellular domain of PSMA were developed, including mAb J591. Initially developed for therapeutic purposes, J591 was also evaluated for SPECT imaging in clinical trials, showing characteristics superior to 111In-capromab, revealing most soft-tissue and bony metastases (10, 11). Despite improved targeting of J591 and next-generation PSMA mAb, the major disadvantage of the use of antibodies for imaging is the slow clearance from nontarget tissues, often requiring several days between tracer administration and imaging. An interesting alternative for molecular imaging of PSMA is the development of small-molecule PSMA inhibitors. Because PSMA possesses an enzymatic site in its extracellular domain that cleaves endogenous substrates such as N-acetylaspartylglutamate and 
polǦɀǦglutaml folic acidǡ a series of substrates has been designed. These smallǦmolecule PSMA inhibitors consist of zinc-binding compounds attached to a glutamate moiety. Several radiolabeled PSMA small-molecules inhibitors have been synthetized, starting with phosphonate and phosphate inhibitors, followed by phosphoramidate-, thiol-, and urea-based inhibitors, which are discussed in an extensive review by Mease et al. (12). Some have shown promising results in early clinical studies, such 
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as 123I-MIP-1072, 123I-MIP-1095 (13), N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-18	ǦfluorobenlǦL-cysteine (14), 68Ga-HBED-CC (15), and BAY1075553 (16). These compounds localize rapidly to tumor lesions, including soft-tissue and bone metastases, but also show high uptake in kidneys and salivary glands, attributed to PSMA expression in these organs. Another approach aiming at circumventing the long circulation time of mAbs, is the use of antibody fragments, such as single-domain antibodies (VHH). Nanobodies display attractive features for molecular imaging, including fast nontarget tissue clearance, good tumor penetration capability, and recognition of unique epitopes that are less accessible for mAbs (17). In this study, we describe the development of a Nanobody targeting PSMA and showing good tumor targeting and fast blood clearance, resulting in impressive tumor-to-background ratios within a few hours after injection. The Nanobody was conjugated to a diethylenetriamine-pentaacetic acid (DTPA) chelator allowing facile and stable radiolabeling with 111In at room temperature in a 1-step procedure. The structure of the Nanobody was optimized to minimize renal retention using a novel method for production and labeling of cys-tagged Nanobodies. We report on the production and radiolabeling of anti-PSMA Nanobodies as well as in vitro and in vivo evaluation in patient-derived PCa xenograft models.
MATeRiALS AND MeTHoDS
immunization and VHH Library Construction A llama (Lama glama) was immunized subcutaneously at days 1, 30, 60, and 90 with 4 androgen-responsive human-derived PCa cell lines (33 x 106 cells per cell line) – LNCaP, PC346C, VCaP, and MDA-PCa-2b – to generate a VHH library targeting PCa. Blood was collected after the third immunization and peripheral blood lymphocytes were isolated. Library construction was performed as previously described (18). 
rieflǡ  was isolated and c was snthetied with reverse transcriptase. VHH ȋvariable domains of camelid heavǦchain antibodiesȌ genes were amplified b 
polmerase chain reaction introducing ot and Sfi restriction enme sites ȋforward and backward primers). VHH fragments were isolated from a 1% agarose gel, digested 
with Sfil and otlǡ ligated into the pͳǦ͸S
S phagemid and transformed into T
ͳ Escherichia coli cells to generate a library of 3.3 x 109 transformants (L1P4 library). The VHH library was kindly provided by Dr. Patrick Chames (IBISA).
Selection and Screening by Phage DisplayA phage display library was produced by infecting the Nanobody library with 
ͳ͵ Ͳ͹οp hperphages ȋrogen iotechniȌ. SǦspecific anobodies were captured by 3 rounds of biopanning. Each round consisted of a negative selection using wild-type B16 cells followed by a positive selection on B16-PSMA-transfected 
502161-L-sub01-bw-Chatalic
S ĆēĔćĔĉĞ TĆėČĊęĎēČ ėĔĘęĆęĊ ĆēĈĊė
103
3.1
cells. rieflǡ ͳͲ7 B16 cells were scraped in phosphate-buffered saline (PBS)/10% fetal calf serum (FCS). B16 cells and phages were incubated in PBS/10%FCS/2% protivar milk (Nutrica) for 30 min at RT. B16 cells were incubated with 2 x 1011 phages in PBS/10%FCS/2% protivar milk for 45 min at RT. Meanwhile, B16-PSMA cells were scraped in PBS/10%FCS and incubated in PBS/10%FCS/2% protivar milk (Nutrica) for 30 min at RT. B16 cells were then spin down, and the supernatant containing unbound phages was incubated with 107 B16-PSMA transfected cells in PBS/1% bovine serum albumin (BSA)/2% protivar milk for 45 min at RT. Cells were washed 10 times with PBS/1%BSA/2% protivar milk and 2 times with PBS. Phages bound to PSMA-transfected B16 cells were eluted with 200 mM triethylamine (Sigma) and 
reamplified in T
ͳ cells. olonies were grown on ʹT ȋͳ͸ gȀ trptoneǡ ͳͲ gȀ east 
etractǡ and ͷ gȀ alȌȀampicillin ȋͳͲͲ ɊgȀmȌȀglucose ȋʹΨȌ agar plates. olonies were scraped from the 2YT plates, and stored at –80oC in the presence of 20% glycerol.
Selected single clones were plated in ͳͲͲ Ɋl ʹTȀampicillin ȋͳͲͲ ɊgȀmȌȀglucose (2%) broth in 96-well plates and shaken overnight at 30oC. From each well, 5 
Ɋl was replated in ͳͷͲ Ɋl ʹTȀampicillin ȋͳͲͲ ɊgȀmȌȀglucose ȋʹΨȌ broth and shaken for 2.5 h at 37oC. Phages presenting a VHH were produced by adding 0.5 x 109 
ͳ͵Ͳ͹ȟp helper phage to each well and incubating for ͵Ͳ minutes at ͵͹oC. Plates were centrifuged (1700 rpm, 10 minutes). Bacterial pellet was resuspended in 2YT/
ampicillin ȋͳͲͲ ɊgȀmȌȀanamcin ȋʹͷ ɊgȀmȌ and grown under vigorous shaing overnight at 30oC. Phage-containing supernatants were tested for binding to PSMA by enzyme-linked 
immunosorbent assa using ͳ͸ and ͳ͸ǦS cells. rieflǡ ͳ͸ and ͳ͸ǦS cells were collecting by scraping in PBS containing 1% BSA. Cells were incubated with phage supernatant for 1.5 h at room temperature, shaking. Binding of phages to PSMA was detected with a horseradish peroxidase-conjugated anti-M13 mouse antibody (27-9421-01, GE Healthcare). Cells were then incubated with o-phenylenediamine dihydrochloride substrate (Sigma) and optical density was measured at 490 nm. Clones found positive in cell enzyme-linked immunosorbent assay were further 
analed b flow ctometr. inding of phages was detected with an antiǦͳ͵ mouse antibody (GE Healthcare), followed by a phycoerythrin (PE)-conjugated anti-mouse goat antibody (550589, BD Biosciences). Fluorescence was measured on a FACScan (BD).
nood euencinǡ Production nd Puriϐiction
Selected clones were seuencedǡ and distinct anobod clones were identified. Sequence of JVZ-007 clone is shown in Figure 1. Selected clones were produced as c-mycǦhisǦtagged proteins to facilitate purification b affinit chromatograph and 
detection b flow ctometr. The plasmid containing ǦͲͲ͹ seuence was isolated from the TG1 cells (JetStarTM ʹ.Ͳ plasmid purification  itǡ 
enomedȌ and 
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transformed into HB2151 cells. Production in HB2151 cells was performed overnight at 37°C in 2YT (16 g/L tryptone, 10 g/L yeast extract and 5 g/L NaCl) medium 
supplemented with ͳͲͲ ɊgȀm ampicillin and Ͳ.ͳΨ glucose. ells were collected b centrifugation for 30 min at 4000 rpm, washed with PBS and lysed by freeze-thaw cycles in lysis buffer (50 mM KPO4 pH 7.8, 400 mM NaCl, 100 mM KCl, 10% glycerol, 
Ͳ.ͷΨ TritonǦͳͲͲȌ. sate was centrifuged and filtered ȋͶͲ Ɋm filterȌǡ and cǦmyc-his-tagged Nanobodies were trapped on a HisTrap FF column (GE Healthcare) on a 
"T preparative protein purification sstem ȋ
 ealthcareȌ and eluted with ͷͲͲ mM imidazole. Buffer was changed for PBS using a Vivaspin sample concentrator (5-kDa cut-off, GE Healthcare). C-myc-his-tagged Nanobody purity was assessed with reducing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blot analysis with anti-c-myc mouse antibody (M4439, Sigma), followed by horseradish peroxidase-anti-mouse goat antibody (p0447, Dako) and visualized with 
a hemiluminescence it ȋThermo 	isher ScientificȌ. The protein concentration was 
determined using a bicinchoninic acid assa it ȋThermo 	isher ScientificȌ.
Production of JVZ-007-cysJVZ-007 Nanobody was cloned from the pHEN vector, introducing a cysteine at the C terminus, and expressed as a fusion protein to SUMO3 (Smt3 ubiquitin-like protein) using the pETM11-SUMO3GFP vector (EMBL). The Nanobody sequence was cloned from the pHEN vector using 2 primers (Figure 2).
EVQLVESGGGLVQPGGSLTLSCAASRFMISEYSMHWVRQAPGKGLEWVSTINPAGTTDY
AESVKGRFTISRDNAKNTLYLQMNSLKPEDTAVYYCDGYGYRGQGTQVTVSSTGT  
1 10 20 30 40 50
60 70 80 90 100 110
EVQLVESGGGLVQPGGSLTLSCAASRFMISEYSMHWVRQAPGKGLEWVSTINPAGTTDY
AESVKGRFTISRDNAKNTLYLQMNSLKPEDTAVYYCDGYGYRGQGTQVTVSS  
1 10 20 30 40 50
60 70 80 90 100 110
A
B
FiGURe 1. Amino acid sequence of JVZ-007 Nanobody (A) and JVZ-007 Nanobody with a cysteine residue at the C terminus (B).
502161-L-sub01-bw-Chatalic
S ĆēĔćĔĉĞ TĆėČĊęĎēČ ėĔĘęĆęĊ ĆēĈĊė
105
3.1
The forward primer contains a restriction enzyme site AgeI and 2 glycine molecules, 
necessar for SentrinǦspecific protease ʹ ȋSenʹȌ digestion ȋͷǯ T T
  

T 

 GAG GTG CAG CTG GTG 3’). The backward primer contains a cysteine sequence, a stop sequence and a HindIII restriction enzyme site (3’ TCA GTA AAG CTT TCA ACA TGA GGA GAC GGT GAC 5’). The Nanobody was ligated into the pETM11-SUMO3GFP vector after digestion with AgeI and HindIII. After expression of the recombinant plasmid in BL21 bacteria and protein extraction, JVZ-007-cys-SUMO3 was isolated with a HisTrap 
column. The S͵ protein was cleaved off b a SǦspecific proteaseǡ Senʹǡ (Addgene (19)). Digestion was performed overnight at 4°C with a ratio of 1:10 (w/w) of SenP2 to JVZ-007-cys-SUMO3. His-tagged SenP2 and SUMO3 were removed with a 
JVZ-007 pIII c-myc-his 
pHEN 
AgeI GlyGly  Cys-stop-HindIII 
pETM11-SUMO3GFP 
AgeI HindIII 
Cys-stop Gly-Gly 
Cys-stop-HindIII 
AgeI GlyGly  
JVZ-007 pIII c-myc-his 
SUMO3 His TEV His 
AgeI HindIII 
A
B
C
D
JVZ-007 
SUMO3 His TEV JVZ-007 His 
SUMO3 His TEV His 
AgeI HindIII 
FiGURe 2. Cloning of JVZ-007 from pHEN vector to pETM11-SUMO3GFP vector. (A) pHEN vector containing JVZ-007 and pETM11-SUMO3GFP. (B) Forward primer containing a restriction enzyme site AgeI and two glycine molecules, necessary for SenP2 digestion. Backward primer containing a cysteine sequence, a stop sequence, and a HindIII restriction enzyme site. (C) Products resulting from digestion with AgeI and HindIII. (D) Ligation product of JVZ-007 into the pETM11-SUMO3GFP vector.
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HisTrap FF column (GE Healthcare). JVZ-007-cys Nanobody purity was assessed with 
reducing SSǦ
. 	 elution profile and SSǦ
 are shown in Figure 3. The sequence of JVZ-007-cys is depicted in Figure 1.
FiGURe 3. 	 elution profile ȋȌ and SSǦ
 ȋȌ showing purification of ǦͲͲ͹Ǧcs anobod from His-tagged SenP2 and SUMO3. X-axis = volume (milliliter, mL); y-axis = UV signal (milliabsorbance unit, mAU). Lane 1 = PageRuler Prestained Protein Ladder (10 to 180 kDa); lane 2 = JVZ-007-cys-SUMO3 (fusion protein); lane 3 = SenP2; lane 4 = SenP2, SUMO3 and JVZ-007 (digestion product); lane 5 = JVZ-007-cys 
ȋ	 flow throughȌǢ lane ͸ α Senʹ and S͵ ȋ	 elutionȌ.
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Flow Cytometry
SǦspecific binding was assessed b flow ctometr on Ǧ͵Ͷ͸ǡ aǡ and Ǧ͵ cells, using an anti-c-myc mouse primary antibody and a PE-conjugated antimouse goat 
secondar antibod. rieflǡ cells were collected b scrapping in polproplene tubes and incubated with the c-myc-his-tagged Nanobody for 60 min at 4oC, followed by incubation with an anti-c-myc mouse antibod ȋͶͶ͵ͻǡ SigmaȌ for ͵ Ͳ min and finall Ǧconjugated anti-mouse goat antibody (550589, BD Biosciences) for 30 min. As negative control, cells were incubated using the same procedure, without the Nanobody. As positive control, cells were incubated with an anti-PSMA mouse antibody (SAB4200257, Sigma), and a PE-conjugated goat anti-mouse antibody (550589, BD Biosciences). Flow cytometry was performed using a BD FACScan system (Becton Dickinson). 
Conjugation to DTPA and RadiolabelingJVZ-007-c-myc-his was incubated with a 5-fold molar excess of p-SCN-Bn-DTPA (Macrocyclics) in 0.1 M sodium carbonate buffer (pH 9.5) for 2.5 h at room temperature. JVZ-007-cys was reduced with 1 mM 2-mercaptoethylamine-HCl in phosphate-buffered saline ( ), 5 mM ethylenediaminetetraacetic acid for 90 min at 37°C. Reduced JVZ-007-cys was then incubated with 5 mM maleimide-DTPA for 2 h at 37°C. Conjugated Nanobodies were then dialyzed for 3 d in a Slide-A-Lyzer (3.5-kDa cut-off; Life Technologies) against 0.25 M ammonium acetate (NH4Ac), pH 5.5.Nanobody-DTPA conjugates were labeled with 111InCl3 (Covidien) in 20 mM sodium acetate, pH 5.0, for 30 min at room temperature. Radioprotectants (3.5 mM ascorbic acid, gentisic acid and methionine) were used to prevent radiolysis. Labeling 
efficienc was assessed b instant thinǦlaer chromatograph using silica gelǦcoated paper (Varian Inc.) and 0.1 M citrate buffer, pH 5.0, as mobile phase. After incubation, 
an ecess of T ȋfinal concentrationǣ Ͳ.ͳͷ mȌ was added to comple free 111InCl3. 
Cell CultureCell lines were purchased from the American Type Culture Collection. B16-PSMA was kindly provided by Marco Colombatti (University of Verona). Cell cultures media and reagents were obtained from Lonza unless stated otherwise. LNCaP, VCaP and PC-3 cells were cultured in RPMI 1640 medium containing 10% (5% for PC-3) FCS. PC-346C 
cells were cultured in ulbeccoǯs modified agleǯs 	ͳʹ medium supplemented with 2% FCS, 0.01% BSA (Boehringer-Mannheim), 1% insulin-transferrin-selenium (Life 
TechnologiesȌǡ Ͳ.ͳ ɊgȀm fibronectin ȋlfa esarȌǡ Ͳ.ͳ n ͳͺͺͳ androgenǡ ͳͲ ngȀm 
epidermal growth factorǡ Ͳ.ͷ ɊgȀm deametasonǡ ͳ n triiodothronineǡ Ͳ.ͳ m 
phosphoethanolamineǡ ͷͲ ngȀm cholera toinǡ and ʹ Ͳ ɊgȀm fetuin ȋall from SigmaȌ. 
ͳ͸ cells were cultured in ulbeccoǯs modified agleǯs medium containing ͳͲΨ 	Sǡ 
ͳͲ m S ȋSigmaȌǡ ʹͲ Ɋ ʹǦmercaptoethanol ȋSigmaȌǡ and ʹ m glutamine. 	or 
ͳ͸ǦSǡ ͳʹͲͲ ɊgȀm geneticin ȋ
Ͷͳͺǡ 
ibcoȌ was added to this medium. Ǧ
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PCa2b cells were grown in Ham’s F12 medium containing 15% FCS, 25 ng/mL cholera 
toinǡ ͳͲ ngȀm epidermal growth factorǡ ͷ Ɋ phosphoethanolamineǡ ͳʹͲ pgȀm hydrocortisone, and 1% insulin-transferrin-selenium. Penicillin (100 units/mL) and streptomycin (100 µg/mL) were added to cell culture media. Cells were grown in 
tissue culture flass at ͵͹ι in a humidified atmosphere containing ͷΨ 2.
Autoradiography and internalizationBinding of 111In-JVZ-007-c-myc-his and 111In-JVZ-007-cys to frozen cryostat section of PDXs and kidneys (mouse/human) was evaluated using autoradiography, as described previously (20). Tissue sections were incubated for 1 h with 111In-JVZ-007-c-myc-his or 111In-JVZ-007-cys (10-9 M). In saturation binding experiments, concentrations ranging from 10-6 M to 10-12 M of 111In-JVZ-007-c-myc-his were used. The internalization of 111In-JVZ-007-c-myc-his and 111In-JVZ-007-cys was assessed using LNCaP and PC-3 cells. Cells were trypsinized and incubated with 111In-JVZ-007-c-myc-his or 111In-JVZ-007-cys (10-10 M) in RPMI 1640/GlutaMAX (Life Technologies)/20 mM HEPES/1% BSA (pH 7.4) for 90 min at 37°C or 4°C. JVZ-007-c-
myc-his was used for blocking (10-6 M). After incubation, the cells were centrifuged, and washed 2 times with PBS. Cell surface-bound Nanobodies were eluted using a solution of 50 mM glycine/100 mM NaCl (pH 2.8), and cells were washed with PBS. Cells were then lysed in 1 M sodium hydroxide to collect internalized Nanobody. 
embraneǦbound and internalied fractions were counted in a ɀ counter. inding was expressed as percentage of added amount of radioactivity per number of cells.
Biodistribution and SPeCT/CT imagingMale NMRI nu/nu mice (8 wk old) were transplanted with PC-310 tumor fragments near the left shoulder and injected subcutaneously near the right shoulder with PC-3 cells (3 x 106 cells, 200 µL, 66% RPMI, 33% Matrigel [BD Bioscience]). Three to 4 wk after inoculation, when tumor size averaged 200 mm3, mice were injected intravenously with radiolabeled Nanobody (200 µL). Radiolabeled Nanobody was diluted in PBS containing 0.1% v/w BSA. When coinjection of lysine (20 mg) and gelofusine (4 mg) was performed, radiolabeled Nanobody was mixed 1:1 with a solution of lysine (400 mg/mL) and 100 µL of this solution were coinjected with 100 µL of gelofusine (40 mg/mL). 
ice were inected with Ͳ.͹  of radiolabeled anobod ȋamount ranging from ͳ Ɋg 
to ͳͲͲ ɊgȌ and euthanied Ͷ or ʹͶ h after inection for biodistribution studies. loodǡ 
tumorǡ and relevant organs and tissues were collectedǡ weighedǡ and counted in a ɀ 
counterǡ with a counting time of ͸Ͳ s per sampleǡ isotopeǦspecific energ windowǡ and a counting error not exceeding 5%. The percentage injected dose per gram (%ID/g) was determined for each tissue sample. 
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For SPECT/CT imaging experiments, mice were injected with 30 MBq of 111In-JVZ007-c-mycǦhis ȋͳͲ ɊgȌ or ͳͷ  of 111nǦͲͲ͹Ǧcs ȋͳͲ ɊgȌ. ice were scanned under 
isofluraneȀ2 anesthesia at 3 and 24 h after injection on a small-animal nano-SPECT scanner (Mediso) with heated bed. SPECT emission scans were acquired for 30-42 min, with a matrix of 256 x 256 and 20 projections (120 s per projection). Multi-pinhole mouse collimators with 9 pinholes (1.4 mm diameter) per head were used. SPECT scans reconstruction and processing were performed with InVivoScope/VivoQuant software 2.0 (inviCRO). All animal experiments were approved by the Animal Experiments Committee under the Dutch Experiments on Animal Act and adhered to the European Convention for Protection of Vertebrate Animals used for Experimental Purposes (Directive 86/609/EEC).
Statistical AnalysisStatistical analysis was performed using GraphPad Prism version 5.01 (GraphPad Software). Biodistribution data are represented as the mean %ID/g ± SD, with group sizes of 4 mice. Statistical analysis of biodistribution data was performed using a 1-way 
 with onferroni postǦhoc testǡ and the level of significance was set at  δ Ͳ.Ͳͷ.
ReSULTS
Generation of Anti-PSMA Nanobodies
 aǦspecific anobod librar was generated b immuniation of a llama with Ͷ a 
cell lines ȋaǡ ͵Ͷ͸ǡ a and ǦaǦʹbȌ. SǦspecific anobodies were retrieved by biopanning using phage display for 3 positive and negative selection rounds with B16-PSMA and B16 cell lines, respectively. Selection on PSMA-expressing cells was preferred rather than using the recombinant PSMA protein, to increase the chance of capturing Nanobodies binding to an accessible epitope on the extracellular 
domain of S. Several distinct SǦspecific anobodies were isolated and sequenced (data not shown). Selected clones were produced as c-myc-his-tagged 
proteins to facilitate purification b affinit chromatograph and detection b flow 
ctometr. SǦspecific binding was assessed b flow ctometr on Ǧ͵Ͷ͸ǡ 
aǡ and Ǧ͵ cells. esults of flow ctometr analsis of a few selected anobodies are displayed in Figure 4. JVZ-005, JVZ-007, and JVZ-012 all bound to PSMA-expressing LNCaP and PC346C, as shown by the increase in the geometric mean of 
the fluorescence intensit. o binding was observed on the SǦnegative ͵ cellsǡ 
showing the specificit of the anobodies for S. ǦͲͲ͹ǡ showing the highest binding, was selected for further evaluation as the imaging probe. Its sequence is indicated in Figure 1. JVZ-007-c-myc-his and JVZ-007-cys were successfully produced in bacteria using the pHEN and pETM11-SUMO3GFP expression vectors, respectively.
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Labeling and in Vitro Binding StudiesJVZ-007-c-myc-his was conjugated to p-SCN-Bn-DTPA via lysine residues, to allow radiolabeling with 111n for ST imaging of a. ǦͲͲ͹Ǧcs was siteǦspecificall conjugated with DTPA by reacting it with maleimide-DTPA. JVZ-007-cys formed dimers via cysteine bridging and mild reduction was necessary to free the thiol in the cysteine. 111nǦradiolabeling was performedǡ with specific activities up to 
͸Ͳ Ȁnmolǡ whereas the labeling efficienc alwas eceeded ͻͲΨ. o release of 111In was observed at 4°C up to 72 h after radiolabeling. Binding to frozen sections of PDXs and kidney using autoradiography is shown in Figure 5 and Figure 6. Binding 
affinit of 111In-JVZ-007-c-myc-his was estimated by saturation binding on the PSMA-positive PC-310 tumor, resulting in an equilibrium dissociation constant value of 27.4 
n ȋͳͶ.ͳ Ȃ ͶͲ.͹ǡ ͻͷΨ confidence intervalȌ. 111In-JVZ-007-c-myc-his and 111In-JVZ-007-cys showed high binding to all PSMA-expressing tumor sections (PC310, LNCaP, PC82, and PC295), with lower binding to the weakly PSMA-positive PC346c. The absence of binding was observed on the PSMA-negative tumors (PC3, VCaP, PC133, PC339, and PC324). These results are in line with previous PSMA RNA expression data of these PDXs (Affymetrix data not shown). Binding to mouse and human kidneys was very low (<1%) in comparison with PSMA-positive tumors. 
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FiGURe 4. Flow cytometry analysis of JVZ-005, JVZ-007, and JVZ-012 on LNCaP (A), PC346C (B), and PC-3 cells (C). Binding was observed on PSMA-positive LNCaP and PC346C cells, whereas no binding was observed on PSMA-negative PC3 cells. Green = in presence of Nanobody; red = in presence of PSMA-
antibod ȋSǦbȌǢ blac α controlǡ in absence of anobodǢ Ǧais α fluorescence intensitǢ Ǧais α number of events. 
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3.1Cell binding assays on PSMA-positive LNCaP cells (Figure 
7) showed 30% and 37% internalization after 90 min at 37°C, for 111In-JVZ-007-c-
myc-his and 111In-JVZ-007-cys, respectively. Cell binding of both tracers was blocked in the presence of an excess of unlabeled JVZ-007-c-mycǦhisǡ confirming 
target specificit. nternaliation of 111In-JVZ-007-c-mycǦhis was confirmed b the strongl reduced amount of radioactivity in the internalized fraction (0.05% of total binding) observed at 4°C. Low binding (<1% relative to LNCaP cells) and absence of internalization of 111In-JVZ-007-c-mycǦhis was observed for the SǦnegative cell line Ǧ͵ǡ confirming anobod 
specificit for S.
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FiGURe 5. (A) Saturation binding of 111In-JVZ-007-c-myc-his on PC-310 frozen sections using autoradiography. (B) Binding of 111In-JVZ-007-c-myc-his and 111In-JVZ-007-cys to tumor and kidney frozen sections using autoradiography. High binding is observed on PSMA-expressing tumor sections (PC310, PC346c, LNCaP, PC82 and PC295) whreas no binding is observed on the PSMA-negative tumors PC3, VCaP, PC133, PC339, PC324) and kidneys (mouse or human). Bmax = maximum binding; DLU = digital light unit; KD = equilibrium dissociation constant. 
111In-JVZ-007-c-myc-his
PC310
PC346c
LNCaP
PC82
PC295
111In-JVZ-007-cys FiGURe 6. Binding of 111In-JVZ-007-c-myc-his and 111In-JVZ-007-cys to PSMA-expressing tumor frozen sections (PC310, PC346c, LNCaP, PC82 and PC295) using autoradiography. 
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FiGURe 7. (A) Internalization of 111In-JVZ-007-c-myc-his in LNCaP and PC-3 cells, after incubation for 90 min at 37°C and 4°C. (B) Comparison of internalization of 111In-JVZ-007-c-myc-his and 111In-JVZ-007-cys in LNCaP cells after incubation for 90 min at 37°C. 111In-JVZ-007-c-myc-his and 111In-JVZ-007-cys internalized in PSMA-expressing LNCaP cells at 37°C.
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FiGURe 8. Biodistribution studies in mice bearing PC-310 and PC-3 tumors. Effect of coinjection of gelofusine and lysine (A) and dose (B) on biodistribution of 111In-JVZ-007-c-myc-his (10 μg) at 4 h after injection. (C) Biodistribution at 4 and 24 h after injection of 111In-JVZ-007-cys (10 μg) with coinjection of gelofusine and lysine. (D) Tumor-to-organ ratios at 4 h after injection of 111In-JVZ-007-c-myc-his (10 μg) or 111In-JVZ-007-cys (10 μg) with coinjection of gelofusine and lysine.
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Biodistribution and SPeCT/
CT imagingThe PSMA-targeting properties of 111In-JVZ-007-c-myc-his and 111In-JVZ-007-cys were evaluated further in mice bearing PC-310 and PC-3 tumors. Biodistribution studies are displayed in 
Figure 8, showing good tumor targeting, with low background intensity except for the kidneys. Four hours after injection, the uptake of 111In-JVZ-007-c-myc-his in the PC-310 tumor was 3.91 ± 1.13 %ID/g. Uptake in the kidneys was 110.89 ± 7.35 %ID/g but could be reduced to 27.77 ± 2.02 %ID/g by coinjection of gelofusine and lysine. Increasing doses of JVZ-007-c-myc-his showed a slight decrease in tumor uptake. Similarly, 111In-JVZ-007-cys in combination with gelofusine and lysine showed uptake in PC-310 and PC-3 tumors of 3.70 ± 0.29 %ID/g and 0.18 ± 0.05 %ID/g at 4 h after injection, respectively. Importantly, kidney uptake was approximately 10-fold lower than that of JVZ-007-c-myc-his, with values of only 3.13 ± 0.30 and 0.61 ± 0.20 %ID/g, at 4 h and 24 h after injection, respectively. Moreover, 111In-JVZ-007-cys showed higher tumor-to-background ratios at 4 h after injection than 111In-JVZ-007-c-myc-his, with a tumor-to-muscle ratio of 104.8 ± 27.4 
and tumorǦtoǦidne ratio of ͳ.ʹ ά Ͳ.ͳ. The tumorǦtoǦblood ratio was significantl lower for 111In-JVZ-007-cys (48.1 ± 5.1) than for 111In-JVZ-007-c-myc-his.
FiGURe 9. SPECT/CT images of mice bearing PC-310 (left shoulder) and PC-3 (right shoulder) tumors. (A) Images acquired 3 h after injection of 111In-JVZ-007-c-myc-his with coinjection of PBS (left) or gelofusine and lysine (right). (B) Images acquired 3 h (left) and 24 h (right) after injection of 111In-JVZ-007-cys with coinjection of gelofusine and lysine. Scale from 0 to 0.2 kBq (A); 0 to 0.015 kBq (B, left); 0 to 0.005 kBq (B, right). PSMA-expressing PC-310 tumor could be clearly visualized with high contrast on the left shoulder, whereas no uptake was observed in PC-3 tumor on the right shoulder. 
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SPECT/CT images of mice bearing PC-310 and PC-3 tumors 3 h after injection of 111In-JVZ-007-c-myc-his and 111In-JVZ-007-cys are shown in Figure 9. PSMA-expressing PC-310 tumor could be clearly visualized with high contrast on the right shoulder, whereas no uptake was observed in PC-3 tumor on the left shoulder. Signal intensity in kidneys of 111In-JVZ-007-c-mycǦhis was ver high but could be efficientl reduced by coadministration of gelofusine and lysine. Importantly, kidney signal intensity of 111In-JVZ-007-cys was markedly lower.
DiSCUSSioNDevelopment of PSMA-based imaging tracers for PCa has increased tremendously in the past few years. After the approval of the PSMA mAb 111In-capromab as an imaging agent in 1997, a panel of novel PSMA-targeted imaging agents was developed, including next-generation antibodies, antibody fragments, aptamers, and PSMA inhibitors (12). PSMA small-molecule inhibitors localize rapidly to tumor lesions, including soft-tissue and bone metastases, but also show high uptake in kidneys and salivary glands. The high uptake of PSMA inhibitors in these organs was attributed to PSMA expression, although the expression of PSMA in these organs was shown to be 100- to 1,000-fold lower than in PCa (6). This lower PSMA expression in normal organs may suggest that other (receptor-mediated) processes may be involved in tracer uptake in normal organs as well. In parallel to these developments, alternative strategies have been pursued using smaller variants of mAb, such as antigen-binding fragments (Fab) and F(ab’)2 (21), and minibodies or diabodies (22, 23), aiming to circumvent the long circulation time of mAb. These antibody fragments have shown fast target recognition and rapid blood clearance 
but also show unspecific accumulation in the liver and idnes.  more recent approach is the use of Nanobodies (VHH), the smallest antibody-based fragments (12-15 kDa), offering ideal characteristics for molecular imaging. Because of their small size below 
the renal threshold for glomerular filtration ȋ͸Ͳ aȌǡ the are mainl cleared via the renal pathway. Moreover, it is possible to humanize Nanobodies for clinical translation using the recently described universal humanized Nanobody scaffold technique (24). Nanobodies targeting PSMA were developed, showing moderate tumor targeting, low liver uptake, and high kidney uptake (25). Retention of tracers in the kidneys might be 
the result of a combination of different factorsǡ including glomerular filtration b the 
idneǡ SǦspecific bindingǡ and trapping of metabolites in the lsosomes of renal tubular cells. Tracer retention in the kidneys is not desirable, because it may interfere with visualization of small tumor lesions in the vicinity of the kidneys and especially with staging of PCa. Renal tracer retention also limits the application of the PSMA tracer 
for radionuclide therap b inflicting a high dose to the idnes. e have developed a Nanobody (JVZ-007) that shows good tumor targeting in PSMA-expressing PC-310 PDX tumors. JVZ-007 was initially produced with a c-myc-his-tag and conjugated to p-SCN-Bn-DTPA via the lysine residues, to allow radiolabeling with 111In for SPECT imaging of PCa. 111In-JVZ-007-c-myc-his was internalized in LNCaP cells and showed high binding 
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on all PSMA-expressing PDX sections in vitro, whereas low binding to the PSMA-negative PDX sections was observed and 50-fold lower binding to the human kidney than the PC-310 tumor, indicating the markedly lower expression levels of PSMA in the kidney. 111In-JVZ-007-c-myc-his was evaluated further in mice bearing PC-310 tumors, showing good tumor targeting as early as 4 h after injection, with low background intensity, except for the kidneys. It was recently described that renal retention of an anti-epidermal growth factor receptor Nanobody could be reduced by coinjection of gelofusine and lysine (26Ȍ. ndeedǡ efficient reduction of renal uptae of our antiǦS anobod was obtained when gelofusine and lysine were coadministered. These results support that high renal uptake may be due to reabsorption in the renal promixal tubule after 
glomerular filtration. oreoverǡ studies from ǯuvetter et al. ȋ27) have also shown that the his-tag plays a major role in the high retention of radiolabeled Nanobodies in the kidneys. Therefore, we have engineered a new Nanobody construct, based on JVZ-007, in which the c-myc-his tag was removed. In addition, we introduced a cysteine 
at the  terminus for siteǦspecific coupling to maleimideǦT. 	or this purpose we used the pETM11-SUMO3GFP expression vector, allowing production of a protein with 
a Ǧterminal csteine and retrieval of the protein b cleavage of S͵ b a specific protease. 111In-JVZ-007-cys showed similar binding on PSMA-expressing cells and PDXs. More importantly, a further drop in renal uptake to 3 %ID/g was observed at 4 h after injection, without loss of tumor targeting. In comparison, these renal uptake values in mice were inferior to those found with other PSMA tracers: 100 %ID/g for 68Ga-HBED-CC-PSMA (1 h) (28) and 111In-D2B-Fab fragments (4 h) (21). Kidney uptake of 78 and 36 %ID/g were reported for 123I-MIP-1095 and 123I-MIP-1072 (4 h), respectively (29). Tumor-to-blood and tumor-to-muscle ratios obtained with 111In-JVZ-007-cys at 4 h after injection were superior to those obtained with 111In-D2B-Fab fragments (21) and comparable to those obtained with 123I-MIP-1095, in LNCaP xenograft mice (4 h) (29Ȍ. The novel method described here for production and siteǦspecific labeling of csǦ
tagged anobodies could have a significant impact for the clinical implementation of 
a wide range of anobodies. The siteǦspecific coupling offers a wellǦdefined labeling procedure, while the absence of the c-myc-his-tag limits reabsorption in renal tubular cells. This minimal renal retention also broadens the applicability of this Nanobody to radionuclide therapy. 
CoNCLUSioN
e developed a specific antiǦS anobod containing a csteine for siteǦspecific conjugation to radioactive labels. The 111In-radiolabeled anti-PSMA Nanobody shows good tumor targeting and fast blood clearance, allowing SPECT/CT imaging within a few hours after injection. Unlike most radiolabeled small-molecule PSMA inhibitors, anti-PSMA Nanobody JVZ-007 displays a low kidney uptake. These results warrant further evaluation of anti-PSMA Nanobody JVZ-007 for detection and radionuclide therapy of metastatic lesions in PSMA-expressing PCa, for which few treatment options are currently available. 
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ABSTRACT
rostateǦspecific membrane antigen ȋSȌ is a wellǦestablished target for nuclear imaging and therapy of prostate cancer (PCa). Radiolabeled small-molecule PSMA inhibitors are excellent candidates for PCa theranostics – the rapidl and efficientl localize in tumor lesions. However, high tracer uptake in kidneys and salivary glands are major concerns for therapeutic applications. Here, we present the preclinical application of PSMA I&T, a DOTAGA-chelated urea-based PSMA inhibitor, for SPECT/CT imaging and radionuclide therapy of PCa. 111In-PSMA I&T showed dose-dependent uptake in PSMA-expressing tumors, kidneys, spleen, adrenals, lungs and salivary glands. Coadministration of 2-(phosphonomethyl)pentane-1,5-dioic acid (2-
Ȍ efficientl reduced SǦmediated renal uptae of 111In-PSMA I&T, with the highest tumor/kidney radioactivity ratios being obtained using a dose of 50 nmol 2-PMPA. SPECT/CT clearly visualized subcutaneous tumors and sub-millimeter intraperitoneal metastases; however, high renal and spleen uptake in control mice (no 2-PMPA) interfered with visualization of metastases in the vicinity of those organs. Coadministration of 2-PMPA increased the tumor-to-kidney absorbed dose ratio during 177Lu-PSMA I&T radionuclide therapy. Hence, at equivalent absorbed dose to the tumor (36 Gy), coinjection of 2-PMPA decreased absorbed dose to the kidneys from 30 Gy to 12 Gy. Mice injected with 177Lu-PSMA I&T only, showed signs of nephrotoxicity at 3 months after therapy, whereas mice injected with 177Lu-PSMA I&T + 2-PMPA did not. These data indicate that PSMA I&T is a promising theranostic tool 
for a. SǦspecific uptae in idnes can be successfull tacled using blocing agents such as 2-PMPA.
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iNTRoDUCTioNProstate cancer (PCa) is a major health problem in men. Prognosis is dependent 
on stage of the disease and the fiveǦear survival rate for advancedǡ disseminated PCa is only 29% (1). Metastatic castration-resistant PCa (mCRPC) is associated with poor prognosis and diminished quality of life. Treatment options for mCRPC patients include taxane-based therapies (docetaxel, cabazitaxel) and novel second-line hormonal therapies (enzalutamide and abiterone), all showing moderate 
survival benefits. nfortunatelǡ those therapies are onl temporaril effective and development of treatment resistance is observed (2, 3). The bone-seeking alpha-
emitting radiopharmaceutical adiumǦʹʹ͵ chloride ȋofigoTM) has recently been introduced, resulting in reduction of bone pain and moderately improved survival in mCRPC patients with bone metastases (4, 5). However, the use of this promising radiopharmaceutical is limited to the treatment of bone metastases. Therefore, there 
is an urgent need to develop more specific therapies that target a visceral lesions as well. Recent developments in PCa-targeted radiopharmaceuticals have focused on 
prostateǦspecific membrane antigen ȋSȌ ligands. S is a favorable target for imaging and radionuclide therapy of PCa, because it is overexpressed in 90-100% of local PCa lesions, as well as in cancerous lymph node metastases and bone lesions. Furthermore, reports indicate that PSMA expression levels are further enhanced in high-grade, metastatic and castration-resistant PCa (6-9). Numerous studies have shown the value of radiolabeled PSMA-targeted agents to visualize PCa lesions, including PCa metastases (10-18). Among the different PSMA-targeting tracers available, several tracers have made their way to the clinic. For PET imaging of PCa, Glu-NH-CO-NH-Lys-(Ahx)-68Ga-HBED-CC, also known as 68Ga-PSMA-11 or 68Ga-PSMA-HBED-CC, is the most commonly used compound (14, 18). Unfortunately, HBED-CC (N,N’-bis[2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N’-diacetic acid), the chelator used in this tracer, is not suitable for radiolabeling with radiometals for therapeutic applications (e.g. 177Lu, 90Y, 213Bi). More recently, a novel 18F-labeled PSMA inhibitor, 18F-DCFPyL, was introduced in the clinic (19). For therapy, anti-PSMA monoclonal antibodies (J591) radiolabeled with 177Lu and 90Y (11, 20, 21) and the small-molecule PSMA inhibitor [131I]MIP-1095 (22Ȍ have shown promising therapeutic efficacǡ although with moderate toicit. Moreover, PSMA ligands with DOTA-derived chelators have been developed, which can be labeled with diagnostic radionuclides, e.g. 68Ga for PET and 111In for SPECT, as well as therapeutic radionuclides, e.g. 177Lu, 90Y or 213Bi for radionuclide therapy. Such theranostic compounds, i.e. PSMA I&T and PSMA-617, are of great interest because they combine the potential of diagnosis and radionuclide therapy using one PSMA targeting molecule (23-27). 
adioligand propertiesǡ e.g. lipophilicitǡ target affinit and metabolic stabilit have been carefully optimized for theranostic applications. Monoclonal antibodies showed 
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slow blood clearance, which may result in myelotoxicity. Small-molecule PSMA inhibitors showed the advantage to localize rapidly in tumor lesions, including soft-tissue and bone metastases. On the other hand, these small inhibitors showed high 
and specific uptae in SǦepressing idnes and salivar glandsǡ which is of maor concern for its application for radionuclide therapy. Strategies should therefore be investigated to limit radiation-induced damage in healthy organs. Here we report on the preclinical application of the DOTAGA-chelated urea-based PSMA inhibitor PSMA I&T for SPECT/CT imaging and radionuclide therapy of PCa. In this study we investigated if coinjection of 111In-PSMA I&T with 2-(phosphonomethyl)pentane-1,5-dioic acid (2-PMPA) could contribute to increasing tumor-to-kidney uptake ratio, thereby facilitating visualization of metastatic lesions in the vicinity of the kidneys, and most importantly reducing toxicity during radionuclide therapy.
MATeRiALS AND MeTHoDS
Cell Culture The human prostate cancer cell line LNCaP was cultured in RPMI 1640 medium (GIBCO, BRL Life Sciences Technologies, The Netherlands), supplemented with 2 mM glutamine (GIBCO) and 10% fetal calf serum (FCS, Sigma-Aldrich Chemie 
ǡ The etherlandsȌ at ͵͹ ι in a humidified atmosphere with ͷΨ 2. LS174T colon carcinoma cells were stably transfected with human PSMA using the plasmid pcDNA3.1-hPSMA and cultured in RPMI 1640 medium supplemented with 2 mM glutamine, 10% FCS, and 0.3 mg/ml G418 (28).
Radiolabeling
111In labelingPSMA I&T (Figure 1), a DOTAGA-chelated urea-based PSMA inhibitor, was synthetized as described previously (25) and kindly provided by the Technical University Munich. PSMA I&T was radiolabeled with 111InCl3 (Mallinckrodt BV, Petten, The Netherlands) in 0.5 M 2-(N-morpholino)ethanesulfonic acid (MES) buffer (twice volume of 111InCl3), pH 5.5, for 10 min at 95 °C under metal-free conditions (29). After incubation, 4 mM 
diethlenetriaminepentaacetic acid ȋTȌ was added to a final concentration of 0.2 mM to complex free 111InCl3. abeling efficienc was determined b instant thinǦlayer chromatography (ITLC) using silica gel coated paper (Agilent Technologies, Palo Alto, CA) and 0.1 M ammonium acetate containing 0.1 M ethylenediaminetetraacetic 
acid ȋTȌǡ p ͷ.ͷǡ as the mobile phase. abeling efficienc eceeded ͻͷΨ in all experiments.
177Lu labelingNo-carrier added (n.c.a.) 177LuCl3 was obtained from Isotope Technologies Garching (ITG) GmbH (Garching, Germany). Labeling was performed in 0.5 M MES buffer 
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(twice volume of 177LuCl3Ȍǡ p ͷ.ͷǡ for ʹͲ min at ͻͷ ι. T was added to a final concentration of 5 mM to complex free 177Lu3+ after reaction. abeling efficienc was determined by ITLC and radiochemical purity by reverse-phase high performance liquid chromatography (RP-HPLC) on an Agilent 1200 system (Agilent Technologies). A monolithic C18 column (Onyx, 4.6 x 100 mm; Phenomenex, Torrance, CA) was 
used at a flow rate of 1 ml/min with the following buffer system: buffer A, 0.1% v/v TFA in water; buffer B, 0.1% v/v TFA in acetonitrile; and a gradient of 97% to 0% buffer A (5-15 min). The radioactivity of the eluate was monitored using an in-line NaI radiodetector ȋatest 
mbǡ Straubenhardtǡ 
ermanȌ. lution profiles were 
analyzed using 
inaǦstar software ȋversion ʹ.ͳͺǢ atest 
mbȌ. abeling efficienc was 95% and radiochemical purity was 93-95%.
Scatchard Analysis of PSMA i&TScatchard analysis was performed to determine the dissociation constant (Kd) of 111In-PSMA I&T and to quantitatively measure PSMA expression on LNCaP and LS174T-
S cells. ells were cultured to confluence in siǦwell plates and incubated for Ͷ h on ice with increasing concentrations 111In-PSMA I&T (0.03 – 30 nM) in 1 ml RPMI 
ͳ͸ͶͲ containing Ͳ.ͷΨ S. onspecific binding was determined b coincubation with 100 µM PSMA I&T. After incubation, cells were washed with PBS and the cell-
associated activit was measured in a shielded wellǦtpe gamma counter. The specific 
binding ȋtotal binding Ȃ nonspecific bindingȌ was plotted against the boundȀfree ratio. Data were analyzed by linear regression to determine PSMA antigen density per cell and to determine the Kd of 111In-PSMA I&T.
AutoradiographyBinding of 111In-PSMA I&T to 10-mm frozen sections of patient-derived xenografts (PDXs) and of human and mouse kidneys was evaluated using autoradiography, as described previously (30). Tissue sections were incubated for 1 h with 111In-PSMA I&T (10-9 M). 
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Animal StudiesAnimal experiments were performed in male BALB/c nude mice (Janvier, le Genest-Saint-Isle, France) and were conducted in accordance with the principles laid out by the revised Dutch Act on Animal Experimentation (1997) and approved by the institutional Animal Welfare Committee of the Radboud University Nijmegen. At 6-8 weeks of age, mice were inoculated subcutaneously with 3 x 106 LNCaP cells (in RPMI-1640 medium:matrigel 2:1, BD Biosciences, Pharmingen) and/or 2.5 x 106 LS174T in RPMI-1640 medium. Because LS174T-PSMA xenografts showed better tumor take and more reproducible growth, the LS174T-PSMA model was selected for pharmacokinetic and therapeutic experiments. The tracer was injected when tumors reached a size of approximately 0.1 cm3. For SPECT/CT imaging of intraperitoneal tumors, mice were inoculated with 1 x 106 LS174T-PSMA cells in RPMI-1640 medium intraperitoneally and imaged 2-3 weeks after inoculation. 
Dose escalation Study
	our groups of five mice with subcutaneous SǦepressing enografts ȋright flanǣ 
aǡ left flanǣ Sͳ͹ͶTǦSȌ received an intravenous inection of Ͳ.ʹ  111In-
S ƬT ȋspecific activit ʹ ȀnmolȌ in the tail vein. The effect of the dose of PSMA I&T on the biodistribution of 111In-PSMA I&T was studied by administering 
different doses ȋͲ.ͳ Ȃ Ͳ.͵ Ȃ ͳ Ȃ ͳͲ nmolȀmouseȌ to groups of five mice. Two hours post injection, mice were euthanized using CO2/O2-asphyxiation and the biodistribution of 111In-PSMA I&T was determined ex vivo. Tumors, blood, and relevant organs and 
tissues were dissectedǡ weighedǡ and radioactivit in each sample was uantified 
using a ɀǦcounter. The results were epressed as percentage of inected dose per gram of tissue (%ID/g).
Reduction of Renal Tracer Uptake with 2-PMPA
	ive groups of five mice with subcutaneous Sͳ͹ͶTǦS and a enografts received an intravenous injection of 0.2 MBq 111In-PSMA I&T (0.3 nmol) in vehicle (PBS/ 0.5% BSA) in the tail vein. Mice were injected with either 111In-PSMA I&T alone 
or in combination with ʹ Ǧ ȋͳͲǡ ʹ Ͳǡ ͷͲ nmolȌ to reduce specific binding in idnes. One additional group was injected with 4 mg gelofusine 6 min before injection of 111In-PSMA I&T to investigate tubular reabsorption mediated renal uptake. Two hours after injection, mice were euthanized and the biodistribution was determined ex vivo. 
To determine the best time point of ʹǦ inectionǡ five groups of five mice with subcutaneous LS174T-PSMA xenografts received an intravenous injection of 0.2 MBq 111In-PSMA I&T (0.3 nmol) with a preinjection (15 or 60 min), a coinjection, or a postinjection (15 or 60 min) of 50 nmol of 2-PMPA. Two hours after injection, mice were euthanized and the biodistribution was determined ex vivo.
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PharmacokineticsTo determine the pharmacokinetics of 111In-PSMA I&T, eight groups of four mice with subcutaneous LS174T-PSMA xenografts received an intravenous injection of 0.2 MBq 111In-PSMA I&T (0.3 nmol) followed by ex vivo biodistribution at 1, 4, 24, and 48 h after injection. Mice were injected with or without 2-PMPA (50 nmol) coinjection to study the effect of 2-PMPA on tumor and kidney retention of 111In-PSMA I&T.
DosimetryBiodistribution data obtained in the pharmacokinetic study were used to estimate the absorbed radiation doses to the organs and tumor. A single-exponential expression was 
fitted to the activit data at ͳǡ Ͷǡ ʹ Ͷ and Ͷͺ hǡ and the cumulative activit concentration 
in each organ was calculated b analtic integration of the fitted epression. Absorbed doses to the organs were calculated according to the MIRD-scheme (31) with the following equation: ∑( ) ( ) ( )= × ←D r Ã r S r rT r S T SS , with ( )D rT  the absorbed dose to a target organ rT , ( )Ã rS  the time-integrated activity in a source organ rS  and ( )←S r rT S  the absorbed dose rate per unit activity of 177Lu. The S-values were obtained for a standardized 25 g mouse from the RADAR realistic animal models (32). The biodistribution data were measured in activity concentration and hence the time-integrated activity concentration was obtained and this was multiplied with the source organ mass, as used in the phantom for the S-value calculation. The dosimetry calculations assume comparable biodistribution of 111In-PSMA I&T and 177Lu-PSMA I&T. Absorbed doses to renal cortex were estimated assuming localization of 177Lu-PSMA I&T in the cortex (33).
SPeCT/CT imagingMice with subcutaneous (n = 4) or intraperitoneal (n = 12) LS174T-PSMA tumors were injected with 20 MBq 111nǦS ƬT ȋͲ.͵ nmolǡ specific activit ͸͹ ȀnmolȌǡ with or without coinjection of 2-PMPA (50 nmol). One hour after injection, mice were euthanized by CO2/O2 asphyxation and images were acquired with the U-SPECT-II/CT (MILabs, Utrecht, The Netherlands) (34). Mice were scanned for 50 min using the 1.0 mm diameter pinhole mouse high sensitivity collimator tube, followed by a CT scan (spatial resolution 160 µm, 65 kV, 615 µA) for anatomical reference. Scans were reconstructed with MILabs reconstruction software, using an ordered-subset expectation maximization algorithm, energy window 154 – 188 kEv, 3 iterations, 
ͳ͸ subsetsǡ voel sie of Ͳ.ʹ mmǡ and 
aussian filter Ͳ.Ͷ mm. STȀT scans were analyzed and maximum intensity projections (MIPs) were created using the Inveon Research Workplace software (IRW, version 4.1). 
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Radionuclide TherapyTo assess potential renal toxicity of 177Lu-PSMA I&T, three groups of four mice with subcutaneous LS174T-PSMA xenografts were injected intravenously with 100 MBq 177Lu-PSMA I&T (0.35 nmol) with or without 2-PMPA (50 nmol) coinjection, or with vehicle (PBS/ 0.5% BSA). Body weight was monitored twice weekly. Renal function 
was assessed three months after treatment b uantification of renal uptae of 99mTc-dimercaptosuccinic acid (99mTc-DMSA) using SPECT (35) and by measuring plasma creatinine levels. DMSA (Renocis, IBA Molecular, The Netherlands) was radiolabeled with 99mTcO4-, which was eluated from a 99Mo/99mTc-generator (GE Healthcare, The Netherlands). Mice were injected with 29 ± 5 MBq 99mTc-DMSA and images were acquired with the U-SPECT-II/CT, 2 h post injection, 20 min acquisition, scan range of 2.6 x 2.6 x 5.2 cm, using the 1.0 mm diameter pinhole mouse high sensitivity collimator tube. Scans were reconstructed with MILabs reconstruction software, using an ordered-subset expectation maximization algorithm, energy window 126-
ͳͷͶ vǡ ͵ iterationsǡ ͳ͸ subsetsǡ voel sie of Ͳ.ʹ mmǡ and 
aussian filter Ͳ.Ͷ mm. Standards containing 99mTc-DMSA (0.036-3.36 MBq) were scanned using the same 
scanning protocol and a standard curve was derived for uantification. Scans were 
uantified b drawing a volume of interest ȋȌ around the idnes using the  software. Four days prior to scanning, plasma samples were collected and creatinine 
levels were analed b eroset ȋbbott iagnosticsȌ. ndpoint criteria were defined as body weight loss of > 20% of the initial body weight or body weight loss of > 15% within two days. One mouse reached a humane endpoint criterion 111 days after the start of therapy. The other mice were euthanized 118 days after the start of therapy 
for histopathological analsis of the idnes. TwoǦρm sections of paraffinǦembedded kidneys were stained with periodic acid Schiff following routine diagnostic procedures and analyzed for morphological alterations by an experienced pathologist (MC).
To determine the therapeutic efficac of 177Lu-PSMA I&T, three groups of ten mice with subcutaneous LS174T-PSMA xenografts were injected intraveneously with 100 MBq 177Lu-PSMA I&T (0.35 nmol) with or without 2-PMPA (50 nmol) coinjection, or with vehicle (PBS/ 0.5% BSA). Tumor growth was monitored by caliper measurements in three dimensions twice weekly. Body weight was monitored twice weekly. Endpoint 
criteria were defined as ȋͳȌ bod weight loss of ε ʹ ͲΨ of the initial bod weight or bod weight loss of > 15% within two days, (2) tumor volume of 2000 mm3, (3) ulceration of the tumor.
Statistical AnalysisStatistical analyses were performed using PASW Statistics version 18.0 (Chicago, IL) and GraphPad Prism version 5.03 (San Diego, CA). Differences in uptake of 111In-
S ƬT were tested for significance using the nonparametric rusalǦallis and Mann-Whitney U test. Survival was described with the median survival, and survival curves were compared with the log-rank test. A p-value below 0.05 was considered 
significant. 
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ReSULTS
111In-P IƬ ows i eciϐicit to P-Eressin P ellsǡ P 
Xenografts, and Kidneys in VitroBinding of 111In-PSMA I&T was assessed in vitro on LNCaP and LS174T-PSMA cells in saturation binding experiments. The equilibrium binding constant (Kd) of 111In-PSMA I&T was 3.9 ± 1.2 nM for LNCaP and 5.6 ± 1.2 nM for LS174T-PSMA. The number of 111In-PSMA I&T binding sites was 43,000 ± 6,000 for LS174T-PSMA and 137,000 ± 13,000 sites/cell for LNCaP.Binding of 111In-PSMA I&T was also evaluated on frozen xenograft tumors and kidney sections using autoradiography as shown in Figure 2. 111In-PSMA I&T showed high binding to all PSMA-expressing xenograft sections (LNCaP, PC310, PC346c, PC295 and PC82) and PSMA-expressing kidneys (mouse and human). Binding to LNCaP tumors was 6 times higher than binding to human kidneys and binding to mouse kidney was 2 times higher than binding to human kidneys. Binding to the PSMA-negative tumors 
ȋ͵ǡ aǡ ͳ͵͵ǡ ͵͵ͻǡ ͵ʹͶȌ was ver lowǡ showing the targetǦspecificit of the tracer.
111In-P IƬ eciϐicll ccumultes in P-Eressin umn enorfts 
in MiceThe optimal tumor targeting doses of 111In-PSMA I&T were 0.1 – 0.3 nmol for LS174T-PSMA tumors and 0.1 – 1.0 nmol for LNCaP tumors (Figure 3A). Tumor uptake with 0.3 nmol 111In-PSMA I&T was 17.0 ± 2.4 %ID/g and 11.7 ± 5.5 %ID/g for LS174T-
S and aǡ respectivel ȋp α Ͳ.ͲͻͷȌ. Tumor uptae was significantl reduced from 0.3 nmol to 1 nmol tracer (p = 0.008) and 1 nmol to 10 nmol tracer (p = 0.008) 
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FiGURe 2. Specificit of 111In-PSMA I&T for detecting PSMA-expressing tumors and tissues. High binding was observed on PSMA-expressing tumor sections (LNCaP, PC310, PC346c, PC295 and PC82) and PSMA-expressing kidneys (mouse and human), whereas no binding was observed to the PSMA-negative tumors (PC3, VCaP, PC133, PC339, PC324).
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for Sͳ͹ͶTǦS and aǡ respectivel. The tracer also specificall accumulated in kidneys, spleen, lungs, salivary glands, and adrenals. The highest uptake was measured in kidneys (122 ± 27.0 %ID/g for 0.3 nmol 111In-PSMA I&T). 
oinection of ʹ-PP iniϐicntl educes enl te of 111in-PSMA i&T To reduce renal retention, different kidney protecting strategies were evaluated (Figure 3BȌ. oinection of Ͷ mg gelofusine did not significantl reduce renal uptae of 111nǦS ƬT ȋp α Ͳ.ͶʹȌǡ whereas coinection of ͳͲ nmol ʹǦ significantl reduced uptake in kidneys (p = 0.008), spleen (p = 0.016), lung (p = 0.032), adrenals (p = 0.032), and LS174T-PSMA tumors (p = 0.008), but not in LNCaP tumors (p = 0.310). The highest tumor-to-kidney ratios for LS174T-PSMA were obtained with 50 nmol 2-PMPA. Coinjection of 50 nmol 2-PMPA resulted in a 7-fold reduction in renal uptake (from 135.9 ± 31.2 %ID/g to 19.5 ± 1.8 %ID/g), whereas tumor uptake was only reduced two-fold: from 14.9 ± 2.8 %ID/g to 6.8 ± 1.0 %ID/g (LS174T-PSMA) and from 
ͳͳ.Ͳ ά ͸.Ͳ ΨȀg to ͷ.Ͷ ά ʹ.͵ ΨȀg ȋaȌ. Timing of ʹǦ inection significantl 
influenced the tumorȀidne tracer uptae ratios ȋpδͲ.ͲͲͳȌ. ost effective renal tracer uptake reduction was obtained by coinjection of 111In-PSMA I&T with 2-PMPA or preinjection of 2-PMPA 15 min before 111In-PSMA I&T. Kidney/tumor tracer uptake 
ratio was significantl higher after coinection as compared to ͳͷ min preinection (p = 0.008) of 2-PMPA (Figure 3C). 
Coinjection of 2-PMPA improves the Tumor-to-Kidney Absorbed Dose RatioThe optimal 111In-PSMA I&T tracer dose (0.3 nmol) was selected to determine the tracer pharmacokinetics. Biodistribution studies were performed with and without 2-PMPA (coinjection of 50 nmol) for renal protection. For 111In-PSMA I&T 
aloneǡ uptae in tumor was the highest at ͳ and Ͷ h after inectionǡ and significantl decreased between 4 and 24 h after injection (p = 0.029) (Figure 4A). For 111In-PSMA I&T with 2-PMPA coinjection, tumor uptake was the highest at 1 h after injection and 
significantl decreased from ͳ to Ͷ h after inection alread ȋp α Ͳ.ͲʹͻȌ ȋFigure 4B). 
ptae in SǦepressing health organs significantl decreased for both groups between 4 and 24 h after injection (p = 0.029).
SingleǦeponential curves were fitted to the biodistribution data and estimated absorbed doses to tumor and organs were calculated (Figure 4C). Estimated absorbed doses from 100 MBq 177Lu-PSMA I&T in tumor, kidneys, spleen, and adrenals were 36, 30, 1, and 2 Gy, respectively, for 177Lu-PSMA I&T alone and 15, 5, 0.2, and 0.3 Gy, respectively, for 177Lu-PSMA I&T with 2-PMPA. Tumor-to-kidney dose ratio was substantially improved from 1.2 to 3.0 when 177Lu-PSMA I&T was co-injected with 2-PMPA. Consequently, at an equivalent absorbed dose to the tumor (36 Gy), coinjection of 2-PMPA decreases absorbed dose to the kidneys from 30 Gy to 12 Gy. These absorbed doses to kidneys were calculated assuming uniform distribution of radioactivity. However, SPECT 
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FiGURe 3. Biodistribution of 111In-PSMA I&T in mice bearing LS174T-PSMA and LNCaP xenografts. Dose optimization (A), effect of 2-PMPA coinjection (10-50 nmol) or preinjection of gelofusine (B), and time schedule optimization of 2-PMPA injection (C) are depicted.
502161-L-sub01-bw-Chatalic
Chapter 3.2
130
scans obtained 1 h after injection of 177Lu-PSMA I&T clearly showed preferential localization of radioactivity in the renal cortex (Figure 5). Therefore, dosimetric calculations were adjusted to estimate absorbed doses to renal cortex, taking into account this preferential localization of 177Lu-PSMA I&T in the cortex. Absorbed doses to renal cortex were 44 and 7.3 Gy for 177Lu-PSMA I&T alone and 177Lu-PSMA I&T with 2-PMPA, respectively. Absorbed doses to other organs from 100 MBq of 177Lu-PSMA I&T were below 1 Gy.
Coinjection of 2-PMPA 
improves Visualization 
of Metastatic Tumor 
Lesions Located Near 
Kidneys and Spleen SPECT/CT imaging with 111In-PSMA I&T, with or without 2-PMPA, clearly visualized subcutaneously growing LS174T-PSMA tumors and intraperitoneally growing LS174T-PSM metastases, whereas no uptake was observed in PSMA-negative LS174T tumors 
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FiGURe 4. Pharmacokinetics and dosimetry of 111In-PSMA I&T in mice bearing LS174T-PSMA xenografts. Biodistribution of 111In-PSMA I&T (0.3 nmol) alone (A) or with coinjection of 50 nmol 2-PMPA (B) at different time points after injection. Absorbed doses (in Gy/100 MBq 177Lu-PSMA I&T) were extrapolated from biodistribution data with and without 2-PMPA coinjection (C).
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(Figure 6A). High renal and spleen tracer uptake was observed in mice that did not receive coinjection of 2-PMPA, which interfered with visualization of metastases growing in the vicinity of these organs (Figure 6B).
Coinjection of 
2-PMPA Protects 
from Nephrotoxicity 
During 177Lu-PSMA i&T 
Radionuclide TherapyNon-tumor bearing mice treated with vehicle or 177Lu-PSMA I&T + 2-PMPA gained body weight over 110 days (Figure 7A). In contrast, an increase in body weight was observed up to 50 days for mice treated with 177Lu-PSMA I&T only, followed by a slow decline in body weight up to 110 days. Three months after therapy, renal function was monitored by measuring renal uptake of 99mTc-DMSA and plasma creatinine levels. Renal uptake of 99mTcǦS was significantl reduced in mice treated with 177Lu-PSMA I&T (1.0 ± 0.3 %ID/g) as compared to mice treated with vehicle (10.5 ± 1.0 %ID/g, p<0.001) or 177Lu-PSMA I&T + 2-PMPA (9.8 ± 1.6 %ID/g, p<0.001) (Figures 7B and 7C). Plasma creatinine levels were increased in mice treated with 177Lu-PSMA I&T (8.2 ± 1.7 %ID/g) as compared to mice treated with vehicle (4.2 ± 1.6 %ID/g, p = 0.029) or 177Lu-PSMA I&T + 2-PMPA (4.7 ± 2.1 %ID/g, p = 0.114) (Figure 7D). Kidneys of mice treated with 177Lu-PSMA I&T + 2-PMPA or vehicle showed normal morphology, whereas kidneys of mice treated with 177Lu-PSMA I&T showed extensive cortical damage (Figure 7e). Glomerular damage was denoted by segmental glomerular basement membrane thickening and wrinkling, and mesangial matrix increase, with pyknotic endothelial cells and podocytes. In addition, there was focal, global glomerular sclerosis. The tubular interstitial compartment of the cortex showed extreme acute tubular necrosis with atypia of the epithelial cells.
FiGURe 5. Localization of 111In-PSMA I&T in mouse kidneys. SPECT/CT images of mice 1 h after injection of 111In-PSMA I&T (0.3 nmol, 20 MBq) without (left) or with (right) coinjection of 50 nmol 2-PMPA, showing tracer localization in the renal cortex.
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T ϐ  177-P ƬT  ϐ  ʹ-PP
174- tumor growth was signiϐicantly inhiited y 100  of 177Lu-PSMA I&T. A more effective growth inhibition was observed with 177Lu-PSMA I&T alone as compared to 177Lu-PSMA I&T + 2-PMPA. Mean doubling time for tumors of mice treated with vehicle, 177Lu-PSMA, and 177Lu-PSMPA + 2-PMPA were 6.1 ± 1.1 days, 13.9 ± 1.7 days, and 7.3 ± 1.7 days, respectively (Figure 8A). Median survival for these groups was 13 days, 29 days, and 19 days, respectively (p<0.0001, Figure 8B). Median 
surial signiϐicantly decreased in the grou that receied ʹ- in comarison with 177Lu-PSMA I&T alone (p = 0.0007).
FiGURe 6. SPECT/CT imaging of 111In-PSMA I&T in PSMA-expressing xenografts. (A) Representative SPECT/CT images of subcutaneous LS174T-PSMA xenografts (right shoulder) and LS174T (left shoulder) 1 h after injection of 111In-PSMA I&T (0.3 nmol, 20 MBq) without (left) or with (right) coinjection of 50 nmol 2-PMPA. (B) Representative SPECT/CT images of intraperitoneal metastatic lesions of LS174T-PSMA cells 1 h after injection of 111In-PSMA I&T (0.3 nmol, 20 MBq) without (left) or with (right) coinjection of 50 nmol 2-PMPA. Metastatic lesions were located around intestines, spleen and pancreas. High signal intensity in kidneys and spleen interfered with visualization of metastases in this area when 2-PMPA was not administered.
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FiGURe 7. Toxicity of 177Lu-PSMA I&T in non-tumor bearing mice. Mice (n = 4 per group) were treated with 177Lu-PSMA I&T (100 MBq, 0.35 nmol) with or without 2-PMPA (50 nmol) on day 0. Control mice 
were inected with vehicle. od weight followǦup ȋȌǡ uantification of 99mTc-DMSA uptake (B), 99mTc-DMSA SPECT/CT scans (C), plasma creatinine levels (D), and periodic acid Schiff stained kidneys from treated mice (E) are displayed. Body weight loss, decreased renal uptake of 99mTc-DMSA, and increased plasma creatinine levels are observed for the group treated with 177Lu-PSMA I&T without 2-PMPA. Kidneys of mice treated with 177Lu-PSMA I&T + 2-PMPA or vehicle show normal morphology, whereas kidneys of mice treated with 177Lu-PSMA I&T show extensive cortical damage. Tubular damage can be visualized by loss of epithelial cells and atypia of the remaining cells (10 X image). In addition, glomerular damage can be visualized by endothelial cell and podocyte pyknosis, focal glomerular basement membrane wrinkling and mesangial matrix increase (40 X image). 
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DiSCUSSioNA theranostic approach for detection, staging, treatment, and follow-up of PCa would be highly valuable to achieve personalized PCa treatment. PSMA is a very interesting target for such a theranostic approach, due to its consistent overexpression on PCa at all stages of disease. In recent years the number of PSMA-targeted agents for diagnostics and therapeutic applications has increased tremendously (36). Currently, two theranostic PSMA-ligands are being evaluated in the clinic, namely PSMA I&T 
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FiGURe 8. Therapeutic efficac of 177Lu-PSMA I&T in LS174T-PSMA tumors. Mice (n = 8 per group) were treated with 177Lu-PSMA I&T (100 MBq, 0.35 nmol), with or without coinjection of 2-PMPA (50 nmol) on day 0. Control mice were injected with vehicle. Kaplan-Meier survival curves (A) and tumor size follow-up (B) are displayed.
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(25-27) and PSMA-617 (23, 37-39). These two compounds have been shown to 
efficientl detect a lesions with high contrastǡ but also displa ver high uptae in kidneys and salivary glands, which raises concerns regarding potential toxicity during radionuclide therapy. Preliminary results of 177Lu-PSMA-617 therapy in patients 
showed no acute renal insufficiencies in ʹ months followǦup timeǡ but longer followǦup is needed to get more insight into late-stage renal toxicity (37). Similarly, no signs 
of renal insufficiencies were reported for patients treated with 177Lu-PSMA I&T over a follow-up period of more than 6 months (40, 41).Our study aimed to investigate the impact of healthy tissue uptake on the theranostic potential of PSMA I&T for SPECT imaging and radionuclide therapy of PCa. Our data showed that 111In-PSMA I&T accumulated in PSMA-positive tumors, but not in PSMA negative tumors. In addition, PSMA-mediated uptake was observed in several normal murine tissues, including kidneys, spleen, salivary glands, adrenals, and lungs, of which kidneys showed the highest uptake. Our biodistribution data of 111In-PSMA I&T were consistent with previously published data for 177Lu-PSMA I&T (25). Moreover, we show that uptake of 111In-PSMA I&T in PSMA-expressing tissues can be blocked by coinjection of 2-PMPA in a dose-dependent manner, with the highest effect being 
obtained in the idnes. oadministration of ʹǦ significantl reduced tumor uptake as well, but to a lower extent than kidney uptake, resulting in increased tumor-to-kidney ratios at all doses tested. Hillier et al. have shown that coinjection of 50 mg/kg 2-PMPA, a phosphonate-based PSMA inhibitor, nearly completely blocked tumor and kidney uptake of the PSMA inhibitor [123I]MIP1095 (42). More recently, Kratochwil et al. have shown the potential of 2-PMPA to selectively block kidney uptake without reducing tumor uptake by injecting 2-PMPA (0.2 – 50 mg/kg) 1 or 16 hours after injection of the PSMA inhibitors 99mTc-MIP1404 and 125I-MIP1095, respectively (43). 
The reported rapid and efficient displacement of renal tracer uptae with minimal effects on tumor uptake and suggested that a higher internalization rate by tumor cells in comparison with renal cells could explain these differential effects on tumor and kidneys. In contrast with data obtained by Kratochwil et al. for 125I-MIP1095 and 99mTc-MIP1404, injection of 2-PMPA (50 nmol per 25 g mouse ~ 0.45 mg/kg) 1 hour after injection of 111In-PSMA I&T did not reduce renal uptake. In our study, only coinjection or 15 min preinjection resulted in effective inhibition of 111In-PSMA I&T renal uptake. This resulted in a seven-fold reduction in renal uptake at 2 h after injection, whereas tumor uptake was reduced only by a factor of two. The differential effect on tumor and kidneys might be explained by differences in the kinetics of tumor and renal uptake of 2-PMPA and PSMA I&T. Because of its small size (Mw = 226 g/mol), high hydrophilicity, and low tissue penetration (44), 2-PMPA might be cleared rapidly from the circulation, resulting in higher accumulation in kidneys than in tumor. Additional studies are needed to determine the kinetics of 2-PMPA uptake in tumor and kidneys, providing more insight into this mechanism and facilitating optimization of 2-PMPA injection schedule in patients. Pre- or coinjection of blocking agents is preferred over postinjection, because the kidneys will be protected from radiation-induced damage 
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from the start of therapǡ which could be especiall beneficial with short halfǦlife radionuclides, e.g. 213Bi.In the case of application of PSMA inhibitors for PET imaging, high uptake observed in kidneys and salivary glands is not of major concern for detection of primary tumors or distant metastases. However, if metastases are situated in the vicinity of organs showing tracer uptake, this could interfere with the interpretation of the images. Our metastatic model indicates that coinjection of 111In-PSMA I&T with 2-PMPA improved the visualization of intraperitoneal tumor lesions in the vicinity of kidneys, adrenals, and spleen. For PSMA-targeted radionuclide therapy, high uptake observed in kidneys and salivary glands are major concerns. To investigate the potential protective effect of 2-PMPA on renal toxicity, a therapeutic study was performed with 100 MBq 177Lu-PSMA I&T with and without coinjection of 2-PMPA. Several groups have reported radiation-induced nephropathy in mice between 15 and 30 weeks after therapy using 177Lu-labeled therapeutic agents, translating into reduced 99mTc-DMSA clearance and increased serum creatinine levels (33, 45, 46). Svensson et al. have reported a threshold dose value of 24 Gy to renal cortex for 177Lu-DOTATATE in nude mice (33). In our study, estimated absorbed doses to renal cortex were 44 Gy and 7.3 Gy, for 177Lu-PSMA I&T and 177Lu-PSMA I&T + 2-PMPA, respectively. Consistently, nephrotoxicity was observed in mice treated with 100 MBq 177Lu-PSMA I&T at 3 months after start of therapy, as shown by the decreased 99mTc-DMSA uptake and increased serum creatinine levels. On the contrary, nephrotoxicity was not observed when 2-PMPA was coadministered. 
Therapeutic efficac of 177uǦS ƬT was significantl reduced b coinection of 2-PMPA, which can be explained by the two-fold higher dose delivered to the tumor cells for 177Lu-PSMA I&T alone in comparison with 177Lu-PSMA I&T with 2-PMPA. To 
improve therapeutic efficacǡ the dose delivered to the tumor for 177Lu-PSMA I&T with 2-PMPA could be increased by administering a double dose of 177Lu-PSMA I&T. This would result in an estimated absorbed dose of 30 Gy to the tumor and 14.6 Gy to the renal cortex, provided that receptor saturation has not been reached. Alternatively, 2 doses of 177Lu-PSMA I&T could be administered at an interval allowing clearance of the tracer.These preclinical results illustrate the potential of PSMA I&T for theranostic approaches in PCa. However, the extrapolation of these data to the clinical situation should be performed carefully. Pitfalls might include differences in expression 
of S in human and its murine homolog 	olhͳ in miceǡ differences in affinities for PSMA expressed on human (xenograft) tumors and Folh1 expressed on murine tissues, and differences in pharmacokinetics in mice and humans. Moreover, safety and pharmacokinetics of 2-PMPA should be tested in patients. In preclinical models, PSMA inhibitors have shown utility for treatment of neurological diseases in which excessive excitatory glutamate transmission is pathogenic (47). Indeed, PSMA inhibition could limit detrimental excess glutamate release in the nervous system, 
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by blocking conversion of N-acetylaspartylglutamate into glutamate. Importantly, PSMA inhibition had no effect on basal glutamate transmission in healthy animals (48Ȍ. ven though ʹǦ has shown high affinit and selectivit towards Sǡ it was not evaluated in patients because of its poor oral bioavailability and limited brain penetration. A more lipophilic PSMA inhibitor, 2-(-3-mercaptopropyl)pentanedioic acid, which is almost as potent as 2-PMPA, was found to be safe and well tolerated in healthy subjects (49). For our application, however, the use of a hydrophilic PSMA inhibitor with poor brain penetration would be preferred, because it would less likely induce adverse events. In conclusion, future research is warranted to address the 
identified pitfalls and translate this concept in a patients.
CoNCLUSioNIn conclusion, PSMA I&T is a highly promising theranostic agent for radionuclide 
imaging and therap of a. oinection of ʹǦ efficientl reduced renal uptaeǡ thereby improving visualization of intraperitoneal tumor lesions in the vicinity of kidneys, adrenals, and spleen and protecting from nephrotoxicity after radionuclide therapy. Because 2-PMPA also reduced tumor uptake, it might hamper therapeutic 
efficacǡ which could be resolved b increasing amounts of inected activit. 
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ABSTRACTIn this study we report on 2 novel 213i-labeled tracers targeting prostate-specific 
membrane antigen (PSMA) for Ƚ radionuclide therapy of prostate cancer (PCa). Small-molecule inhibitor PSMA I&T and nanobody JVZ-008 were labeled with 213Bi 
and their biodistribution profiles were ealuated in mice bearing LCaP enografts. DNA damage response was followed after 213Bi-PSMA I&T and 213Bi-JVZ-007-cys-DOTA (213Bi-JVZ-008) treatment using LNCaP cells and LNCaP xenografts. Treatment of LNCaP cells in vitro with 213Bi-PSMA I&T and 213Bi-JVZ-008 induced DNA double-strand breaks (DSBs), as indicated by the presence of increased numbers of 53BP1 
and ɀHʹA nuclear foci. 213Bi-PSMA I&T showed clearly higher tumor uptake than 213Bi-JVZ-008 in mice. 213Bi-PSMA I&T and 213Bi-JVZ-008 induced DSBs in vivo in LNCaP tumors at 1 h after injection. DSBs were still observed 24 h after injection. These promising preliminary results warrant further evaluation of the therapeutic potential of 213Bi-labeled tracers for treatment of metastasized PCa.
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iNTRoDUCTioNLate stage metastasized prostate cancer (PCa) is associated with a poor survival and diminished quality of life. Taxane-based therapies and second-line hormonal therapies 
show only moderate surial benefits and are often associated with toicity (1). The recently introduced bone-seeking radiopharmaceutical 223RaCl2 (ofigoTM) results in an overall survival advantage of 3.6 months in castration-resistant prostate cancer patients with bone metastases (2). The short range and high linear energy transfer 
(LET) of Ƚ-particles, as emitted by 223Ra, generates localized DNA double-strand breaks 
(Ss) in bone lesions, with limited myelotoicity. A PCa-targeted Ƚ therapy approach 
would enable Ƚ-particles to target and treat potentially all PCa metastases and circulating tumor cells. Recent developments in PCa-targeted radiopharmaceuticals 
hae focused on prostate-specific membrane antigen (PSMA), oerepressed in the majority of PCa at all stages. In this study we evaluated 2 tracers targeting PSMA 
coupled to the Ƚ-emitter 213Bi. The small molecule inhibitor PSMA I&T and the nanobody JVZ-008, both showing rapid accumulation in PSMA-expressing tumors, 
represent ideal molecular carriers for the short-lied Ƚ-emitter 213Bi (3-5). In this 
short report, we describe radiolabeling, tumor targeting and biodistribution profiles of 213Bi-PSMA I&T and 213Bi-JVZ-007-cys-DOTA (213Bi-JVZ-008), as well as the resulting DNA damage response in vitro and in vivo using the PSMA-expressing LNCaP PCa model. 
MATeRiALS AND MeTHoDSAll reagents used were purchased from Sigma-Aldrich unless stated otherwise.
Synthesis and Radiolabeling of 213Bi-PSMA i&T and 213Bi-JVZ-008PSMA I&T was kindly provided by the Technical University Munich (3) and JVZ-007-cys was synthetized as described previously (5). JVZ-008 was obtained by conjugation of JVZ-007-cys to maleimide-DOTA (Chematech) according to the protocol described for maleimide-DTPA (5). 213Bi was eluted as BiI
ͶΫ
/BiI5ʹΫ from a 225Ac/213Bi generator 
(nstitute for Transuranium Elements) using 6ͲͲ ɊL Ͳ.1 M HCl/Ͳ.1 M a. 	or PSMA I&T labeling, the 213i eluate was added to a labeling ial containing 1ʹͲ ɊL ʹ M TRS, 
ͷͲ ɊL ʹͲΨ ascorbic acid and ʹ-Ͷ nmol PSMA ƬT (pH ͺ.7). 	or -ͲͲͺ labeling, the 213i eluate was added to a labeling ial containing ͺ Ͳ ɊL ʹ  M TRS, ͷͲ ɊL ʹ ͲΨ ascorbic acid and 4 nmol JVZ-008 (pH 7.9). The reaction mixture was heated for 10 min at 
ͻͷιC. After reaction, TPA was added to a final concentration of Ͳ.Ͳ3 mM to comple free 213Bi. Incorporation yield was determined by instant thin-layer chromatography (iTLC, Agilent Technologies) using 0.1 M NH4OAc/ 0.1 M EDTA (pH 5.5) and 0.1 M sodium citrate (pH 6.0) as eluent for 213Bi-PSMA I&T and 213Bi-JVZ-008, respectively. Radioactivity corresponding to 213Bi-PSMA I&T (Rf = 0.5), 213Bi-JVZ-008 (Rf = 0) and 
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free 213i (Rf α 1) was uantified using a gamma counter (Perin Elmer). ncorporation yield always exceeded 95%. 
	or animal eperiments radiolabeled tracers were purified and formulated in a physiological buffer. 213i-PSMA ƬT was purified using a asisTM HL column (Waters) preconditioned with 1 mL ethanol and 2 mL water. 213Bi-PSMA I&T was 
loaded on the column and eluted with ͷͲͲ ɊL ethanol. The olume was reduced to 
ͷͲ ɊL by eaporation, ͷͲ nmol 2-(phosphonomethyl)pentane-1,5-dioic acid (PMPA; Santa Cruz) was added and PBS/ 0.5% BSA was added up to 1 mL. Mice 
receied ʹͲͲ ɊL of this solution. 213i--ͲͲͺ was purified by size exclusion chromatography using an illustra NAP-5 column (GE Healthcare Life Sciences) preconditioned with 5 volumes of 0.5% BSA and 
eluted with 1 mL PS in 1ͲͲ ɊL 
fractions. The first ͷ fractions were pooled and mice were 
coinected with 1ͲͲ ɊL of this 
solution combined with 1ͲͲ ɊL 
gelofusine (ͶͲ mg/ml). Specific activity was 30 MBq/nmol and 7 MBq/nmol at time of injection for 213Bi-PSMA I&T and 213Bi-JVZ-008, respectively.
Cell CultureThe human PCa cell line LNCaP was cultured in RPMI1640 (Life Technologies), with 2 mM glutamine (Life Technologies) and 10% fetal calf serum at 37 °C with 5% CO2.
in Vitro experimentsCells were seeded in 12-well plates (5 x 104 cells in 1 mL/well) on sterile 13-mm diameter coverslips (VWR) and allowed to grow for 2 days. Subsequently, cells were 
treated for ʹͲ min at 37ιC with 3ͲͲ ɊL of 213Bi-PSMA I&T (10-7 M, 0.3 MBq), 213Bi-JVZ-008 (10-7 M, 0.3 MBq), 213Bi-DTPA (2 x 10-6 M, 0.3 MBq), or medium containing labeling buffer. Immediately after treatment, cells were washed with 1 mL phosphate-buffered saline (PBS) and incubated with normal medium for 1, 2, 4, 24 or 48 h. 
FiGURe 1: Scheme depicting labeling procedure with 213Bi.  
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After incubation, cells were washed with ʹ mL PS, fied for 1ͷ min in Ͳ.ͷ mL ʹΨ paraformaldehyde, and washed with 1 mL PBS.
in Vivo experimentsAll animal experiments were conducted in accordance with the revised Dutch Act on Animal Experimentation (1997) and approved by the institutional Animal Welfare Committee of the Radboud University Nijmegen. Female nude BALB/c mice (age, 6-8 wk; Janvier) were inoculated subcutaneously with LNCaP cells (3 x 106 cells, ʹͲͲ ɊL, 33Ψ RPM/67Ψ matrigel). Three wees after inoculation (tumors 4-5 mm in diameter), 213Bi-PSMA I&T (0.2 nmol, 5.4-6.6 MBq) was injected intravenously with 10 nmol 2-(phosphonomethyl)pentane-1,5-dioic acid (2-PMPA) for renal protection (6). 213Bi-JVZ-008 (0.7 nmol, 4.5-5.4 MBq) was injected intravenously with 4 mg gelofusine for renal protection (5).At 1 and 24 h after injection, mice were euthanized and relevant organs were dissected 
and weighed. Tumors were fied in ͶΨ paraformaldehyde. 	or biodistribution studies 
at 1 h after inection, radioactiity in each organ was determined in a ɀ-counter by 
measuring the ɀ-emission of 213Bi (440 kEv), and the percentage of the injected 
dose per gram (Ψ/g) was calculated. After radioactie decay, fied tissues were 
embedded in paraffin. 
Immunofluorescence Staining
To analyze the A damage response induced by the Ss, fied cells or Ͷ-ρm tissue sections were stained with primary antibodies [anti-53BP1 (NB100-304, Novus 
iologicals, dilution 1/1ͲͲͲ) or anti-ɀHʹA (Ͳͷ-636, Merc-Millipore, dilution 
1/ͷͲͲ)Ȑ and secondary antibodies (Alea 	luor ͷͻͶ or Ͷͺͺ, Life Technologies). ɀHʹA and 53BP1 imaging was performed using a TCS SP5 confocal microscope (Leica). 
ReSULTS
213Bi-Radiolabeling of PSMA i&T and JVZ-008The labeling procedure is depicted in Figure 1. Radiolabeling with 213Bi was achieved 
within 1ͷ min with a specific actiity (non-decay-corrected) of ͷͺ M/nmol and 29 MBq/nmol for 213Bi-PSMA I&T and 213Bi-JVZ-008, respectively. Incorporation yield was > 95%.
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FiGURe 2: Representative pictures of DNA double strand breaks in LNCaP cells at 1 h after treatment with vehicle (A) or at 1 h (B) and 24 h (C) after treatment with 213Bi-tracers (scale bar = 5 
Ɋm). Arrowheads indicate 
Ƚ-tracs.
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FiGURe 3. Representatie oerlay field pictures of A double strand breas in LCaP cells at 1 h after treatment with vehicle or at different time points after 213i-tracer treatment (scale bar α ʹͲ Ɋm). lue α 
AP, green α ɀHʹA, red α ͷ3P1.
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213Bi-PSMA i&T and 
213Bi-JVZ-008 induce 
DSBs in LNCaP Cells 
in VitroP h o s p h o r y l a t i o n of histone H2AX 
(ɀHʹA) and accumulation of p53-binding protein 1 (53BP1) at the site of DSBs are biomarkers of radiation-induced DSBs (7). acground ͷ3P1 and ɀHʹA nuclear foci, most liely arising from replication stress, were observed in vehicle-treated LNCaP cells. Treatment of LNCaP cells with the targeted tracers 213Bi-PSMA I&T and 213Bi-JVZ-008 and the nontargeted tracer 213i-TPA all induced Ss, as indicated by the presence of ͷ3P1 and ɀHʹA foci (Figure 2 and 3). At early time points, the DNA damage was visible as single foci 
and linear tracs, i.e. Ƚ-tracs. Tracs were isible at least until Ͷ h after treatment, but were lost at 24 and 48 h after treatment. Single DSB foci were still present at these later time points.
213Bi-PSMA i&T and 213Bi-JVZ-008 Accumulate in LNCaP Tumors in MiceAccumulation of 213Bi-PSMA I&T and 213Bi-JVZ-008 was observed in LNCaP tumors and in kidneys (Figure 4). Tumor uptake at 1 h after injection was 5.75±2.70 %ID/g and 2.68±0.56 %ID/g for 213Bi-PSMA I&T and 213Bi-JVZ-008, respectively. Tumor-to-kidney uptake ratios of both compounds were similar.
213Bi-PSMA i&T and 213Bi-JVZ-008 induce DSBs in LNCaP Tumors in Mice 213Bi-PSMA I&T and 213i--ͲͲͺ induced Ss in LCaP tumors, as reflected by increased numbers of 53BP1 and H2AX foci 1 h after injection, as compared to nontreated mice. DSBs were still observed 24 h after injection (Figure 5 and 6). 
Ƚ-tracs were obsered shortly after treatment and were no longer detectable ʹͶ h after injection, in line with the in vitro observations.
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FiGURe 4: Biodistribution of 213Bi-PSMA I&T and 213Bi-JVZ-008 in LNCaP xenografts.
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DiSCUSSioN
Here, we report on the preclinical results of PSMA-targeted Ƚ radionuclide therapy with 2 novel PSMA-targeting agents–the small-molecule PSMA inhibitor 213Bi-PSMA I&T and the anti-PSMA nanobody 213Bi-JVZ-008. 
PSMA has emerged as a aluable target for specific deliery of diagnostic and therapeutic radionuclides to prostate tumors, owing to its high expression in the majority of PCa tumors. Up to now, PSMA-targeted radionuclide therapy strategies 
hae mainly focused on Ⱦ-emitting radionuclides. Studies with small molecule inhibitors and antibodies, such as 131I-MIP-1095, 177Lu-PSMA-617, 177Lu-PSMA I&T, and 177Lu-ͷͻ1 hae shown the safety and therapeutic efficacy of this approach (3, 4, 
8-11). 
Ƚ-particles hae higher energies (ͶȂͻ Me) and shorter path lengths (ͶͲȂ1ͲͲ ρm) 
than Ⱦ-particles (energy: Ͳ.1Ȃʹ.ʹ Me, path length: 1Ȃ1Ͳ mm). The high LET of 
Ƚ-particles causes comple Ss (12), resulting in deletions, chromosome aberrations and cell death (13). High LET radionuclides therefore have a higher relative biological effectiveness for cell killing (14, 15) and may significantly enhance the efficacy of radionuclide therapy. 
FiGURe 5: Representative pictures of DNA double strand breaks in LNCaP xenografts of nontreated (NT) mice or at 1 and 24 h after injection of 213Bi-PSMA I&T or 213i--ͲͲͺ (scale bar α ͷ Ɋm). Arrowheads 
indicate Ƚ-tracs.
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FiGURe 6: Representative pictures of DNA double strand breaks in LNCaP xenografts of nontreated (NT) mice or at 1 and 24 h after injection of 213Bi-PSMA I&T or 213i--ͲͲͺ (scale bar α ʹͲ Ɋm).
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	our studies hae reported on PSMA-targeted radionuclide therapy using Ƚ-emitting radionuclides. In vitro and in vivo treatment with the monoclonal antibody J591 labeled with 213Bi showed promising results (16, 17). However, in vivo application of this tracer appeared challenging because the short 213Bi half-life (45.6 min) does not match with slow antibody pharmacokinetics. Two studies showed the ability of 
anti-PSMA-targeted liposomes/lipid esicles loaded with the Ƚ-emitter 225Ac to kill PSMA-expressing cells in vitro (18, 19). However, because of the high recoil energy when daughter products are released, in vivo stability of these nanocarriers should be addressed (20). 
n the present study, we show for the first time the application of 213Bi with low-molecular weight PSMA-targeting agents. Treatment of LNCaP cells with 213Bi-PSMA I&T and 213Bi-JVZ-008 resulted in production of DSBs, both in vitro and in vivo. However, induction of DSBs was also observed in vitro after treatment with the nontargeted agent 213Bi-DTPA, with similar DSB foci kinetics as 213Bi-PSMA I&T and 213Bi-JVZ-008. This suggests that DNA damage was already induced by 213Bi-DTPA from the medium during the 20 min incubation period. Because of the high cytotoxicity of 213Bi and its short half-life, this in vitro model appeared suboptimal and the tracers were further evaluated in vivo. In our xenograft model, a 2-fold higher tumor uptake was observed for 213Bi-PSMA I&T than for 213i--ͲͲͺ. Ss (including Ƚ-tracs) were induced 
by both tracers in LCaP tumors. Ƚ-tracs were no longer detectable at ʹͶ h after treatment, indicating that a fraction of the DSBs in the tracks was repaired.For clinical translation, it is important to note that PSMA is also expressed in normal tissues and dosimetric calculations predict the highest absorbed doses in salivary glands and kidneys (4, 9). Howeer, so far studies with Ⱦ-emitting radionuclides reported only mild early side effects, such as xerostomia, mild hematotoxicity and mild nephrotoxicity in a minority of the treated-patients (10). 
CoNCLUSioNPreclinical evaluation of 213Bi-PSMA I&T and 213Bi-JVZ-008 revealed good tumor targeting and production of DSBs in PSMA-expressing LNCaP tumors in vivo. These 
results warrant further ealuation of therapeutic efficacy and toicity. Proiding a 
faorable safety profile, these noel tracers could offer a promising new treatment option for PCa patients with metastatic lesions.
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Prostate cancer (PCa) is the second most frequently diagnosed cancer in men and the 
fifth leading cause of cancer death worldwide (1). Early detection of PCa is essential, as treatment options for advanced disseminated PCa are limited. A single tool that can be applied for diagnosis and therapy in a “theranostic” approach for PCa would be a major breakthrough. This powerful combination would not only allow non-invasive detection of PCa lesions, but also to monitor disease progression and treatment 
efficacy. Howeer, a few pitfalls hae to be considered if this goal is to be realized. Theranostic agents are designed to accumulate in tumors, either by nontargeted mechanisms, e.g. the enhanced permeability and retention (EPR) effect, or by targeted mechanisms. Nontargeted mechanisms have a broader applicability, but do not provide the same uptake ratio between tumor target tissues and healthy nontarget 
tissues. Theranostic agents can be designed to specifically target tumor-associated 
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Figure 1. Factors to be considered for the design of theranostic agents for prostate cancer in nuclear medicine.
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biomarkers, which are overexpressed on PCa cells. Several biomarkers have been 
identified as interesting targets for radionuclide imaging and therapy of PCa, including 
prostate-specific membrane antigen (PSMA), prostate stem cell antigen (PSCA), and gastrin-releasing peptide receptor (GRPR). The important factors to be considered for the development of theranostic agents for PCa in nuclear medicine are depicted in Figure 1.
Which Target?PSMA is overexpressed on 90-100% of PCa, including lymph node and bone metastases (2-4). However, it is also expressed in various normal organs, such as prostate, kidneys, and salivary glands (5). Although PSMA is an excellent target for imaging of metastatic spread of PCa, its expression in normal prostate may limit the performance of PSMA-targeted tracers for initial staging. Furthermore, expression of PSMA on kidneys and salivary gland might be a limiting factor for the successful application of PSMA-targeted radionuclide therapy.PSCA is overexpressed in about 90-100% of PCa and increased expression is found in advanced PCa and bone metastases (6-9). A study from Ananias et al. has shown overexpression of PSCA in 95% of lymph node metastases and 94% of bone metastases, although staining intensity was lower than for PSMA (9). Exploration of this target as imaging agent has been more limited than GRPR and PSMA. One of the main factors driving radiotracer development towards GRPR and PSMA might have been the availability of peptide ligands binding GRPR, and small-molecule inhibitors of PSMA, which are easy to produce and show favorable pharmacokinetics.GRPR appears as a promising target for detection of primary PCa, as its expression on normal prostate is relatively low. GRPR is overexpressed in a majority of primary PCa, and in about 50% of lymph node metastases and bone metastases (10). It has been shown that GRPR-expression is down-regulated by androgen deprivation, limiting the use of GRPR-targeted tracer for anti-androgen treated recurrent PCa (11). GRPR could be a promising target for radionuclide therapy as well, owing to its low expression on normal tissues, except for the pancreas. However, radionuclide therapy is usually 
only applied in late-stage disease. Therefore more studies are needed to define the expression of GRPR in late-stage hormonally treated, castration-resistant prostate cancer (CRPC). The expression of GRPR on CRPC has not been studied extensively. 
This lac of information is mainly due to the absence of a alidated and specific 
RPR-
antibody. Alternatiely, 
RPR mRA epression leels hae been uantified using polymerase chain reaction. 
A multitargeting approach has been proposed, using bispecific tracers targeting PSMA and GRPR, which would enable tumor-targeting in different stages of PCa progression (12, 13). However, it should be noted that the combination of PSMA and GRPR targeting might lead to a combination of disadvantages of both approaches, e.g. 
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tracer uptake in organs expressing PSMA, e.g. kidneys and salivary gland, as well as in those expressing GRPR, e.g. pancreas. Alternatively, a more personalized multitracer approach could effectively contribute to individual management of PCa patients. In such an approach, the most suitable tracer (combination) would be selected based on target expression as determined on biopsy material. This strategy is not without pitfalls, as biopsy material might not represent the heterogeneity and complexity of the patient’s tumor, and hence may only serve as an indication. 
Which Targeting Molecule?Next to selecting the most suitable target, the most appropriate targeting molecule 
should be identified. Targeting molecules should meet important criteria, such as 
easy manufacturing, low immunogenicity, in io stability, efficient tumor targeting, 
tumor specificity, fast clearance, and low uptae in healthy organs.Peptides usually meet most of these criteria, and therefore represent a promising class of targeting molecules. However, natural peptides are prone to in vivo degradation by proteolytic enzymes. Strategies have been implemented to increase radiopeptide in 
io stability by introducing structural modifications (e.g. ey amino acid substitution by D-amino acids or unnatural amino acids, cyclization, etc.), although such 
modifications can cause undesired changes in pharmacoinetics or impair receptor 
affinity. Alternatiely, radiopeptides can be administered together with an enzyme inhibitor to protect them from enzymatic degradation. It has recently been shown that coinjection of a neutral endopeptidase (NEP) inhibitor, such as phosphoramidon (PA), can stabilize radiolabeled bombesin, minigastrin, and somatostatin analogs in vivo, leading to enhanced tumor uptake and improved tumor visualization (14). In Chapter 2.2 of this thesis, we have shown that in vivo stabilization of the GRPR-antagonist peptide JMV4168 enhanced PET imaging and radionuclide therapy in a preclinical model of PCa. For PSMA, there is no naturally occurring peptide ligand. Different classes of molecules have been considered, ranging from small-molecule inhibitors, antibody fragments, to antibodies. Antibodies have very good targeting properties, but show slow accumulation in tumors and slow clearance from the blood pool and background organs. Alternatively, antibody fragments (Fab, F(ab’)2, scFv, diabodies, minibodies, 
a.o.) can be used, but these usually show less affinity for their targets, and lower absolute uptake in tumor. In addition, high renal retention is often observed with antibody fragments. In some cases, renal reabsorption in proximal tubular cells can be diminished with compounds such as lysine, arginine, gelofusine, and albumin fragments. In Chapter 3.1 of this thesis, we have designed a PSMA-targeting 
nanobody for imaging and radionuclide therapy of PCa. This tracer displays specific tumor targeting and, more importantly, low renal retention. Unfortunately, tumor targeting remained lower than the clinically used small-molecule inhibitor PSMA 
ƬT. Small-molecule inhibitors, which specifically bind to the catalytic site of PSMA, 
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hae shown efficient and fast accumulation at tumor sites, accompanied by mostly low background radioactivity. However, high uptake in kidneys and salivary glands is observed as well.  In Chapter 3.2 of this thesis, we have shown that renal and spleen uptake of an 111In-labeled small-molecule PSMA inhibitor, 111In-PSMA I&T, could 
be significantly reduced by coinection of a small hydrophilic PSMA inhibitor. This led to improvement of metastatic lesion visualization near the spleen and kidneys, and protection of the kidneys from radiation-induced damage during radionuclide therapy in mice.  However, the translation of this concept into a clinical setting might be challenging, mainly because the patterns of expression of human PSMA/FOLH1 and its mouse ortholog Folh1 differ in mice and humans (15). In patients, dosimetry calculations have shown that salivary glands might be the most at risk during radionuclide therapy. First radionuclide therapy results using 177Lu-PSMA-617 and 177Lu-PSMA I&T have shown no major renal toxicity (16-19), however it should be kept in mind that chronic renal toxicity is a late-occurring side effect. Reports have shown that expression of PSMA in normal organs is 100-1,000 fold lower than in tumors. It is not clear why the small-molecule inhibitors have such a high uptake in salivary glands. Better accessibility of the binding sites in the salivary glands to small molecules, or cross-reactivity with other receptors, splice variants or paralogs of PSMA might be an explanation. Anti-PSMA antibodies (e.g J591) do not accumulate in kidneys and salivary glands, and are therefore interesting for PSMA-targeted radionuclide therapy. To circumvent the long circulation time of antibodies, a pretargeting approach could be used, in which a radiolabeled hydrophilic molecule is “clicked” to a functionalized 
PSMA-targeted antibody after leaing sufficient time for antibody accumulation at the tumor site and clearance of unbound antibody from the circulation. The use of an antibody with a low internalization rate is required for this approach. 
Which Radionuclide?The choice of the radionuclide is essential in the design of tracers for imaging and therapy. For PET imaging, 68Ga emerges as a useful radionuclide, which can be eluted from a commercially available 68Ge/68Ga generator and offers straightforward radiolabeling procedures. Because of its short half-life (68 min), the use of 68Ga-radiopharmaceuticals is limited to centers equipped with a 68Ge/68Ga generator. 18F is more widely applied. 18F can be produced in large quantities in a cyclotron, and because of the longer half-life (110 min), 18F-radiopharmaceuticals can be shipped to hospitals within a range of ca. 200 km. However, most methods for labeling peptides with 18F are laborious and require multistep procedures with moderate labeling yields. A good alternative is the Al18F labeling method (20), allowing fast and facile labeling of peptides in a 1-step procedure. In Chapter 2.1 of this thesis, we designed a new GRPR-antagonist 
conugate, Mͷ13ʹ (A-MPAA-ȾAla-ȾAla-(H-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2), with a NODA-MPAA chelator for high-yield complexation of Al18F. Labeling of JMV5132 with Al18F was completed within 20 minutes without a need for 
purification. PET images obtained with Al18F-JMV5132 showed a higher resolution 
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than with 68
a-MͶ16ͺ (TA-ȾAla-ȾAla-ȏH-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2]), but Al18F-JMV5132 showed higher hepatobiliary excretion. JMV5132 could be further improved by adding a hydrophilic glycosylated spacer, which would reduce lipophilicity and hepatobiliary excretion of the Al18F-labeled tracer. For PSMA targeting, several 18F-labeled PSMA ligands have been developed for PET imaging of PCa. Recently, a promising 18F-labeled PSMA ligand was introduced, [18F]-DCFPyL [2-(3-(1-carboxy-5-[(6-[18	Ȑfluoro-pyridine-3-carbonyl)-aminoȐ-pentyl)-ureido)-pentanedioic acid] (21). A direct comparison of [18F]-DCFPyL with 68Ga-HBED-CC-PSMA has indicated that [18F]-DCFPyL could detect all lesions detected by 68
a-HE-CC-PSMA, with significantly higher Sma alues and higher tumor-to-background ratios. Moreover, in 3/14 patients, [18F]-DCFPyL detected additional suspicious PCa lesions.
	or therapy, Ⱦ-particle emitting radionuclides are the most widely applied. 177Lu-PSMA-617 and 177Lu-PSMA I&T have been recently introduced for the treatment of metastatic castration-resistant PCa (16-19). Additionally, there is an increasing 
interest for Ƚ-particle emitting radionuclides. Ƚ-particles hae higher energies and 
shorter path lengths than Ⱦ-particles. The high linear energy transfer of alpha particles causes more complex DNA double-strand breaks (DSBs), resulting in a higher relative biological effectiveness for cell killing (22, 23). Therefore the use of alpha-emitters 
may significantly enhance the efficacy of radionuclide therapy.  Two studies hae reported on PSMA-targeted radionuclide therapy using the 213Bi-labeled monoclonal antibody J591 (24, 25). However, the slow pharmacokinetics of antibodies do not match with the short half-life of 213Bi. In Chapter 3.3 of this thesis, we have shown the application of two 213Bi-labeled low-molecular weight PSMA-targeting agents, the DOTAGA-conjugated small-molecule inhibitor PSMA I&T and the DOTA-conjugated anti-PSMA Nanobody JVZ-008, for alpha radionuclide therapy of PCa. These novel tracers could offer a promising new treatment option for PCa patients with metastatic lesions. However, because of the PSMA-mediated uptake in kidneys and salivary gland, toxicity should be investigated carefully. Alternatively, a pretargeting approach using e.g. J591 could be considered to overcome slow antibody pharmacokinetics and toxicity to kidneys and salivary glands.
How to Prevent Tumor Regrowth?Even though radionuclide therapy can elicit tumor shrinkage, tumor regrowth is often observed after a few weeks or months. It is essential to determine the causes of tumor regrowth in order to maximize the radiotherapeutic effect. Regrowth of tumor cells may be caused by several factors, such as heterogeneous target expression, heterogeneity of tracer uptake, or radioresistance of tumor cells. Depending on the underlying cause, combination of treatments can be tailored to improve treatment 
efficacy. To achiee targeting of a wider range of tumor lesions, the combination of radionuclides with different penetration ranges in tissues has been considered (26). Combination with agents that inhibit DNA damage repair has been considered to circumvent resistance to radiation-induced DNA damage. A recent paper described 
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a sensitization strategy to enhance EGFR-targeted alpha-particle radiotherapy with a small-molecule inhibitor of DNA-dependent protein kinase, catalytic subunit (PKcs) (27). More recently, inhibition of heat shock protein 90 (HSP90), a protein associated with radioresistance, was used to potentiate radiation effects in tumorigenic cell lines (28). The genetic changes and the underlying pathways that are induced by radionuclide therapy are not well understood. More knowledge on these mechanisms and identifying the crucial checkpoints will allow development of novel combination 
strategies to improe efficacy of radionuclide therapy and preent deelopment of radioresistance. 
CoNCLUDiNG ReMARKSIn conclusion, there is no perfect theranostic agent for imaging and therapy of PCa at all disease stages yet, but the studies described in this thesis have shown strategies 
that could be implemented to improe the detection and treatment of PCa at a specific stage of the disease. Early diagnosis of PCa may be achieved using GRPR antagonists (in combination with a NEP inhibitor), or small-molecules PSMA inhibitors. Detection of PCa recurrence and metastatic spread may be best achieved using small-molecule PSMA inhibitors, which offer very high imaging contrast. Expression of GRPR in late stage PCa should be investigated further to assess the applicability of GRPR antagonists for radionuclide therapy of metastatic CRPC. Small-molecule PSMA inhibitors are promising for treatment of late-stage PCa, but the use of a pretargeting approach using antibodies could potentially spare healthy tissues such as kidneys and salivary glands. Finally, a multitracer-based selection platform could be helpful for theranostic strategies to be implemented in a personalized approach in the management of PCa.
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The aim of the studies described in this thesis was to develop and optimize theranostic strategies for imaging and radionuclide therapy of prostate cancer (PCa). These theranostic approaches might ultimately contribute to a more personalized management of PCa patients.
Section 1 of this thesis introduces the concept of theranostics in nuclear medicine. In Chapter 1.1 an introduction to PCa is provided, describing current diagnosis and staging procedures, treatment planning, and follow-up methods. Next, the clinical relevance of theranostic approaches is described, and the principles of molecular imaging and radionuclide therapy are laid out, together with the radionuclides used for imaging and therapy. Finally, molecular targets for PCa are introduced, with a focus 
on the gastrin-releasing peptide receptor (
RPR) and prostate-specific membrane antigen (PSMA). Moreover, PCa-targeted molecular imaging and radionuclide therapy approaches are discussed. Chapter 1.2 describes novel strategies to improve the application of radiopeptides for imaging and therapy. After the successful application of 111In-octreotide for imaging of neuroendocrine tumors in the clinic, radiopeptides targeting different receptor families have been developed for imaging of several types of diseases as well as for radionuclide therapy. Several approaches have been considered to improve the imaging performance of radiopeptides, including the use of receptor antagonists, in vivo stabilization of radiopeptides by in vivo enzyme inhibition, the use of positron-emitting radionuclides for positron emission tomography (PET) imaging, and the combination of nuclear and optical imaging. Strategies used to 
improe therapeutic efficacy of radiopeptides include the use of receptor antagonists, the combination of radionuclides with different penetration ranges, the combination 
of radionuclide therapy with chemotherapeutics, the introduction of Ƚ-particle-emitting radionuclides, and the introduction of methods to predict therapy response. Some of these strategies have been implemented in this thesis, as described below.
Section 2 of this thesis focuses on the development of GRPR-targeted theranostic strategies for PCa. GRPR antagonists have attracted considerable attention after reports have shown that GRPR antagonists show higher tumor uptake and lower accumulation in GRPR-positive nontarget tissues than GRPR agonists. More importantly, GRPR antagonists do not elicit side effects. The statin-based GRPR antagonist JMV594 (H-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2) has been widely used in the design of GRPR-targeted imaging agents. In Chapter 2.1 of this thesis, we describe the development of an 18F-labeled GRPR antagonist for high resolution and sensitive PET imaging of PCa and compared the imaging properties of this tracer with those of 68Ga-labeled analogs. For this purpose, J594 was conjugated to a NODA-MPAA chelator for high-yield complexation of Al18F. The resulting compound, JMV5132 
(A-MPAA-ȾAla-ȾAla-MͷͻͶ), was labeled with Al18F in a 1-step procedure 
within ʹͲ min. Mͷ13ʹ and the TA-analog MͶ16ͺ (TA-ȾAla-ȾAla-MͷͻͶ) were radiolabeled with 68Ga for comparison. Al18F-JMV5132, 68Ga-JMV5132, and 68Ga-JMV4168 were evaluated in vivo in mice with subcutaneous PC-3 xenografts. Two hours after injection, uptake values of 68Ga-JMV4168, 68Ga-JMV5132 and Al18F-JMV5132 in PC-3 tumors were similar. PET images obtained with Al18F-JMV5132 
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showed a higher resolution than with 68Ga-JMV4168, but Al18F-JMV5132 showed higher hepatobiliary excretion than 68Ga-JMV4168. In Chapter 2.2 of this thesis, the application of DOTA analog JMV4168 in a theranostic approach for PC is described. In this study we demonstrated that in vivo stabilization of the GRPR antagonist JMV4168 could enhance PET imaging and radionuclide therapy in a preclinical model of PCa. Neutral endopeptidase (NEP) is a key proteolytic enzyme responsible for in vivo degradation of several peptide families, amongst which bombesin analogs. We have shown that coinjection of a NEP inhibitor (e.g. phosphoramidon (PA)) can protect 68Ga- and 177Lu-JMV4168 from enzymatic degradation, leading to a remarkable 
enhancement of diagnostic sensitiity and therapeutic efficacy. n PC-3 tumor-bearing mice, tumor uptake of 68Ga-/177Lu-JMV4168 at 1 h after injection was increased by a factor of 2 when PA was coadministered. PA coinjection also enhanced PC-3 tumor signal intensity in PET imaging with 68Ga-JMV4168. Treatment of PC-3 tumor-bearing mice with 177Lu-JMV4168 plus PA showed increased DNA damage, slower tumor regrowth and higher survival rates as compared to mice treated with 177Lu-JMV4168 
without PA. e concluded that this strategy might be beneficial to improe diagnosis and treatment of PCa and other GRPR-expressing malignancies and warrants clinical translation.Despite the promise of GRPR antagonists in (pre)clinical studies, recent efforts for imaging and therapy of PCa in nuclear medicine have focused mainly on the development of PSMA-targeted tracers. In Section 3 of this thesis, the development and optimization of imaging and therapeutic tracers targeting PSMA are described. Small-molecule PSMA inhibitors have attracted considerable attention for imaging of PCa, 
due to their efficient accumulation in tumor lesions and fast clearance from nontarget tissues. However, their application in radionuclide therapy could be hampered by their high uptake in some PSMA-positive nontarget organs, such as kidneys and salivary glands.  In Chapter 3.1 of this thesis, we describe the development of a Nanobody targeting PSMA for targeted imaging and therapy of PCa. Nanobodies are the smallest antibody-based fragments and possess valuable molecular imaging properties, such 
as high target specificity and rapid bacground clearance. n this study we described the application of the 111In-labeled anti-PSMA Nanobody JVZ-007 for SPECT/CT imaging of PCa. JVZ-007 was initially produced with a c-myc-hexahistidine (his) 
tag allowing purification and detection. 111In-JVZ007-c-myc-his showed good tumor targeting properties in vivo and in vitro, but had unfavorable renal retention. Renal uptake of 111In-JVZ-007-c-myc-his was effectively reduced by coinjection of gelofusine and lysine. Subsequently, the c-myc-his tag was replaced by a single cysteine at the 
C terminus, allowing site-specific conugation of chelates for radiolabeling. The replacement of the c-myc-his tag by the cysteine contributed to further reduction of renal uptake without loss of targeting. Because of its low renal uptake, this novel anti-PSMA Nanobody JVZ-007-cys could offer an advantage compared to small-molecule PSMA inhibitor for radionuclide therapy. Alternatively, strategies to reduce uptake of small-molecule PSMA inhibitors in PSMA-positive nontarget tissues can be considered. In Chapter 3.2 of this thesis, we 
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describe the application of the small-molecule PSMA inhibitor PSMA I&T for single photon emission computed tomography/computed tomography (SPECT/CT) imaging 
and radionuclide therapy of PCa. n this study we showed that PSMA-specific uptae in normal organs can be reduced using blocking agents such as 2-(phosphonomethyl)pentane-1,5-dioic acid (2-PMPA). In mice with subcutaneous PSMA-expressing xenografts, 111In-PSMA I&T showed dose-dependent uptake in PSMA-expressing tumors, kidneys, spleen, adrenals, lung and salivary glands. PSMA-mediated renal 
uptae was efficiently reduced by co-administration of ʹ -PMPA, with the highest tumor/kidney ratios being obtained at 50 nmol 2-PMPA. In SPECT/CT imaging experiments, co-administration of 2-PMPA with 111In-PSMA I&T improved visualization of sub-millimeter intraperitoneal metastases near the kidneys and spleen. Moreover, co-administration of 2-PMPA increased the tumor-to-kidney absorbed dose ratio during 177Lu-PSMA I&T radionuclide therapy. As a result, mice injected with 177Lu-PSMA I&T showed signs of nephrotoxicity at 3 months after therapy, whereas mice injected with vehicle or 177Lu-PSMA I&T + 2-PMPA showed no signs of nephrotoxicity.Despite the encouraging results of radionuclide therapy using 177Lu-PSMA I&T, tumor 
regrowth was obsered a few wees after therapy. To improe the efficacy of PSMA-targeted radionuclide therapy, we investigated the feasibility of alpha radionuclide therapy using 213Bi-labeled PSMA I&T and anti-PSMA nanobody JVZ-007 (Chapter 
3.3). Labeling of PSMA I&T and JVZ-007-cys-DOTA (JVZ-008) with 213Bi was optimized, and preliminary in vitro and in vivo evaluation were performed using LNCaP cells and LNCaP xenografts. 213Bi-PSMA I&T and 213Bi-JVZ-008 induced DNA double-strand breaks (DSBs) in LNCaP cells in vitro and in LNCaP-xenografts in vivo, as indicated by 
the presence of increased numbers of ͷ3P1 and ɀHʹA nuclear foci. Linear tracs of foci (alpha tracks) were observed in the nucleus at early time points, but were no longer visible after 24 h. However, single foci were still observed 24 h after treatment. 213Bi-PSMA I&T showed a 2-fold higher tumor uptake than 213Bi-JVZ-008 in LNCaP-
enografts. 	urther studies are reuired to determine the benefits of PSMA-targeted alpha radionuclide therapy over beta radionuclide therapy.These preclinical studies have highlighted the challenges in the development of theranostic agents for PCa. Strategies have been implemented in this thesis to improve 
PET/SPECT imaging uality and therapeutic efficacy of 
RPR- and PSMA-targeting 
theranostic agents. These encouraging preclinical findings warrant further clinical studies to elucidate the value of GRPR- and PSMA-targeted imaging and radionuclide therapy in PCa patients.
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SAMeNVATTiNGHet doel van het onderzoek beschreven in dit proefschrift is de ontwikkeling en het 
erbeteren an het gebrui an radioactiee tracers oor het afbeelden (imaging) en behandelen (radionucliden-therapie) van prostaatkanker. De zogenaamde theranostische benaderingswijze (gebruik van tracers die voor zowel diagnostiek als voor therapie gebruikt kunnen worden) kan uiteindelijk bijdragen aan een meer op de patiënt toegesneden therapie voor prostaatkankerpatiënten.
Sectie 1 van dit proefschrift introduceert het concept van theranostics in de nucleaire geneeskunde. In Hoofdstuk 1.1 worden prostaatkanker, de huidige diagnostiek- en stageringsmogelijkheden en opties voor behandelingen kort beschreven. Vervolgens worden de klinische relevantie van theranostische toepassingen en de principes achter moleculaire beeldvorming en radionuclidentherapie, alsmede diverse radionucliden die toegepast worden voor beeldvorming, diagnose en therapie beschreven. Tenslotte worden moleculaire doeleiwitten (targets) aanwezig op prostaatkankercellen en waaraan de tracers kunnen binden, geïntroduceerd en bediscussieerd. In dit proefschrift is de nadruk gelegd op de “gastrin-releasing peptide receptor” (GRPR) 
en het ǲprostate-specific membrane antigenǳ (PSMA), twee belangrie targets op prostaatkanker. Hoofdstuk 1.2 beschrijft nieuwe strategieën voor de toepassing van kleine tracer moleculen (in dit geval “radiopeptiden”) om tumoren zichtbaar te maken en te behandelen. Een mede door ons ontwikkelde tracer, indium-111 (111In)-gelabeld octreotide, bleek neuroendocriene tumoren in patiënten heel goed te kunnen 
afbeelden, en olgens hetzelfde principe worden nu radiopeptiden ontwield oor 
zowel het afbeelden als oor radionuclidentherapie an andere typen tumoren, zoals prostaatkanker. Om beeldvorming met behulp van radiopeptiden te verbeteren, zijn verschillende strategieën toegepast en beschreven: het gebruik van receptor-antagonisten, het verhogen van de stabiliteit van radiopeptiden door het remmen van peptidase activiteit in het lichaam, het gebruik van positron-emitterende radionucliden voor zeer gevoelige positron emission tomography (PET) imaging en de combinatie van nucleaire en optische imaging technieken. Om daarnaast de therapeutische effectiviteit van radiopeptiden te verbeteren, zijn de volgende benaderingen toegepast en beschreven: het gebruik van receptor-antagonisten, de combinatie van radionuclidentherapie met andere stoffen die gezonde organen beschermen of die de gevoeligheid van het tumorweefsel voor radioactieve straling verhogen en het gebruik van alfa-emitters, radionucliden die radioactieve deeltjes uitzenden met hoge energie maar over een kortere afstand (penetratie range) en dus veiliger voor omliggend weefsel. 
Sectie 2 van dit proefschrift beschrijft de ontwikkeling van theranostische strategieën voor prostaatkanker via de GRPR. Verschillende studies hebben aangetoond dat, in vergelijking met GRPR agonisten, GRPR antagonisten een hogere opname in de tumor 
502161-L-sub01-bw-Chatalic
SĆĒĊēěĆęęĎēČ
177
4
en een lagere opname in gezonde weefsels laten zien. Daarnaast induceren GRPR antagonisten geen biologische effect na binding aan de receptor en daarom hebben zij minder bijwerkingen. In onze studies is de GRPR antagonist JMV594 (H-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2) gebruikt als basis voor de ontwikkeling van nieuwe GRPR-tracers. In Hoofdstuk 2.1 wordt de ontwieling an een fluor-1ͺ (18F)-gelabelde GRPR antagonist beschreven, waarmee met hoge resolutie en een hoge sensitiviteit prostaatkanker met de PET imaging techniek afgebeeld kan worden. Daarnaast worden de imaging-eigenschappen van deze tracer vergeleken met gallium-68 (68Ga)-gelabelde analoga. Deze 68Ga-gelabelde tracers hebben een kortere halfwaardetijd, wat een nadeel kan zijn tijdens imaging studies in patiënten. Voor de nieuwe 18F-labeling is J594 geconjugeerd aan een andere chelator, NODA-MPAA, voor stabiele labeling met Al18F2+. Het product, Mͷ13ʹ (A-MPAA-ȾAla-
ȾAla-MͷͻͶ), hebben we erolgens gelabeld met Al18F2+ via een geoptimaliseerde 1-staps procedure, die in minder dan 20 minuten uitgevoerd kan worden. JMV5132 
en het TA-analogon eran, MͶ16ͺ (TA-ȾAla-ȾAla-MͷͻͶ), zin in deze studies beide radioactief gelabeld met 68Ga en ter vergelijking meegenomen. Al18F-JMV5132, 68Ga-JMV5132 en 68Ga-JMV4168 zijn vervolgens onderzocht in muizen met subcutane humane prostaattumoren. Twee uur na injectie van de tracer was de opname van 68Ga-JMV4168, 68Ga-JMV5132 en Al18F-JMV5132 in de tumoren vergelijkbaar. 
PET afbeeldingen erregen met Al18F-JMV5132 waren van een hogere kwaliteit, maar lieten helaas ook een hogere ongewenste uitscheiding via de lever zien. In Hoofdstuk 2.2 wordt een nieuwe en verbeterde toepassing van JMV4168, een DOTA-analogon, voor diagnose en therapie van prostaatkanker beschreven. Deze studie laat in een preklinisch model (een muis met een humane prostaattumor) zien dat de stabilisatie van de GRPR-antagonist JMV4168 leidt tot betere PET beelden en radionuclidentherapie. Het enzym neutral endopeptidase (NEP) is één van de 
belangriste enzymen in ons lichaam erantwoordeli oor de afbraa an dierse peptiden, waaronder die van de door ons toegepaste GRPR-tracers. In dit hoofdstuk wordt beschreven dat co-injectie van een NEP-remmer, zoals phosphoramidon (PA), het 68Ga- en lutetium-177 (177Lu)-gelabelde JMV4168-peptide kan beschermen tegen 
enzymatische afbraa. it leidt tot een aanzienlie erbetering an de diagnostische sensitiviteit en de therapeutische effectiviteit in dit muizenmodel. Het gelijktijdig toedienen van de enzymremmer PA resulteerde in een verdubbeling van de opname van 68Ga-/177Lu-JMV4168 in prostaattumoren. Het gelijktijdig toedienen van PA verhoogde tevens de intensiteit van het PET imaging signaal van 68Ga-JMV4168 in de tumor. De behandeling van prostaattumoren in muizen met het therapeutische 177Lu-JMV4168 peptide met gelijktijdige toediening van PA resulteerde ook in een toename van DNA schade in de tumorcellen, resulterend in een vertraagde tumorgroei en een verhoogde overleving van de muizen ten opzichte van muizen behandeld met alleen 177Lu-JMV4168. Deze strategie zou mogelijk toegepast kunnen worden in de kliniek en de diagnose en behandeling van prostaatkanker en andere GRPR-positieve tumoren kunnen verbeteren. Naast aandacht voor GRPR antagonisten, is er momenteel veel belangstelling voor de ontwikkeling en toepassing van tracers die binden aan PSMA. In Sectie 3 van dit 
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proefschrift wordt de ontwikkeling en optimalisatie van verschillende van dergelijke tracers beschreven. Zogeheten “small-molecule PSMA-remmers” (PSMA-remmers 
met een laag molecuulgewicht) loaliseren heel effici´nt in PSMA-positiee tumoren en worden snel uitgescheiden uit bijna alle gezonde weefsels. Echter, er werd een hoge opname van deze tracers gevonden in nieren en speekselklieren, wat een struikelblok zou kunnen vormen voor veilige toepassing van radionuclidentherapie met deze PSMA-bindende tracers.In Hoofdstuk 3.1 wordt de ontwikkeling van een nieuwe, PSMA-bindend Nanobody voor imaging en therapie van prostaatkanker beschreven. Nanobodies zijn kleine 
antilichaam eiwitten, die met hoge affiniteit binden aan hun doelwit, in dit geal PSMA. Nanobodies zijn kleiner en stabieler dan gewone antilichamen en ze worden sneller uitgescheiden. In deze studie worden de ontwikkeling en toepassing van 111In-gelabeld anti-PSMA Nanobody JVZ-007 voor zogenaamde SPECT/CT imaging van prostaatkanker beschreven. JVZ-007 hebben we aanvankelijk geproduceerd met een aminozuurstaart van c-myc-hexahistidine (c-myc-his-tag) om de Nanobody te kunnen zuiveren en meten. In muizen met prostaattumoren toonde 11In-JVZ007-c-myc-his inderdaad de gewenste hoge opname in de tumoren, maar ook een ongewenste hoge opname in de nieren. Deze opname in de nieren konden we verminderen door co-injectie van gelofusine en lysine. In vervolgexperimenten hebben we de c-myc-his-tag vervangen door een enkel cysteine-aminozuur aan de zogenaamde C-terminus 
an het eiwit, waardoor site-specifiee oppeling an chelatoren oor het radioactief labelen mogelijk werd. Het vervangen van de c-myc-his tag droeg sterk bij aan het reduceren van Nanobody opname in de nier zonder daarbij de binding aan de tumoren te verminderen. De lagere nieropname van het anti-PSMA Nanobody JVZ-007-cys in vergelijking met toepassing van de populaire “small-molecule PSMA-remmers”, die een hoge nieropname laten zien, zou een belangrijk voordeel op kunnen leveren tijdens radionuclidentherapie.Vervolgens hebben we mogelijkheden onderzocht om de ongunstige hoge opname van de al genoemde “small-molecule PSMA-remmers” in nieren en speekselklieren te reduceren. In Hoofdstuk 3.2 van dit proefschrift hebben we de toepassing beschreven van de small-molecule PSMA-remmer PSMA I&T voor toepassing in SPECT/CT imaging en radionuclidentherapie van prostaatkanker. In deze studie laten we zien dat PSMA-
specifiee opname in gezonde organen erminderd an worden door gebrui te maken van PSMA-bindende stoffen zoals bijvoorbeeld 2-(phosphonomethyl)pentane-1,5-dioic acid (2-PMPA). In muizen met een prostaattumor laat 111In-PSMA I&T een 
dosisafhanelie opname in PSMA-positiee tumoren en in organen zoals nieren, 
binieren, milt, long en speesellieren zien. e nieropname onden we heel effici´nt reduceren door het gelijktijdig toedienen van 2-PMPA. De beste effecten werden verkregen bij 50 nmol 2-PMPA. In SPECT/CT experimenten verbeterde het gelijktijdig toedienen van 2-PMPA en 111In-PSMA I&T de beeldvorming van uitzaaiingen bij de nieren en de milt. Daarnaast verbeterde 2-PMPA de mogelijkheden om 177Lu-PSMA I&T te gebruiken voor radionuclidentherapie. Muizen behandeld met alleen 177Lu-PSMA I&T ontwikkelden 3 maanden na therapie nierschade door de hoge dosis 177Lu in de 
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nieren, maar muizen geïnjecteerd met een combinatie van 177Lu-PSMA I&T en 2-PMPA vertoonden geen tekenen van nierschade.Na de aanvankelijk bemoedigende effecten van 177Lu-PSMA I&T-therapie, toonden de muizen enkele weken na therapie opnieuw tumorgroei. Om de werking van PSMA-radionuclidentherapie verder te verbeteren werden daarom de mogelijkheden van zogenaamde alfa-radionuclidentherapie, een therapie met uiterst effectieve alfastraling, onderzocht. Hiervoor werden PSMA I&T en anti-PSMA Nanobody JVZ-007 gelabeld met de alfastraler bismuth-213 (213Bi), (Hoofdstuk 3.3). Nadat eerst de labeling van PSMA I&T en JVZ-007-cys-DOTA (JVZ-008) werd geoptimaliseerd, hebben we proeven uitgevoerd met prostaattumorcellen in vitro en muizen met humane prostaattumoren. 213Bi-PSMA I&T en 213Bi-JVZ-008 bleken meer schade in tumorcellen te veroorzaken dan de eerder toegepaste 177Lu-gelabelde tracers. Lineaire sporen van schade (de kenmerkende alfasporen) waren zichtbaar in de celkern in de eerste 24 uur na bestraling. De opname van 213Bi-PSMA I&T in de tumoren was twee keer zo hoog als die van 213Bi-JVZ-008. Om alle voor- en nadelen van PSMA-gerichte alfa radionuclidentherapie goed in kaart te brengen is echter verder onderzoek nodig.In onze preklinische studies hebben wij diverse mogelijkheden voor de ontwikkeling van imaging- en therapiestrategieën voor prostaatkanker onderzocht. In dit proefschrift staan diverse benaderingen beschreven die de kwaliteit van PET en SPECT imaging en de therapeutische werking van GRPR- en PSMA-bindende tracers kunnen verbeteren. Na de positieve preklinische bevindingen beschreven in dit proefschrift zijn er nu klinische studies nodig om GRPR- en PSMA-gerichte imaging en radionuclidentherapie van prostaatkanker verder te ontwikkelen. 
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sàur, e suis tr°s fi°re de deenir docteur °s sciences, et ǯesp°re bientØt deenir une super maman comme toi. Geoffrey, tu es presque comme mon frère. Merci pour ton amitié qui a persisté depuis notre enfance jusqu’à ce jour. Papa, Maman, je ne pourrai jamais vous remercier autant de m’avoir soutenue toutes ces années. Merci de m’avoir guidée dans mes choix d’études et de carrières et de m’avoir laissé la liberté de faire 
mes propres choi. ǯesp°re ue ous ²tes fiers de os filles, et de ce lire ui ous est dédié.
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